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 ABSTRACT  
 In the recent decade, an increasing amount of protein post-translational 
modifications (PTMs) have been discovered, which are important epigenetic markers 
widespread on nucleic and cytoplasmic proteins. Lysine (Lys), as the only ε-amino group 
containing amino acid, carries many different PTMs, which play important functions in 
the regulation of chromatin structure and gene transcription. Methylation and acylation as 
the two main groups of Lys modifications are of great significance to the biochemistry 
studies. However, the detailed molecular mechanisms and signaling pathways are 
remaining elusive, due to the difficulty of site-specific incorporation into target proteins 
for molecular biologists.  
Therefore, it becomes a challenging but fruitful task for chemical biologists to 
prepare sufficient amount of protein of interests (POIs) with PTMs in their homogeneous 
states. Based on the noncanonical amino acid (ncAA) incorporation technique, the Liu 
group designed a combinatory methodology for the semi-synthesis of protein with site-
specific Lys PTMs. Mainly two systems have been set up based on the introduction of 
different noncanonical amino acids via amble codon suppression followed by certain 
bioorthogonal reactions.  
This dissertation will begin with a summary of recent PTM functional studies, 
followed by a detailed analysis of two ncAA systems for the preparation of POIs with site-
specific Lys PTMs, Nε-(4-azidobenzoxycarbonyl)-δ,ε-dehydrolysine (AcdK) for Lys 
methylation, and azidonorlucine (AznL) for Lys acylation. The further biological 
investigations are highlighted to demonstrate their applications. Another AcdK based 
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design for the installation of Lys acylation via KAHA ligation strategy will be discussed, 
followed by a brief discussion of some other extensions. Last but not the least, we will 
talk about a novel visualization strategy for protein fatty acylation modifications by 
HaloTag recognition. Optimizations are still needed for this on-going project. 
With the combination of ncAA incorporation and bioorthogonal reactions, we can 
theoretically incorporate any Lys PTMs with their native structures into target proteins at 
specific sites. The protein products we generate can be directly applied for enzymatic 
assays in vitro performing similarly as native proteins. Notably, we also provide two 
useful functional groups, aldehyde and azido, as very important chemical biology handles 
for other protein functionalization purposes.  
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AA Amino acid 
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AlK Allysine 
Amp Ampicillin 
AznL Azidonorlucine 
Bu Butylation 
C Cysteine  
CloK Nε-(8-chlorooctanyl)lysine  
Cm Chloramphenicol 
CoA Coenzyme A 
Cro Crotonylation  
DMSO Dimethyl sulfoxide 
DUB Deubiquitinase  
E. coli Escherichia coli  
EPL Expressed Protein Ligation  
EtOAc Ethanyl acetate 
ESI-MS Electrospray ionization mass spectrometry  
FAD Flavin adenine dinucleotide 
  ix 
FPLC Fast protein liquid chromatography 
HMTs Histone methyltransferases 
HRP Horseradish peroxidase  
K Lysine 
Kac Lys acetylation 
KAHA α-Ketoacid–hydroxylamine peptide ligation 
KAT Potassium acyltrifluoroborate 
KAT Lysine acetyltransferase 
Kan Kanamycin 
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MS/MS Tandem mass spectrum technique  
MW Molecular weight 
  x 
ncAA Noncanonical Amino Acid  
NCL Native Chemical Ligation 
o/n Overnight 
POI Protein of Interests 
PTM Post-Translational Modification 
Pr Propionylation 
PylRS Pyrrolysyl-tRNA synthetase  
r.t. Room temperature  
sfGFP Superfolder green fluorescent protein  
Sirt Sirtuin deacetylase 
TCEP Tris-(2-carboxyethyl)phosphine  
Tet Tetracycline  
Ub Ubiquitin or Lys ubiquitination 
ULP Ubiquitin-like proteins 
WT Wild-type 
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CHAPTER I  
INTRODUCTION 
1.1 Extensions of proteinogenic amino acids 
The Mather Nature chooses 20 proteinogenic amino acids (AAs) for almost the 
entire life systems, encoded by the combination of three base pair as the information 
transduction of “Centre dogma”[1]. Although large amount of protein sequences and 
structures can be made with the combination of these 20 AAs, challenges still exist due to 
the limited chemical diversity when facing the various earth environments[2]. The 
selenocysteine and pyrrollysine as the 21st and 22nd amino acids are also installed in native 
proteins. But due to its limited application in rare species, extensions of AA side chains 
are still needed. Coenzymes and cofactors have been one of the decent solutions to provide 
functional groups not exist among the 22 proteinogenic AAs to facilitate many enzymatic 
processes. However, they are mainly linked to enzyme active sites which can hardly 
regulate the entire protein. 
Similar to the mRNA maturation process, some of the proteins are also undergoing 
editing process after been expressed by the ribosome. A typical example is the maturation 
of insulin, where the original proinsulin was an entire peptide that will be cleaved into 
three fragments. The fragment A and B was conjugated via disulfide bonds after the 
removal of C-peptide[3]. Another example of protein editing is known as “Protein splicing”, 
in which the removal of intein followed by the conjugating of C-terminus to another 
component, mainly peptide but also other small molecules[4]. However, these approaches 
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can only change the substrate protein between two states and are generally irreversible, 
which makes it not suitable in response to the frequently changing environments. 
To meet the need of more robust and widely applicable protein covalent 
regulations, post-translational modifications (PTMs) on the protein amino acid residues 
have been gradually discovered. These modifications with various structures cannot only 
regulate the physical and chemical properties of the original proteins[5], but also provide 
diverse chemical handles for protein-protein interactions (PPI) or protein-small molecule 
interactions[6]. PTM on proteins, together with DNA modifications and RNA interference, 
is becoming three key subfields of epigenetics. Although the study of PTMs has become 
a cutting edge of chemical biology field since its infancy, the chemical biology techniques 
are still one of the bottlenecks for further functional studies. 
 
1.2 PTM and Epigenetics 
Cellular proteins are undergoing post-translational modifications (PTMs) 
including phosphorylation on Ser, Thr, Tyr and His, methylation on Lys and Arg, 
glycosylation on Ser and Asn, lipidation on Lys and Cys, etc. Although these PTMs are 
generally related to many important cellular activities, detailed molecular mechanisms are 
remaining unclear[7]. Histone proteins, for instance, have various types of PTMs at their 
N-terminal tails, which is closely regulating gene expression and chromatin structure[8]. 
Especially with the existence of sophisticated cross-talk regulation between different 
PTMs, it is a prerequisite to get sufficient amount of proteins with site-specific PTMs for 
further biological studies[9].  
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In the post-genomic era, a growing number of different protein PTMs are gradually 
being discovered on both cytoplasmic and nucleic proteins with the help of tandem mass 
spectrum technique (MS/MS) and proteomic techniques[10]. Three groups of proteins or 
enzymes are closely related to them, namely “Writer”, “Reader”, and “Eraser”, which is 
catalyzing the reactions of installing, recognition and removing of different PTMs. Known 
as “epigenetic markers”, these PTMs are generally known as critical to the gene 
transcription and metabolic regulation[11]. Especially on histones, these so called “Histone 
code” are attracting more and more research focus, but the detailed molecular mechanisms 
as well as their signaling pathways remain elusive[12].  
 
1.3 Traditional Lys PTMs 
Lysine (Lys, K), as the only free ε-amino group containing amino acid among 20 
proteinogenic amino acids, can undergo many different types of acylations and alkylations. 
Some traditional ones are listed and summarized here. 
 
1.3.1 Lys methylation 
Lys methylations widely exist on histone and non-histone proteins, which can be 
divided into three levels, namely mono-methylation (Kme), di-methylation (Kme2), and 
trimethylation (Kme3)[13]. As one of the main groups of Lys modifications, histone 
methylation influences the structure and functions of eukaryotic chromatin, and recruits 
various binding proteins for transcription regulation[14]. In addition, Lys methylation can 
also regulate the functions of important transcription factors such as p53 and NF-κB[15]. 
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Therefore, a primary prerequisite for the further biological investigations is to get protein 
of interests (POIs) with sufficient quantity in their homogeneous PTM states (Figure 1) 
[16]. 
 
Figure 1 Lys methylation and chemical biology approaches for the site-selective Lys 
methylation in proteins 
 
1.3.2 Lys Acetylation 
As one of the main groups of protein PTMs, Lys acetylation (Kac) have been 
known and studied for decades, which are closely related to many important cellular 
activities. Especially for the PTMs on the histone N-terminal tails, also known as “histone 
code”, can regulate chromatin structures and gene transcription functions. As a conserved 
protein PTM mode, Lys acetylation links acetyl-coenzyme A from metabolism with 
genetic information delivering, as well as the cellular signaling pathway.  
From a biochemistry point of view, Lys acetylation can mask the positive charge 
on Lys under physiological condition. This charge removal fact can change the basic 
physical properties of protein substrates, and significantly impact their interactions with 
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other micro-molecular binders. Especially for the nucleosome, the charge-charge 
interaction between highly positively charged histone proteins with DNA is of great 
importance, which can be interrupted by Lys acetylation. 
For PTM studies, one of the key points for our investigation is their regulation, 
including the installation, the recognition or binding, and the removal. All these three 
processes are enzymatic procedure, which are catalyzed by three groups of very 
specialized enzymes. Marked as “Writer, reader, and eraser”, the three enzyme families 
corresponding to acetylation are also known as Lys acetyltransferases (KATs) to add 
acetyl groups to proteins, acetyllysine binders to selectively interact with acetylated 
proteins, and Lys deacetylases (KDACs) to remove acetyl groups from proteins[17]. Till 
now, KATs identified in human and mouse cells can be divided into three major groups 
as GCN5, CBP/p300 and MYST11, which need acetyl-coenzyme A (acetyl-CoA) as the 
only essential cofactor to install an Ac group to POIs. Bromodomain has been reported as 
a AcK binder existing in about 46 proteins in the human genome. Over 50 % have been 
shown to bind with AcK, especially with the histone N-terminal tail.  
On the other hand, 18 KDACs have been identified in the human genomes. Since 
they mainly catalyze the deacetylation over histones, they are also called as histone 
deacetylases (HDACs)[18]. All the enzymes belonging to HDAC family can be divided 
into two distinct families. The first group enzymes relay on an Zn2+ at the catalytic site 
(HDAC1–11), while the second group depends on NAD+. Specially named as Sirtuin 
deacetylases (Sirt), there are in total 7 members (Sirt1–7)[19], existing in the nucleus, 
cytoplasm and mitochondria. Although sharing similar structures and mechnisms, 
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different SIRT enzymes may catalyze the removal of some other types of Lys acylations, 
which will be discussed in Part 1.4.1. 
Recently MS and MS/MS advance have showed the wide existence of Lys 
acetylation in the human proteome. Noted as acetylome, the identification and 
quantification of Lys acetylation have dramatically increased our understanding of the 
function, regulation and localization of AcK. 
 
1.4 Novel Lys PTMs 
Besides the widely existing acylation types as Kac, Lys propionylation (Kpr), Lys 
butylation (Kbu), and Lys lipoylation (Klip), modern tandem mass spectrometry (MS/MS) 
and proteomic techniques have identified an increasing amount of other acylation types 
with more complicated structures and functions (Figure 2). These novel post-translational 
acylations also widely exist in human proteome, including histone and non-histone 
proteins. Two typical examples are lysine succinylation (Ksu) and glutarylation (Kgl) 
discovered recently. The introduction of Ksu or Kgl can reverse the positively charged 
state of lysine side chain into a negatively charged one. Although these modifications are 
believed to play important roles in transcription and metabolic regulation, detailed 
molecular mechanisms are still remaining unclear. 
Among the novel Lys PTMs, three anion-carrying modification models are 
becoming more and more interesting, malonylation, succinylation, and glutarylation, 
which can reverse the positive charge state of the lysine ε-amine and thus regulate protein 
structures and functions[2].  Besides, over ten different Lys acylation types have been 
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discovered, the study of which will advance our understanding of protein regulations and 
their related cell activities.  Although cell biologists have showed the important roles of 
PTMs, the detailed molecular mechanisms are remaining unclear. 
 
 
Figure 2 Various Lys PTMs structures including acylations and methylations 
 
1.4.1 Lys malonylation, succinylation, and glutarylation 
Protein Lys acetylation is a well-studied PTM with a fine regulatory mechanism 
for several important cellular processes. As one of the simplest acylation structures, its 
chemical essence is to mask the positive charge on Lys under physiological condition. 
Additionally, several novel acylation PTMs cannot just mask the positive charge, but even 
introduce a new negative charge. This charge reversing process can obviously perform 
even stronger interference to the charge interaction and bring in new binding possibilities. 
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Three of these new Lys PTMs as malonylation, succinylation, and glutarylation have 
greatly expanded our imagination of the natural types of modifications on proteins. With 
an excess free carboxyl group, these acidic Lys modifications belong to the same family 
with similar structures. Thus, discovered in the last decades by the Zhao group, these 
modifications are drawing more and more interests recently[20]. 
Although discovered recently, their existences are not low at all[21]. MS/MS based 
proteomic studies have shown their wide existence over metabolic proteins and histone 
proteins. Especially in mitochondria, Ksu is believed to be closely related to the 
tricarboxylic acid (TCA) cycle, which builds up the bridge between metabolism and 
genetic regulation.  
As for the PTM enzymes of “Writer, reader, and eraser”, very little has been known 
for these three acidic modifications. Although they share very similar structures, their 
regulation and signaling pathways may be completely distinct. With a high level of 
succinyl-CoA in mitochondria and malonyl-CoA, for instance, it is even unclear whether 
the succinylation is an enzymatic process or not. Recently, GCN5 as the lysine 
acetyltransferase 2A together with its complex has been reported as the first potential 
histone H3 succinyltransferase[22]. But nothing has been reported for Kmal or Kgl. 
The removal of the three acidic PTMs has been reported as the Sirtuin 5 (SIRT5) 
as we mentioned above. The hindance of investigation mainly comes from a difficulty in 
the site-specific introduction of these novel PTMs into POIs. Therefore, we will provide 
a new synthetic technique for the study of Lys succinylation in Part 4. By applying our 
technique, we will further study their regulation by SIRT5. 
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1.4.2 Lys ubiqutination and Ub-like protein modifications 
There is a very specialized class of Lys acylation modifications as peptidonylation 
and proteinylation, in which a peptide or a small protein is covalently linked to the ε-amino 
group of Lys. Protein ubiquitination, for instance, is one of the most important and widely 
existing PTM in eukaryotes. Discovered only in last decades, numerous studies have been 
carried out to investigate its critical roles in a vast number of cellular activities and 
diseases. Due to a large variety of different linking modes including mono-, di-, and poly-
ubiquitination, the biological functions and regulations of ubiquitination are generally 
elusive as a special “Ubiquitin code”[23].  
Apart from ubiqutination, several other small proteins are also widely added to 
protein substrates. Named as “ubiquitin-like protein (UBL)”, this ubiquitin family 
contains about 20 eukaryotic proteins sharing β-grasp fold structures[24]. Typical examples 
are SUMO and NEDD, corresponding to SUMOylation and Neddylation. UBLs have 
related structures, however, they participate in very different cellular processes and are 
controlled by various mechanisms. The protein substrates, mechanisms, and functions of 
Ub and UBLs are largely unclear, which brings many research opportunities to investigate 
their molecular mechanisms. The synthetic study of proteins with Ub or UBL 
modifications is one of the main challenges for chemical biologists and bioorganic 
chemists[25]. More discussion about Lys ubiquitination can be found in Part 1.5.2. 
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1.4.3 Other Acylation Modifications 
Beside all the Lys modifications discussed above, many other minor modification 
modes have also been discovered recently. Although not common, they can play 
significant roles in certain cellular processes. Typical examples are Lys phosphoglylation, 
Lys 2-hydroxylisobutylation[26], Lys β-hydroxylbutylation[27], Lys 4-
oxononanoylation[28], etc. 
 
1.5 Case studies  
Since Lys PTMs are playing important roles in many cellular activities, several 
fields have drawn special efforts. In this part, we will discuss several special Lys 
modification cases as PTMs on the histone tails, protein Lys ubiquitination, and protein 
Lys lipidation.  
 
1.5.1 Histone Lys PTM and cross-talk 
One of the main battlefields for PTM study is the Lys modification on histone 
proteins, which is of primary interest for epigenetics. Here a brief introduction of histone 
and nucleosome is provided. Human chromatin is made up with heavily condensed DNA 
over many protein complex units. Noted as nucleosome, each of these units has a histone 
octamer wrapped by 146 bp of DNA. The octamer is composed with two copies of each 
histone protein as H2A, H2B, H3 and H4. These single nucleosomes are linked together 
by DNA in between to form a nucleosomal array, which is stabilized by histone H1. The 
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nucleosomal arrays are further packed into higher-order chromatin structures with the help 
of other non-histone proteins interacting.  
Histones have a conserved sequence and a special histone fold structure with its 
flexible N-terminal tail. When folding as octamer, the globular domains of different 
histone proteins are packed together, while the N-terminal tails are all protruding outside 
of the nucleosome. Since the binding with other regulatory proteins such as transcription 
factors are mainly with its N-terminal tails, the modifications on these residues can 
significantly influence the protein-protein interactions[29]. 
Many PTMs have been discovered heavily localized at all four histone N-terminal 
tails such as traditional modes as Lys acetylation, Lys methylation, Ser phosphorylation; 
new modes as Lys ubiquitination, Lys sumoylation, Lys succinylation, etc. As we 
mentioned above, histone modifications at its N-terminal tail can interrupt the histone-
DNA interactions, which will further affect the higher-order chromatin structures and alter 
the transcription activities by recruiting binding proteins. These epigenetic effects are 
involved in many cellular activities such as DNA replication, DNA repair, cell cycle, cell 
differentiation etc. Therefore, the misregulation of histone N-terminal PTMs can lead to 
the generation of many human diseases. To investigate these binding proteins are still one 
of the main tasks for current chemical biology and enzymology fields[30]. 
Another important point for the histone PTM is about the sophisticated network of 
cross-regulation[9]. Also named as cross-talks, One PTM can play a regulatory role in 
another PTM, which really makes the histone PTM as another level of genetic code. Noted 
as “Histone code”, one PTM is able to influence the installation of one or multiple PTMs 
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subsequent on the same histone or between histone molecules or even across different 
nucleosomes[31]. These two ways are marked as “in cis” or “in trans”, respectively. For 
instance, we will study the cross-talk between methylation and acetylation on human p53 
in the Chapter 4. These special “histone code” are recognized and read by special binders 
to facilitate the installation of other PTMs or to initiate the downstream signaling pathway. 
 
1.5.2 Protein Lys ubiquitination 
Ubiquitination is a special modification discovered not long ago. As a small 
protein with 76 AAs, ubiquitination is quite distinct from other small modifications due to 
a large area it can provide. Till now, more than 57000 Lys sites have been found with 
ubiquitination, making it as the second most widely existing PTMs. Besides modifications 
over other protein substrates, Ub can undergo ubiquitination itself as well. With seven 
different Lys sites (K6, K11, K27, K29, K33, K48, and K63) and a N-terminal amino 
group, there are eight possible di-Ub linkages. Ubiquitination can have a large variety of 
different modes as mono- ubiquitination, di-ubiquitination, oligo-ubiquitination, and poly-
ubiquitination. As for poly-ubiquitination, they can form long chain or branched chain 
structures with one Ub linked with two Ubs.  
Due to many different linking modes, ubiquitination plays various roles in cells, 
including many physiological activities. The malfunction and misregulation of protein Lys 
ubiquitination can result in many disease-related processes, such as DNA damage and 
proteasomal degradation[32]. More importantly, poly-ubiquitination is generally believed 
for the target protein degradation process. Marked as “Ubiquitin code”, it has been a case-
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by-case issue, and the detailed molecular mechanism is still remaining unclear so far[33]. 
Another important direction is to investigate the PTM enzymes related as “writer, reader, 
and eraser”. Many efforts have been focused on the enzymatic ubiquitination process. Also 
known as ubiquitination cascade, a sequential action of three enzymes is needed to add a 
Ub unit to the protein target. Noted as E1, E2, and E3, different numbers of them can 
produce an even larger selectivity combination over protein substrates[34]. The E3 ligases 
will finally attach an Ub unit to the target protein. All these three enzymes are tightly 
regulated by other binding proteins to avoid cellular pathology.  
Similar to other Lys PTMs, Lys ubiquitination is also a reversible process that can 
be removed by a group of enzymes deubiquitinases (DUBs). Belonging to Cys hydrolases, 
DUBs carefully control the ubiquitination level and sites for protein substrates to maintain 
cells in the physiological state. Extended studies have been carried out to study the 
installation and removal of Ub in the past two decades[35], however, many important 
questions are still remaining unclear.  
 
1.5.3 Protein Lys lipidation 
Beside the acidic modifications discussed above, another special modification 
mode will be brief talked about in this paragraph. Proteins can undergo lipidation on Lys, 
Cys or N-terminal amino group in general[36]. As a widely existing phenomenon, lipidation 
together with the lipid trafficking can control many important cellular functions. With a 
large amount of different lipids and their derivatives including fatty acids, phospholipids, 
cholesterol, etc, there is an even larger library for the choices of protein lipidation[37]. 
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The discovery of lipidation as one of the widely existing covalent modification to 
many protein substrates has revealed a complex network of cellular membrane system. 
Proteins with lipidated residues can play vital roles under physiology conditions[38], and 
the malfunction or misregulation can also cause many human diseases[39]. Since cell 
membranes are made of lipids in all kingdoms of life, the lipid linked on proteins can play 
roles as an interaction handle for membrane or other binding proteins for the purpose of 
discretion out of cells. This evolves in the both metabolism and epigenetic controls, 
because even transcription factors can also undergo Lys lipidation, such as myristilation. 
Additionally, the potential changes in the lipid composition can have influence over 
membrane architecture, and further control the recruitment of protein binders to 
membranes. This process can play important roles on organismal physiology. 
However, the lack of biochemical methods and chemical biology tools is the main 
hindrance for the study of protein lipidation. Besides Sirt6 reported as an eraser for fatty 
acylation[40], little information has been reported for lipidation regulation. With a high 
hydrophobicity, a non-reactive and non-polar hydrocarbon chain, fatty acylation has a 
very poor handling capacity which is hard to develop antibody against. Due to the bad 
physical performance, chemically synthesizing membrane proteins become equally 
difficult[41]. For the purpose of lipidomic study, precise and sensitive labeling molecules 
and methods are of great significance especially with the existence of a complicated lipid 
trafficking and metabolic systems[42]. Projects related to Lys lipidation will be discussed 
in Chapter 5 and 6. 
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1.6 Biological Trials for the Preparation of Proteins with Site-specific Lys PTMs  
Although the study of protein PTMs have been highly evaluated for long, limited 
achievement has been made in the last decades, because traditional biological techniques 
fail to achieve the goal to install PTMs into specific sites of POIs. It is almost impossible 
to purify target proteins with PTMs from natural source due to the wide distributions, 
heterogeneous states and dynamic properties, and additionally these proteins usually 
contain more than one modification. Recombinant protein expression is a routinely used 
technique for the preparation of proteins from certain heterogenetic cells. But traditional 
biological technique can hardly control the PTM states from the genetic level.  
 
1.6.1 The enzymochemical synthesis 
Enzymatic preparation is another strategy for the installation of certain PTMs, in 
which a specific “Writer” enzyme can catalyze the installation of a corresponding 
modifications into proteins substrates. Histone methyltransferases (HMTs) are a group of 
enzymes to catalyze the methylation of histones in biological systems, which can 
potentially be applied to methylate protein substrates at few identified sites in vivo or in 
vitro. However, HMT-catalyzed enzymatic assay may result in heterogeneous protein 
methylation due to its substrate promiscuity and inability to control the three-methylation 
levels, which is very difficult to be separated from each other. 
Researchers started with the enzymatic synthesis approach, nonetheless, the 
enzymes for most of the novel modifications are unexplored[5]. Protein total and semi-
synthesis can theoretically provide native proteins with natural or non-natural structures. 
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However, both NCL and EPL are time-consuming comparing with the normal protein 
expression with a general requirement for Cys. In addition, Cys alkylation and Dha based 
bioorthogonal reactions can generate proteins Lys acylation mimics. With the introduction 
of metal-catalyzed reactions into classic bioorthogonal reaction field, coupling reaction on 
Dha can generate carbon-carbon linking modifications[6]. However, the products are in 
general not stereochemically pure. 
 
1.6.2 The direct incorporation 
Another approach is to apply ncAA for the incorporation of proteins with Lys 
acylations. Initiated by the Chin group, many simple PTMs have been successfully 
incorporated mainly based on the pyrorolysine system, such as Kac, Kpr, Kbu, Kcr, and 
Khib[8]. Although it is a straightforward and convenient method, a PylRS mutant is 
necessary to recognize the particular modified Lys, which can be tedious and does not 
guarantee to be successful. For instance, Lys with charge-containing side chain such as 
succinylation, or large acylation modifications such as lipidation or Ubiquitination is not 
accessible for the direct incorporation strategy. For instance, all our trials for the 
incorporation of malonyllysine, succinyllysine, and glutaryllysine have turned out to be 
failure in the selection of PylRS mutants. And therefore, a more robust and versatile 
strategy is needed for the installation of Lys PTMs. 
Meanwhile, peptides with Kme2 have been prepared for enzymatic assays[43].. Due 
to the lack of a robust synthetic method for the preparation of proteins with Kme2, many 
important biological questions remain unclear. Therefore, to develop universal and 
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reliable methodologies for the protein methylation is a fruitful but challenging task in front 
of protein chemists. So far, several protein chemistry approaches have been developed, 
and we will summarize and compare their advantages and disadvantages below.  
 
  18 
CHAPTER II 
PROTEIN CHEMICAL BIOLOGY TECHNIQUES FOR LYSINE PTMS 
2.1 Protein Total/semi-synthesis 
In this chapter, I would like to give a brief introduction to several key chemical 
biology techniques for the synthetic study of Lys PTMs that will be directly or indirectly 
applied to the later chapters, protein synthesis, bioorthogonal reactions, and ncAA[44].  
In the past several decades, protein total synthesis and semi-synthesis set up a new 
avenue for the study of macromolecules and laid the foundation of protein chemical 
biology. When discussing about current protein chemical biology techniques, the first key 
word is synthesis without any doubt. Thus, a brief discussion of protein synthesis will 
initiate this chapter. 
 
2.1.1 Peptide Synthesis and PTM Analogs 
In the recent decades, the development of bioorganic chemistry has enabled 
chemical biologist a detailed control of biomacromolecules with defined structures. The 
development of novel protecting group, new generations of coupling reagents, and solid 
phase peptide synthesis (SPPS) are greatly facilitating the formation of peptides[45]. With 
excess amount of another amino acid moiety and coupling reagents, the amide bond 
formation between amino acids can be very efficient with a yield of around 99 %. Besides 
natural amino acids applicable for SPPS, any molecules with both a carboxyl group and 
an amino group can be coupled into a peptide chain. Therefore, amino acids carrying 
PTMs or their structures can be directly installed into target peptides, which can be 
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otherwise hard to synthesize or easily degraded. Phosphohistidine (pHis), for instance, is 
one of the naturally existing phosphorylated amino acids, which is generally an 
intermediate for protein phosphoration mechanism[46]. Phosphorhistidinetriazole designed 
and synthesized by the Muir lab can be an easily synthesized analog for it[47]. Additionally, 
the same lab has designed and prepared a N-substituted aminooxy amino acids for the 
conjugating to ADP-ribose as analog for ADP-ribosylation. Although easily accessible, 
concerns exist about whether these peptide based PTM mimics can be able to reflect the 
real biological functions or regulatory mechanism accurately enough comparing with the 
full protein with three-dimensional folded structures[48].  
 
2.1.2 Peptide ligation strategies and the application on Lys PTMs 
Although SPPS largely increased the peptide synthesis efficiency, the overall yield 
still drops to a very low level after a sequential ligation of 50 AAs. Thus, ligation strategies 
are necessary to join multiple peptide chains into an entire protein after cleavage from the 
resin. To carry out the peptide ligation under mild aqueous condition without any side 
chain protecting groups are always a dream for peptide chemists. And in 1994 the Kent 
group[49] first introduced the native chemical ligation (NCL) reaction to lay the foundation 
of protein total synthesis. And by applying the discovery of protein splicing process, intein 
based protein semi-synthesis, also known as expressed protein ligation (EPL) has been 
developed in 1998[50]. In the later decades, many modifications have been made to extend 
the limitation of the necessary N-terminal Cys and important improvements have been 
achieving to build up masked thioesters. Examples are the ligation of peptidylhydrozine.  
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Protein total synthesis[51] and semi-synthesis[52] can generate tailor-made proteins 
with theoretically any natural or non-natural structures[53] to solve many biological 
questions that are otherwise hard to achieve[54]. For instance, protein total-synthesis 
procedures have been applied for the synthesis of many target proteins with site-specific 
Kme3 so far, such as the histone H3K9me3 by the McCafferty group in 2003[55], histone 
H3K9me3 by the Aimoto group in 2013[56], histone H3K4me3 by the Liu group in 2014[57], 
and H3Kme3 library by the Muir group in 2014[58], etc. However, to the best of our 
knowledge, no other strategies have been known to be able to site-specifically install a 
Kme3 in proteins[59].  
Apart from the ligation to form the backbone of peptide chain, NCL has also been 
applied for the formation of isopeptide bonds, especially for the ligation of Ub and UBLs 
mentioned above. So far, Ub chains with different unit numbers have been achieved with 
total-synthesis[25]. Here one typical example from the Brik group of chemical 
ubiquitination of H2B at Lys34 will be discussed[60]. In the process, Ub was first ligated 
to the second segment (22-57) by isopeptide bond at thiol-functionalized Lys side chain. 
The product was then conjugated to the first segment (1-20). With a convergent peptide 
ligation strategy, a Thz protected segment 3 (59-96) and a segment 4 (98-125) was ligated, 
and the activation of the peptide 1+2 hydrazine facilitated its ligation with peptide 3+4 
(Figure 3). 
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Figure 3 Scheme for the convergent synthesis of H2B K34Ub 
 
2.1.3 The shortage of protein total and semi-synthesis 
Although NCL and EPL have been widely used to prepare proteins with natural or 
non-natural structures, several shortages exist to cause significant concerns about the 
protein products. Artificial proteins ligated from synthetic peptides need HPLC 
purification followed by the refolding process before biological studies.  
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Another key point harasses the real extension of protein synthesis to a wider 
biological interest is the hardcore organic synthesis behind it. Till now, few labs over the 
world have the expertise to perform a total synthesis of a protein over 200 AAs, although 
it had been claimed not a challenge anymore for over ten years. Therefore, to discover 
simpler and more convenient strategies of protein synthesis especially suitable for 
biologists are one of the main directions for the further chemical biology development. 
 
2.2 Bioorthogonal Reactions and Protein Labeling 
The foundation of bioorganic chemistry is the development and application 
different reactions suitable to life-related systems for the functionalization of POIs[61]. In 
this part, a brief introduction of bioorthogonal reaction will be provided followed by a 
discussion of applying it to generate Lys PTM mimetics. 
 
2.2.1 The definition and application of bioorthogonal reactions 
The term “Bioorthogonal reaction”, first proposed by the Bertozzi lab, was used to 
describe those chemical reactions with the capability of undergoing in living cells[62]. Due 
to the lack of reactions powerful enough, not too many of them can meet this requirement. 
Therefore, the term was extended to reactions on biological molecules with selectivity. 
Some of them can undergo in cell lysate with the selectivity over various proteins, while 
the others can undergo with purified proteins over different amino acid residues. Although 
being distinct from the original dream, bioorthogonal reactions have still been an 
important weapon for further biological studies[63]. 
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Till now, a large variety of bioorthogonal reactions have been developed for 
various purposes such as bioconjugation, labeling, localization, stabilization, etc. Typical 
reactions are Staudinger reaction, traceless-Staudinger ligation, thiol-ene reaction, Click 
reaction, reductive amination reaction, etc, with special functional groups. These warheads 
can be native amino acid side chains or been installed via other approaches[64].  
With the development of organic chemistry especially metal-catalyzed carbon-
carbon coupling reactions, an increasing number of reactions have been transferred from 
glass flasks to macromolecular systems[65]. To develop and discover novel bioorthogonal 
reaction with good reliability, high efficient, no toxicity is still one of the main tasks for 
bioorganic chemistry. 
 
2.2.2 To install Lys PTM mimics via bioorthogonal reactions 
The early trials of applying bioorthogonal reactions into the PTM studies started 
with the design and synthesis of POIs with methyllysine analogs (MLAs). Based on the 
alkylation of cysteine (Cys) on the entire expressed protein level, Shokat and coworkers[66] 
installed S-(2-aminoethyl)-L-Cys containing various methylation levels as mimics of 
Kme1, Kme2, or Kme3, respectively (Figure 4A). With the incorporation of MLAs into 
recombinant histones, they were able to further investigate the regulatory functions of 
methylation to the chromatin structure and functions.  
Besides MLAs, by using thiol-ene reaction, we can convert Cys to Lys analogs 
with acylation modifications such as small molecular acetylation or ubiquitination[67] 
(Figure 4B). However, due to the lack of residue selectivity over different Cys, this 
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strategy requires a single Cys among the POI sequence, which can be generated from site-
directed mutagenesis.  
 
Figure 4 Cys selective modification for Lys alkylation or acylation analog installation 
(A) Cys alkylation for Lys alkylation analog installation; (B) Cys thiol-ene reaction for 
Lys acylation analog installation 
 
A similar but slightly advanced approach is to carry out bioorthogonal reactions 
on dehydroalanine (Dha) at a specific site to generate modified proteins. Michael addition 
reactions on Dha, as an α,β-unsaturated carbonyl group, will result in MLAs with similar 
structures as the alkylation of Cys. In these methods, the Dha is first installed into POIs in 
a site-specific manner via different strategies, such as the oxidative elimination 
mechanism[68], non-oxidative elimination mechanism[69], bis-alkylation-elimination 
mechanism[70], etc (Figure 5A&B). Then, the Dha can undergo thiol-ene reactions with 
various kinds of nucleophiles to generate corresponding PTM analogs including 
methylation, phosphorylation, glycosylation, etc. For instance, by using this approach, the 
Davis group[69] prepared modal proteins with site-specific Kme2 analog incorporated with 
over 95 % yield (Figure 5C). Although the site specificity is guaranteed, an extra sulfur 
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atom is usually remaining in the final products, introduced from the Michael addition 
reactions. To avoid the appearance of a sulfur atom, Park et al.[71] developed Zn-Cu 
bimetal-catalyzed radical addition reactions over Dha to introduce pure carbon-carbon 
bond linked modified Lys structures in 2016. Methylated H3K79 was generated for the 
further investigation of the biological functions and PTM cross-talks (Figure 5D). 
Additionally, Davis and the coworkers[72] reported a similar approach for the generation 
of theoretically any PTM structures. Termed as “Posttranslational mutagenesis”, alkyl 
halides are used to react with Dha with radical mechanism to form native carbon-carbon 
bond linkages in this method. Although an improvement has been made, this strategy still 
provides a D/L enantiomer mixture, which is unable to be separated. Additionally, radical 
based reactions can also be applied to other amino acid modifications[73]. 
 
 
Figure 5 The generation of Dha for Lys PTM analog installation. (A) the Dha 
generation from Cys; (B) the indirect installation of Dha with selenium containing ncAA; 
(C) the conversion of Dha to Lys alkylation mimics via thiol-ene reaction; (D) the 
conversion of Dha to Lys PTM and analogs 
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2.3 NcAA Incorporation Technique 
The last main chemical biology technique is the ncAA approach for the installation 
of non-natural structures, which will be discussed in this part. Comparing with the residue-
replacement approach[74], the amber-suppression approach can guarantee the site-
specificity, which makes it more suitable for the synthetic purpose. People’s effort to 
introduce methyllysines into proteins with their native structures started from the direct 
incorporation, in which the codon suppression technique was applied to install them 
during translation for the generation of posttranslationally modified proteins. 
 
2.3.1 Introduction to ncAA technique 
The trials of non-natural amino acid incorporation via biosynthesis approach 
started with the chemical misacylation of tRNAs with the corresponding amino acids in 
vitro[75]. The Schultz group developed a strategy in which a modified amino acid can be 
installed into a peptide chain at specific site by an aminoacyl tRNA synthetase (aaRS) and 
tRNA pair in response to the amber stop codon (TAG)[76]. Also known as non-canonical 
amino acid incorporation (ncAA), This aaRS-tRNA pair is specially generated to charge 
the unnatural amino acid from a selection of a mutant library to guarantee its orthogonality 
over other native aaRS for natural ones.  
For the selection of PylRS mutant, a “double sieved” selection process followed 
by a screening process is generally used. A pBK plamid with the PylRS library was used 
to transform a pY+ cell line containing a pY+ plasmid. The Cm resistance gene on pY+ 
plasmid has a TAG codon. The cells are let to grow on a media with the existence of both 
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ncAA and Cm. Only if the PylRS mutant can encode the amber codon with either natural 
or non-natural amino acid, the cell can still be alive. Those cells will be harvested and 
lysed to purifie plasmids to transform pY- cells. The pY- cells contain a pY- plasmid with 
TAG in bacterial RNA Ribonuclease (Barnase). When growing on plate without ncAA, 
all the mutants which charge TAG with natural AAs will not survive. The cells are harvest 
and lysed to purify their pBK plasmids. The positive-negative selection process will be 
repeated for over three times. The A detailed process will be discussed in Part 3.5, which 
generally provides several mutant candidates (Figure 6A).  
To further optimize and find out the best one, a screening step will be carried out 
through comparing the expression of GFP. The pY+ plasmid with certain PylRS mutant 
candidate under the control of T7 promotor with an amber codon TAG incorporated. 
Under the existance of ncAA, the T7 polymerase can be expressed and sequentially 
facilitate the expression of downstream GFP. The fluorescence visible by naked eyes is 
corresponding to the efficiency of ncAA incorporation (Figure 6B). Generally, after the 
selection and screen to get the best mutant, the gene will be installed to pBAD plasmid. 
An expression of model proteins with the ncAA installed will be carried out for ESI-MS 
analysis to confirm the molecular weight (Figure 6C). 
Till now, about 150 ncAAs have been installed into proteins with various 
structures[77]. With these new functional groups incorporated, many novel bioorthogonal 
reactions can be applied to protein bioorganic field, which also lays the foundation of this 
thesis. 
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Figure 6 The selection, screening and expression of ncAA. (A) a “double sieved” 
selection process; (B) the screening process; (C) the expression of GFP with ncAA 
 
2.3.2 The direct incorporation of Lys PTM into proteins 
With the help of ncAA technique, many naturally existing modified amino acids 
have been installed into POIs with their naturally modified structures, including Kac[78], 
Kpr[79], Nε-crotonyllysine (Kcr)[80], Nε-2-hydroxyisobutyryllysine (Khib)[26], etc (Figure 
7A). A routine selection process was carried out for each of these PylRS mutants. 
Although convenient and direct, the direct incorporation may not be perfect to all 
the Lys PTMs for several reasons. First, the selection of PylRS mutant is routine but 
requiring special expertise that not many biochemistry labs can have. Second, the 
searching for optimized PylRS mutant may not always work. Due to the non-polarity of 
the enzyme active site, all the trials of direct incorporation for acidic PTM as Kmal, Ksu, 
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Kgl have turned out to be failure. Last but not the least, some of the Lys modifications 
with large volumes such as ubiquitination and lipidations are not applicable to this 
approach. 
 
 
Figure 7 Examples of directly incorporation of PTMs or bioorthogonal reactions on 
ncAA-containing proteins (A) the direct incorporation of AcK; (B) the installation of 
Kme1 with the incorporation of Boc protected precursor followed by the deprotection 
process. 
 
2.3.3 The combination of ncAA with bioorthogonal reaction approach 
Besides the direct incorporation of posttranslationally modified Lys into proteins, 
a combination of ncAA with bioorthogonal reaction is opening another avenue. As 
mentioned above, the main advantage for the ncAA incorporation is to install a non-natural 
functional group (FG) into a desired position in protein, which can further undergo certain 
reactions to be converted to Lys PTMs. At the same time, the bioorthogonal reactions can 
largely extend the scope for ncAA. 
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Lys mono-methylation, for example, cannot be directly incorporated because aaRS 
fails to differentiate it from Lys. However, several precursors with protecting groups on 
the ε-amino group, also known as “Masked Lys”, such as the tert-Butyloxycarbonyl (Boc) 
group[81], allylcarbamoyl group[82], and photocaging groups[83], were successfully 
incorporated via the ncAA technique. The deprotection of these groups under various 
conditions could release proteins with site-specific Kme1 in situ (Figure 7B).  
However, the approach for the Kme1 incorporation is not applicable for the Kme2, 
because a protected Kme2 side chain will generate a quaternary amino group with a 
positive charge, whose recognition will be hard for aaRS with a hydrophobic active site[84]. 
A novel approach for the installation of Kme2 will be discussed in the next Chapter.  
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CHAPTER III 
THE SYNTHETIC INVESTIGATION OF LYSINE DIMETHYLATION 
3.1 Research background 
Because of a limited understanding of protein Lys methylation, chemical biologists 
have been trying to achieve the site-selective installation of different level of methyllysine 
into proteins for decades, Kme, Kme2 and Kme3. The Cys alkylation strategy mentioned 
in Part 2.2 can only provide methyllysine mimics in general. With a much higher 
abundance of Lys comparing with Cys, it’s almost not possible to directly distinguish one 
desired Lys from a pool of others, especially for histone proteins. Therefore, we cannot 
eraser all the other Lys residues to guarantee the site-specificity. Additionally, the 
selection of a special PylRS mutant for Kme has turned out to be a failure. The small 
structural difference after methylation cannot be easily distinguished with the original Lys, 
and the negative selection can hardly pass. Therefore, protein chemistry has been drawing 
extensive efforts so far.  
 
3.1.1 The chemical installation of Kme1 
One widely used approach is to install a protected Kme into POIs. Also known as 
“masked Lys”, these protected Lys derivatives can undergo a deprotection step to release 
Kme as expected. The Chin group[81] introduced a first example of installing Boc protected 
Kme into histone H3K9, whose acid-deprotection could release Kme with native strature. 
With the development of these “bond-cleavage” bioorthogonal reactions, many other 
ncAA with protecting groups have been applied, such as an allylcarbamoyl-protected Kme 
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into H2BK27 by the Schultz group, photocaged Kme derivatives separately by the Liu 
group into GFP and the Chin group.  
 
3.1.2 The chemical installation of Kme2 
However, these approaches abovementioned can only apply for Kme, which will 
generate a positively charged state for Kme2 and not suitable for the enzymatic 
recognition anymore. It was not until 2010 that the Chin group[85] developed a novel 
method for the generation of Kme2-containing histone H3K9me2. First, a Boc-protected 
Lys was installed at the H3K9 site via the ncAA technique, followed by the global 
protection of all the other existing Lys side chains with the Benzyloxycarbonyl (Cbz) 
protecting group. Then, the Boc group deprotection will selectively release the only Lys 
at the specific site, which can further undergo reductive methylation reaction with 
formaldehyde to form Kme2 only at H3K9 site (Figure 8).   
 
 
Figure 8 The combination of ncAA and bioorthogonal reactions for the site-specific 
incorporation of Kme2 with a global protection-deprotection based approach. 
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Finally, all the Cbz groups are removed to finally generate the Kme2-containing 
protein in its fully native structure. However, concerns exist about proteins sensitive to the 
global protection/deprotection conditions of the other Lys side chains. 
 
3.2 Methodology Design of AcdK 
Although elegent, the global protection and deprotection procedures, as well as the 
acid deprotecting process for Boc group, are not under mild condition, which raises 
concern about protein unfolding. Thus, we plan to develop novel methods for the robust 
and convenient introduction of Lys dimethylation. In order to install lysine dimethylation 
into POIs at specific sites, we envision a reversed approach that allysine (AlK) can 
undergo the reductive amination with dimethylamine to generate Kme2 in proteins, which 
may be genetically encoded via the amber suppression mutagenesis approach. Comparing 
with the method mentioned above to react formaldehyde with a Lys on POI, the aldehyde 
group is directly installed onto POIs, which excessive amount of dimethylamine will be 
provided outside (Figure 9A). 
With the concern of the cellular toxicity from the aliphatic aldehyde group on its 
side chain, a precursor of AlK is needed which can further undergo deprotection to 
generate AlK in vivo. Therefore, Nε-(4-azidobenzoxycarbonyl)-δ,ε-dehydrolysine (AcdK) 
was then designed out as an amino acid precursor of AlK,  with a shielded side chain 
aldehyde as a similar design an o-azidobenzyloxycarbonyl lysine from the Deiters group[86] 
(Figure 9B). In the structure, the azidobenzoxycarbonyl moiety reduced by a phosphine 
reagents can further trigger the self-cleavage process to release a δ, ε-dehydrolysine[65]. 
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The automatic hydrolysis of δ, ε-dehydrolysine in water will instantaneously generate 
AlK. In that case, the AcdK genetically incorporated into proteins can undergo Staudinger 
reduction with tris-(2-carboxyethyl)phosphine (TCEP) to release AlK, which will further 
undergo reductive amination with dimethyllysine with the existence of NaCNBH3 to 
finally generate proteins with site-specific lysine dimethylation (Figure 9C). As discussed 
above, both Staudinger reduction and reductive amination are typical bioorthogonal 
reactions which can be carried out under mild physiological conditions, our approach can 
be theoretically applied for the preparation of any native proteins with site-specific Kme2 
as well as the preparation of proteins with site-specific Kme or even other alkylations by 
simply changing dimethylamine to methylamine or any corresponding alkylamines during 
the reductive amination step[87].  
The idea of AlK comes from the human elastin and collagen, in which AlK is a 
naturally existing derivative of lysine[88]. Although the free aldehyde group may form 
intramolecular imine with other free amino groups on either Lys side chains or the N-
terminal amine, this process is reversible and the incubation with high concentration of 
external small molecular amine for hours can guarantee the formation of desire imine 
product.  
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Figure 9 Chemical biology approaches for the site-selective Lysine dimethylation in 
proteins. (A) the general design of AcdK; (B) the structure of AcdK; (C) the conversion 
from AcdK to Kme2. 
 
3.3 The Synthesis of AcdK  
3.3.1 General description 
A synthetic route of AcdK is a complicated process. It starts with the selective 
DIBAL reduction of the side chain of natural L-glutamate to form an aldehyde group. The 
yield reaction followed by the Curtius rearrangement to form the acylazide as an activated 
acyl group. After the coupling reaction to form an ester bond, the deprotection will finally 
generate the product as dilithium salt of AcdK as designed. Although the overall synthesis 
involves 9 steps in total, gram quantities of AcdK have been routinely produced. The 
synthesis was further optimized to improve the overall yield. The finally optimized yields 
for each step was presented in Figure 10. This part is originally designed and achieved by 
Dr. Yadagiri Kurra. 
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Figure 10 Scheme for the synthesis of AcdK 
 
3.3.2 Detailed procedure 
The synthesis of compound (S)-2-(1,3-dioxoisoindolin-2-yl)pentanedioic acid (2):  
To a 500 mL round bottom flask was added L-glutamic acid (30 g, 0.2 mol), phthalic 
anhydride (29.6 g, 0.2 mol), triethylamine (2.79 mL, 0.02 mol) and toluene (250 mL). The 
mixture was heated to reflux, and the water formed in the reaction was collected using a 
Dean-Stark apparatus. After 24 h, the reaction was cooled to room temperature and solvent 
was removed under reduced pressure. EtOAc was added to dilute the reaction and pH was 
adjusted to 2 with HCl (3.0 M). Then the mixture was extracted with EtOAc (300 mL × 3) 
and the organic layers were dried and concentrated. The resulting solid was washed with 
EtOAc and then filtered to collect the solid. Drying the solid under high vacuum afforded 
the N-protected L-Glutamic acid (2) (22.5 g, 41% yield). 
The synthesis of compound dimethyl (S)-2-(1,3-dioxoisoindolin-2-yl)pentanedioate 
(3): (2) (22.5 g, 0.081 mol) was dissolved in MeOH (200 mL) and cooled to 0 oC. SOCl2 
(23.5 mL, 4 e.q.) was added dropwise. The mixture was warmed to room temperature 
naturally and stirred overnight. All the volatiles were removed under reduced pressure and 
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then diluted with EtOAc. The organic layer was washed with aqueous NaHCO3, dried, 
and concentrated to give methyl ester 3 (25.4 g, 100%). 
The synthesis of compound methyl (S)-2-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoate 
(4): 3 (25.4 g, 0.083 mol) was dissolved in anhydrous diethyl ether (300 mL), cooled to -
78 oC. DIBAL-H (99.8 mL, 1.0 M in hexane, 1.2 eq.) was added dropwise under argon 
protection. Stirring continued for another 1 h. Water (10 mL) was added. The reaction was 
warmed to room temperature and continually stirred for 1 h. The precipitate was removed 
with Celite and the filtrate was concentrated to produce the crude aldehyde (4), which was 
used directly to the next step without further purification. 
The synthesis of compound 1-(tert-butyl) 7-methyl (S,E)-6-(1,3-dioxoisoindolin-2-
yl)hept-2-enedioate (5): Anhydrous THF (80 mL) was added to a round bottom flask and 
cooled to 0 oC. NaH (1.9 g, 60% dispersion in mineral oil, 1.2 eq.) was added carefully. 
Then tert-butyl 2-(diethoxyphosphoryl)acetate (11.99 g, 1.2 eq.) was added dropwise. 
After bubbles ceased to release, 4 (~ 0.0396 mol) in THF (20 mL) was added and the 
mixture was warmed to room temperature. After 2 h, NH4Cl aqueous was added to quench 
the reaction. After diethyl ether extraction, the organic phase was dried and concentrated. 
The residue was purified via column chromatography with hexane/EtOAc (3:1 v/v) as 
eluent to give product 5 (6.9 g, 22% yield, two steps). 
The synthesis of compound (S,E)-6-(1,3-dioxoisoindolin-2-yl)-7-methoxy-7-oxohept-
2-enoic acid (6): (5) (6.9 g, 0.0184788 mol) was dissolved in CH2Cl2 (70 mL), cooled to 
0 oC. Trifluoroacetic acid (14.15 mL, 10 eq.) was added dropwise. Then the solution was 
warmed to room temperature and stirred for 1.5 h. The reaction was diluted with CH2Cl2, 
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washed with H2O, then dried and concentrated. The residue was purified via column 
chromatography with hexane/EtOAc (1:1 v/v) as eluent to afford pure acid 6 (6.1 g, 85% 
yield). 
The synthesis of compound methyl (S,E)-7-azido-2-(1,3-dioxoisoindolin-2-yl)-7-
oxohept-5-enoate (7): 6 (5.0 g, 0.015758 mol) was dissolved in acetone (150 mL), cooled 
to 0 oC and then added diisopropylethylamine (6.587 mL, 2.4 eq.). Ethyl chloroformate 
(3.3 mL, 2.2 eq.) was added dropwise and the solution was stirred at 0 oC for 1 h. Sodium 
azide (5.12 g, 5 eq.) in water (25 mL) was added and the reaction mixture was warmed to 
room temperature. After 1 h with stirring, brine was added and extracted with EtOAc. The 
organic layer was dried and concentrated. The residue was purified via column 
chromatography with hexane/EtOAc (3:1 v/v) as eluent to afford pure methyl ester 7 (4.6 
g, 85% yield). 
The synthesis of compound methyl (S,E)-6-((((4-azidobenzyl)oxy)carbonyl)amino)-
2-(1,3-dioxoisoindolin-2-yl)hex-5-enoate (8): 7 (4.6 g, 0.01344 mol) was dissolved in 
toluene, and heated to reflux for 2 h under argon protection. Then (2-
azidophenyl)methanol (2 g, 1.0 eq.) was added and the mixture was continuously refluxed 
for another 2 h under argon protection. It was then cooled to room temperature. The 
solvent was removed under reduced pressure and the residue was purified via column 
chromatography with hexane/EtOAc (3:1 to 1:1 v/v) as eluent to afford product 8 (5.1 g, 
92% yield). 
The synthesis of compound methyl (S,E)-2-amino-6-((((4-
azidobenzyl)oxy)carbonyl)amino)hex-5-enoate (9): 8 (5.1 g, 0.011 mol) was dissolved 
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in ethanol/dichloromethane (16 mL/25 mL) and hydrazine monohydrate (0.85 mL, 1.6 eq.) 
was added. The mixture was stirred at room temperature overnight. The white solid 
formed in the reaction was filtered away and the filtrate was concentrated. The residue 
was purified via column chromatography with methanol/ammonium 
hydroxide/dichloromethane (15:50:450 v/v/v) as eluent to afford amine 9 (2.2 g, 60% 
yield). 
The synthesis of compound AcdK (1): 9 (2.2 g, 0.0066 mol) was dissolved in THF/H2O 
(25 mL/12.5 mL) and LiOH (0.3168 g, 2 eq.) was added. After stirring for 1 h, the 
undissolved impurities were filtered away and the filtrate was concentrated under vacuum 
to afford amino acid 1 (2.1 g, 96% yield). 1H NMR (CD3OD, 300 MHz) 7.40 (d, 2H, J = 
4.5 Hz), 7.07 (d, 2H, J = 4.5 Hz), 6.43 (dd, 1H, J = 0.9, 8.7 Hz), 5.12 (dd, 1H, J = 4.5, 8.7 
Hz), 5.08 (s, 2H), 3.20 (dd, 1H, J = 0.9, 4.2 Hz), 2.12-2.07 (m, 2H), 1.76-1.73 (m, 1H), 
1.60-1.56 (m, 1H). 13C NMR (CD3OD, 75 MHz) 181.4, 154.6, 139.8, 133.6, 129.3, 123.9, 
118.6, 110.4, 65.5, 55.7, 36.0, 26.1 (Figure 11). 
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Figure 11 1HNMR and 13CNMR of AcdK 
 
3.4 The Construction of a PylRS mutant library  
To start with, we built up a Methanosarcina mazei pyrrolysyl-tRNA synthetase 
(MmPylRS or short for PylRS) gene library with four sites random mutations. The codon 
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for one active site residue Y384 was randomized as codons for residues Y, F, and W, and 
then codons for three active site residues Y306, L309, and C348 were randomized as NNK 
nucleotides (N=A or C or G or T, K=G or T). For the site-direct mutagenesis as described, 
several pairs of primers were used for PCR with Phusion DNA polymerase, as pBK-
mmPylRS-348NNK-F (5’-ACC ATG CTG AAC TTC NNK CAG ATG GGA TCG GGA 
TGC ACA CGG-3’), pBK-mmPylRS-348NNK-R (5’-AAA CTC TTC GAG GTG TTC 
TTT GCC GTC GGA CTC-3’), pBK-mmPylRS-306-309-NNK-F (5’-CTT GCT CCA 
AAC CTT NNK AAC TAC NNK CGC AAG CTT GAC AGG GCC CTG CCT-3’), pBK-
mmPylRS-306-309- NNK-R (5’-CAT GGG TCT CAG GCA GAA GTT CTT GTC AAC 
CCT-3’). The gene was finally colon to pBK plasmid as reported by the Schultz group. 
The products from PCR was phosphorylated by T4 polynucleotide kinase and ligated by 
T4 ligase. The final mutant pBK-MmPylRS library plasmid mix was used to transform 
Top10 cells with a kanamycin (Kan) selection marker. 
 
3.5 The Selection, Screening and Incorporation of AcdK  
WT PylRS-tRNAPyl pair and its mutants have been widely applied for the genetic 
incorporation of many ncAAs into naturally expressed proteins at amber mutation sites in 
different cell strains[84]. Mainly lysine derivatives, the Liu group also extended it for 
phenylalanine derivatives[89]. After getting sufficient amount of AcdK in its dilithium salt 
form, we started to carry out the selection and screening of PylRS-tRNAPyl mutant library 
for the incorporation of AcdK into E. coli via the amber codon suppression strategy[90]. A 
double sieved selection procedure[78] generally reported for the identification of mutant 
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aminoacyl-tRNA synthetases for ncAAs in E. coli has been employed, which contains a 
three positive selections coupled with a two negative selections in between.  
 
3.5.1 The positive selection of AcdK 
To start with, we carried out the first positive selection. The mutant library pBK-
MmPylRS plasmid mix was used to transform Top10 electrocompetent cells that contains 
the positive selection plasmid to yield a cell library greater than 1×109 cfu. For this 
positive selection plasmid, also known as pY+, was previously constructed containing 
several parts including a gene coding tRNAPyl, a tetracycline (Tet) selection marker, a 
chloramphenicol (Cm) acetyltransferase gene for Cm resistance, an amber mutation at its 
D112 position, a T7 RNA polymerase gene with two amber mutations at positions 1 and 
107, and a green fluorescent protein GFPUV gene under control of a T7 promoter. After 
the transform, cells were then plated on the GMML agar plates (1×M9 Salts, 1 % glycerol, 
300 µM Leucine, 2 mM MgSO4, 0.1 mM CaCl2, and 0.2 % NaCl) with 12 µg/mL Tet, 25 
µg/mL Kan, 102 µg/mL Cm, and 1 mM AcdK, and let to grow at 37 °C for 72 h. Colonies 
on the plates were collected and selected pBK-MmPylRS mutant plasmids were extracted.  
 
3.5.2 The negative selection of AcdK 
Then we can carry out the first negative selection by using the extracted pBK-
MmPylRS plasmids from the positive selection to transform Top10 electrocompetent cells 
with the negative selection plasmid as pY-. Similar to the positive selection plasmid, the 
negative selection plasmid is also a specialized plasmid for the selection process, with an 
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Amp selection marker, genes coding tRNAPyl, and barnase with two amber mutations at 
Q2 and D44. After been plated on LB agar plates with 50 µg/mL Kan, 200 µg/mL 
ampicillin (Amp), and 0.2 % arabinose, but without the existence of AcdK to make sure 
that any non-specific installation of natural amino acids will cause cell death. After 
incubating the plate at 37 °C for 16 h, survived cells were collected and their plasmids 
were extracted for the second positive selection.  
After three rounds of positive selections and two rounds of negative selections, we 
carried out the screening by the visualization of GFPUV expression. The clones picked 
after the third positive selection was let to grow on LB plate with 102 µg/mL Cm, 25 
µg/mL Kan, and 12 µg/mL Tet but with or without 1 mM AcdK. Besides a pBK plasmid 
contained a mutant PylRS gene, the pY+ plasmid in these cells had a tRNAPyl gene, a Cm 
resistance gene with an amber mutation at D112, as well as a GFPUV gene under the control 
of a T7 promoter. Since two amber mutations were installed in T7 RNA polymerase gene 
at positions 1 and 107, the expression of GFPUV would be promoted by the successful 
suppression of two amber mutations in the T7 RNA polymerase. By measuring the 
fluorescent intensity of GFPUV expression, we can select a best colony from a large 
number of candidates after the third positive selection. The mutant with the best amber 
suppression efficiency in E. coli was identified as L309T/C348G/Y384F (Figure 12). The 
gene mutant corresponding to this PylRS mutant noted as AcdKRS was then cloned into 
pEvol plasmid backbone together with the tRNAPyl.  
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Figure 12 Screening of the clones after the third positive selection on LB plates. 
  
3.6 The expression, purification of sfGFP-D134AcdK and its conversion to AlK 
3.6.1 Sequence information 
DNA sequence: sfGFP-D134TAG-His6: 
atggttagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtgatgtgaatggccataaatttag
cgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcaccaccggtaaactgccggttcc
gtggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcatatgaaacgccatgatttcttta
aaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcacctataaaacccgtgcggaagtt
aaatttgaaggcgataccctggtgaaccgcattgaactgaaaggtattgattttaaagaatagggcaacattctgggtcataaact
ggaatataatttcaacagccataatgtgtatattaccgccgataaacagaaaaatggcatcaaagcgaactttaaaatccgtcaca
acgtggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatggcccggtgctgctgccggat
aatcattatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaatttgttaccgc
cgcgggcattacccacggtatggatgaactgtataaaggcagccaccatcatcatcaccattga 
 
Protein sequence: sfGFP-D134AznL-His6 (MW: 27866.35): 
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(M)VSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGK
LPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGT
YKTRAEVKFEGDTLVNRIELKGIDFKE(Aznl)GNILGHKLEYNFNSHNVYITADK
QKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLS 
KDPNEKRDHMVLLEFVTAAGITHGMDELYKGSHHHHHH 
 
3.6.2 The expression of sfGFP-D134AcdK 
With the pEVOL-AcdKRS-PylT at hand, we also got another plasmid pBAD-
sfGFP-D134TAG containing a gene for the expression of the superfolder green 
fluorescent protein (sfGFP) with an amber mutation at the D134 position, as well as a His6 
tag at the C-terminal as gift from Ryan Mehl at Oregon State University. The newly 
constructed plasmid pEVOL-AcdKRS-tRNAPyl and the expression plasmid pBAD-
sfGFP-D134TAG were used to co-transform E. coli BL21(DE3) cells. A single colony 
was picked and let to grow in 5 mL LB medium with 100 mg/mL Amp and 34 mg/mL Cm 
at 37 °C for o/n. Then, the transformed cells were used to inoculate 50 mL 2YT medium 
with 100 mg/mL Amp and 34 mg/mL Cm, which can express full-length sfGFP with 
AcdK at its D134 position (sfGFP-D134AcdK) after been induced by 0.2% arabinose and 
0.5 mM IPTG. After growing at 37 °C for 6 h, the cells were collected by centrifugation 
(6,000 rpm for 15 min). After been resuspended in a 25 mL lysis buffer (50 mM NaH2PO4, 
300 mM NaCl, 10 mM imidazole, pH 8.0) and sonicated in an ice water bath three times 
(4 min each, with a 5 min interval between each run), the cell lysate was precipitated by 
centrifugation (10000 rpm for 30 min). The supernatant was added to 1 mL Ni 
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SepharoseTM Fast Flow column (GE Healthcare) and the flow-through was then removed. 
The resin was washed with a wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH 8.0) and finally eluted with an elution buffer (50 mM NaH2PO4, 300 mM 
NaCl, 250 mM imidazole, pH 8.0). After been concentrated with Amicon Ultra-15 
Centrifugal Filter Devices (10000 MWCO cut, Millopore), the purified sfGFP-D134AcdK 
was analyzed by SDS-PAGE. A clear band can be clearly seen only with 0.5 mM AcdK 
afforded in the media, while none for the one without AcdK added (Figure 13A). The yield 
of sfGFP-D134AcdK is 7 mg/L with the presence of 0.5 mm AcdK, determined by the 
BCA method. 
 
3.6.3 The characterization and labeling of sfGFP-D134AcdK 
Additionally, we took electrospray ionization mass spectrometry (ESI-MS) to 
analyze the purified sfGFP-D134AcdK, in which two major peaks showed up (Figure 
13B). One of the major peaks showing as 28013 Da suggests sfGFP-D134AcdK with a 
theoretical MW of 28013Da, while the other major peak showing as 27839 Da agrees with 
the reduction product of AcdK after incorporation into sfGFP-D134AcdK to sfGFP-
D134AlK with a theoretical MW of 27839 Da. This implies part of the AcdK is already 
reduced and rearranged to AlK without the addition of phosphine reagents during the 
protein purification process with no reducing reagent added, possibly due to reactions with 
endogenous thiol- containing reagents such as glutathione and H2S in E. coli cells. Since 
AcdK will finally been converted to AlK in POIs, this partial conversion of AcdK to AlK 
is not a problem. To further confirm the key aldehyde group in sfGFP-D134AlK, a simple 
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dye labeling test was also carried out using a hydroxylamine-fluorescein conjugated dye. 
(Figure 13C). Because the boiling process can cause the denature of sfGFP and losing its 
original fluorescence, no fluorescence could be detected for the negative control WT-
sfGFP sample. 
 
Figure 13 The expression of sfGFP-D134AcdK and its conversion to sfGFP-D134AlK 
(A) SDS-PAGE of sfGFP-D134AcdK; (B) ESI-MS of sfGFP-D134AcdK; (C) 
fluorescence labeling of sfGFP-D134AcdK showing the partial deprotection in cell; (D) 
the conversion of sfGFP-D134AcdK. Adapted with permission from [87]. 
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3.6.4 The conversion to sfGFP-D134AlK 
After confirming the expression of sfGFP-D134AcdK, Tris(2-
carboxyethyl)phosphine (TCEP) was added to the purified protein sample to a final 
concentration of 5 mM, and the reaction mixture was let to incubate at 37 oC for 1 h, 
followed by the dialysis to 10 mM pH=7.8 ammonium bicarbonate (ABC) buffer and sent 
for the characterization by ESI-MS. The main peak showing as 27839 Da similar to the 
peak in the previous figure implies sfGFP-D134AlK. Since AlK contains an aliphatic 
aldehyde group, which will undergo addition reaction to form gem-diol in aqueous 
solution, another unexpected peak was also detected as 27857 Da suggesting its 
corresponding hydrated form with water addition (Figure 13D). Since the gem-diol 
formation is a reversible step in equilibrium, it is not supposed to interfere with the 
following bioorthogonal reactions. This suggests that sfGFP-D134AcdK can be 
completely converted to sfGFP-D134AlK by simply reacting with TCEP.  
 
3.7 Methodology investigation on sfGFP 
With the protein product sfGFP-D134AlK at hand, we wanted to test our design 
for the generation of Kme2 at the specific site. After removing all the small molecule 
reactants by dialysis to 200 mM phosphate buffer pH=7, the reductive amination reaction 
was then carried out to convert sfGFP-D134AlK to sfGFP with Kme2 at D134 site (sfGFP-
D134Kme2) by incubating with excess dimethylamine followed by the reduction of 
NaCNBH3.  
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The protein with 10-100 µM final concentration was first incubated with 100 mM 
of dimethylamine for 6 h in order to convert the allysine into imine. The potential cross-
linking between allysine and the native lysine residues can also be removed because the 
imine formation is a reversible process under aqueous condition especially with the 
existence of excess external small molecular amine. After the incubation with alkylamine, 
100 mM final concentration of NaCNBH3 was then added and let to incubate at 37 oC for 
o/n. Different conditions have been tried to optimize the reaction yield. After finishing the 
reaction, the reactant mixture was dialyzed back to phosphate buffer to remove all the 
small molecular reagents. The reaction product was first analyzed by the Western blot 
with pan-anti-Kme2 antibody, which showed a clear band after reaction but not for the 
control without reaction (Figure 14A). An ESI-MS analysis was further applied to confirm 
the conversion from sfGFP-D134AlK to sfGFP-D134Kme2 as 27869 Da (Figure 14B). 
Besides, tandem MS (MS/MS) analysis was also carried out in order to guarantee the site-
specificity of our reactions. The trypsinized sfGFP-D134Km2 fragments were detected to 
show that the Kme2 at the desire position (Figure 14C). 
Additionally, by simply changing dimethylamine to monomethylamine, we also 
made sfGFP with methyllysine (Kme) at its D134 site (sfGFP-D134Kme) via a similar 
reaction procedure. Although we fail to detect sfGFP-D134Kme via Western blot analysis 
due to the lack of a robust pan-anti-Kme antibody, the finally synthesized sfGFP-
D134Kme product successfully gave out a peak at 27855 Da in ESI-MS, which agreed 
with the theoretical mass as 27854 Da (Figure 14D). Notably, some side peaks in Figure 
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14B or Figure 14D are representing some unknown impurities or potential side reactions 
not fully studied. 
 
Figure 14 Methodology investigation of reductive amination on sfGFP-D134AlK (A) 
SDS-PAGE and Western blot of sfGFP-D134AlK after the reductive amination reaction 
with dimethylamine; (B) ESI-MS of the same product after reductive amination reaction; 
(C) MS/MS analysis the same product. Adapted with permission from [87]. 
 
To summarize, both Staudinger reduction and reductive amination can be carried 
out in the phosphate buffer pH 7 at room temperature. Under this physiological condition, 
no protein precipitation or aggregation has been observed, while sfGFP’s fluorescence 
remains without being quenched. These facts again proof that the tandem reactions are 
compatible with natural proteins with native folding states. 
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3.8 The preparation and application of histone with site-specific Kme2 
3.8.1 Background and general design 
After the test of methodology on model protein sfGFP as a water-soluble protein 
with medium size, we moved to the synthesis of histone H3 proteins with site-specifically 
installed Kme2 as a water non-soluble protein purified from the inclusion body. Histone 
dimethylation is a very important epigenetic marker wildly existing over different lysine 
sites, which plays important roles in the regulation of gene expression and transcription 
factor interaction. Lysine-Specific Histone Demethylase 1 (LSD1) belongs to an important 
LSD family enzyme catalyzing the removal of methylation, which is a Flavin adenine 
dinucleotide (FAD)-dependent histone demethylase that selectively targets H3 at K4 and 
K9 positions but inert toward other lysine sites. Therefore, we would like to use different 
methylated H3 generated from our method as probes to study the substrate specificity of 
it. To further confirm and extend the previous reported results, we chose three different 
lysine sites on histone H3 as H3K4, H3K9, and H3K36 to install dimethylation 
modifications. 
 
3.8.2 The expression of H3 with AcdK incorporated 
To start with, AcdK was installed into all the three histone protein precursors at 
specific positions, and the proteins were expressed and purified according to a typical 
histone purification protocol. Plasmids pETduet-H3K4TAG, pETduet-H3K9TAG, and 
pETduet-H3K36TAG constructed by our group was used separately to co-transform E. 
coli BL21(DE3) cells together with the plasmid pEVOL-AcdKRS. The transformed cells 
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were placed on LB agar plates with 100 µg/mL Amp and 34 µg/mL Cm. A single colony 
was picked, and 5 mL LB medium seed culture was set up with 100 µg/mL Amp and 34 
µg/mL Cm. After been inoculated to 250 mL 2YT medium, cells were let to grow at 37 °C 
for 2.5 h until OD600 reached 0.6, followed by the induction of protein expression with the 
addition of 1 mM IPTG, 0.2 % arabinose and 0.5 mM AcdK. After induction for 8 h, cells 
were collected (4000 rpm for 20 min), washed with the lysis buffer (20 mM Tris, 500 mM 
NaCl, 0.1% Triton X-100, and pH 7.5; 20 mL) and resuspended in the lysis buffer. The 
cell pallets were then sonicated under ice bath for 3 times (2 min each time with an interval 
of 10 min) and centrifuged under 6000 rpm for 20 min to remove the supernatant. The 
precipitate was resuspended in a 25 mL wash buffer (20 mM Tris, 500 mM NaCl, and pH 
7.5) inclusion body and washed for 3 times, and the supernatant was removed by 
centrifugation at 6000 rpm for 20 min after each resuspension. The histone solubilization 
buffer (6 M urea, 20 mM Tris, 500 mM NaCl, pH 7.5) was used to finally dissolve the 
inclusion body, and the solution was centrifuged at 10000 rpm for 30 min to remove any 
precipitants. The collected supernatant ran through a 1 mL GE Healthcare Ni-NTA Fast 
Flow column, washed with 50 mL of histone wash buffer (6 M urea, 20 mM Tris, 500 mM 
NaCl, 20 mM imidazole, pH 7.5), and finally eluted by 10 mL histone elution buffer (6 M 
urea, 20 mM Tris, 500 mM NaCl, and pH 7.5). The eluate was collected, concentrated, 
and analyzed by SDS-PAGE followed by the Western blot with anti-H3 antibody (Figure 
15A). 
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3.8.3 The conversion of AcdK to Kme2 in H3 
A similar reaction procedure of Staudinger reduction followed by the reductive 
amination was applied to them for the generation of Kme2 derivatives, respectively. 5 mM 
TCEP was first added to each protein solution for the reduction of the AcdK incorporated 
for 2 h, followed by the addition of 100 mM dimethyllysine and 10 mM NaCNBH3 to 
undergo reductive amination for 8 h. The final protein products were analyzed by SDS-
PAGE with both pan anti-Kme2 antibody and then anti-H3 antibody after stripping-off 
process. The results showed that strong bonds could be detected for all the three histone 
variants only after the reaction steps, while the histone protein amounts remained similar 
(Figure 15B). Additionally, we used western blot by a site-specific antibody for H3K4me2, 
or anti-H3K4me2 antibody, showing a band being detected for the histone product 
H3K4me2 (Figure 15C). The protein products were further applied to MS/MS analysis 
after the trypsinization into fragments, and the site-specificity of the reductive amination 
reaction was confirmed as expected (Figure 15D).  
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Figure 15 The conversion of AcdK to Kme2 in histone H3 (A) SDS-PAGE and Western 
blot for the expression of three H3 varients with AcdK installed; (B) Western blot for the 
AcdK containing H3 after reductive amination with dimethylamine; (C) Western blot of 
H3K4me2. Adapted with permission from [87]. 
 
3.8.4 Substrate preparation for LSD1 assay 
To synthesize H3K4me and H3K9me, reduced H3K4AcdK and H3K9AcdK was 
mixed with 100 mM methylamine and 20 mM NaCNBH3 were added for reductive 
amination for 8 h. The protein products were analyzed by SDS-PAGE and western blot 
with pan anti-Kme2/Kme antibody and anti-H3 antibody. One more thing worth 
mentioning that H3K4me and H3K9me had also been made with the same approach as 
their dimethylated derivatives. However, the products were failing to be detected by the 
pan-anti-Kme antibodies from commercial resources (Result not shown). After the 
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removal of small molecular reactants, all the three dimethyl-H3 products were dialyzed to 
PBS pH=7 and the supernatant as stock solution will be used as substrates of LSD1 to test 
its selective demethylation activity. 
 
3.9 The LSD1 assay over H3K4me2, H3K9me2 and H3K36me2 
We got the pET-15b-LSD1 plasmid containing gene coding LSD1 with His6-tag 
from Professor Zigmund Luka at Vanderbilt University with the permission of using from 
Professor Yang Shi at Harvard University.  
 
3.9.1 The expression of LSD1 
LSD1 expression and purification protocol was adopted from a previous 
publication with some modifications. The plasmid was used to transform E. coli 
BL21(DE3) cells for expression. The cells were grown in 10 ml of LB Medium with 100 
µg/mL Amp for o/n, and then used to inoculate in 1 L 2YT medium with 100 µg/mL Amp 
for expression. When OD600 reached to 1.4-1.6, 0.5 mM IPTG was added to induce the 
protein expression at 25 °C for 7 h. After collecting and washing the cells with cold 100 
mM Tris Buffer pH 7.7, the pallets were stored at -80 °C for further purification.  
Frozen cells were resuspended in 80 ml 100 mM Tris lysis buffer pH 7.5 that 
contained 25 mM MgCl2, 5 mM CaCl2 1 mM PMSF and 10 µg/mL DNase I. After the 
sonication, 14 mM β-mercaptoethanol was provided to the lysis buffer. Then, the cell 
debris was pelleted at 10000 rpm for 40 min. Ammonium sulfate was then added to the 
supernatant to precipitate the expressed LSD1 at 0 °C, and the fraction between 26% and 
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36% saturation was collected. To our experience, ammonium sulfate precipitation was 
preferred comparing with the Ni-NTA affinity purification, due to a relatively low yield 
of the Ni-NTA method. Then a 20 mM Tris (pH 8.1) buffer containing 50 mM NaCl, and 
5 mM β-mercaptoethanol was used to dissolve the protein pellets, and the buffer was 
concentrated. During the redissolving and protein concentration process precipitation of 
LSD1 was observed. After redissolving the pellet, solution was dialyzed against the 
redissolving buffer to remove the remaining ammonium sulfate. FPLC purification was 
further carried out with Q Sepharose anion exchange column with a gradient from 20 mM 
Tris (pH 8.1) buffer A containing 50 mM NaCl and 5 mM β- mercaptoethanol to 20 mM 
Tris (pH 8.1) buffer B with 1 M NaCl and 5 mM β-mercaptoethanol. Fractions at around 
20% of buffer B were collected and confirmed as purified LSD1. SDS-PAGE was used to 
analyze the purified enzyme (Figure 16A). 
 
Figure 16 The LSD1 enzymatic assay over histone with Kme2 installed. (A) SDS-
PAGE of LSD1 expression; (B) LSD1 assay for all three H3 varients. Adapted with 
permission from [87]. 
 
3.9.2 The setting up of LSD1 enzymatic assay 
The setting-up of the enzymatic assay is following a reported literature, in which a 
25 ul reaction solution containing 10 µM FAD and 5 µM LSD1 was added to dimethyl-
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H3 products and incubated for 4 h, respectively. The control reaction was set up without 
the addition of LSD1 but with the same amount of H3 and FAD. Both assays were 
analyzed by SDS-PAGE followed by the western blotting with pan-anti-Kme2 antibody. 
After the stripping-off process, anti-H3 was also applied to confirm the similar amounts 
with or without the enzymatic reaction.  
To summarize, the result showed LSD1 could remove dimethylation at H3K4 
completely and H3K9 mostly but stayed completely inert toward dimethylation at H3K36 
(Figure 16B). 
 
3.10 The expression of p53 and preparation of methylated p53 
3.10.1 Background and general design 
In the previous parts, we have showed the accessibility of our method to small 
insoluble proteins as histone from inclusion body, and medium-sized soluble proteins as 
sfGFP. To push the application of our strategy one step more, we further chose p53 as an 
example of relatively large soluble proteins with multiple cysteine residues to test its 
reliability of mono- or di-methylation installation at specific sites. As a tumor antigen 
transcription factor with 393 amino acids, the mutations on human p53 are associated with 
about 60% of known tumors. It has been reported that p53 undergoes methylation at its 
K372 site, which can activate its transcription activity[91]. Previous research also 
speculated this modification would recruit another important modification enzyme Tip60, 
but no more evidence has been shown. Tip60 is a histone acetyl-transferase with a 
chromodomain to bind methyllysine, and it can acetylate p53 at the position of K120[92]. 
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One of the possible reason is there is no easy way to get a special variant of hp53 with 
Kme or Kme2 at the desire site. Therefore, we wanted to further confirm this suspicion 
via our method to expressed p53 proteins with lysine mono- or di-methylation installed.  
 
3.10.2 The expression of hp53-K372AcdK 
To begin with, p53 with AcdK at K372 site was expressed in E. coli with a similar 
protocol as sfGFP-D134AcdK. We started with the trial of p53 expression in E. coli[93] 
with the plasmid pGEX-2T-GST-hp53 as a gift from Dr. Wei Gu’s group in Columbia 
Unviersity, Due to a very low yield, we decided to fuse a sfGFP protein with a C-terminal 
His6-tag to the C-terminus of hp53, as well as a GST tag at its N-terminus to optimize the 
expression and purification. The PCR amplification of the pGEX-2T-GST-hp53backbone 
was carried out by using two primers (5’-GCC CAA GCT TCC GGG AAT TCA TCG 
TGA CTG AC-3’ and 5’-ACT CGA GCT CGT CTG AGT CAG GCC CTT CTG TC-3’) 
by Phusion DNA polymerase, and the sfGFP with His6-tag was amplified from pBAD-
sfGFP as a gift from Dr. Ryan Mehl’s group in Oregon State University by using two 
primers (5’-ACG CGA GCT CGA GAA CCT GTA TTT CCA AGG TGC CAT G-3’ and 
5’- CCC AAG CTT TTA ATG GTG ATG ATG ATG GTG GCT GCC T-3’). Both 
products after PCR were digested by enzyme combination of HindIII and SacI, and ligated 
together with T4 ligase according to a standard protocol to finally generate plasmid of 
pGEX-2T-GST-hp53-sfGFP-His (Figure 17A). After its sequence confirmation, site-
directed mutagenesis was then carried out to introduce an amber mutation at the K372 site 
of p53. Again, PCR with Phusion DNA polymerase was carried out by using two primers 
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(5’-TAG AAG GGT CAG TCT ACC TCC CGC C-3’ and 5’-GGA CTT CAG GTG GCT 
GGA GTG AG-3’), whose mutated product was phosphorylated and then ligated. The 
finally constructed plasmid pGEX-2T-GST- hp53(K372TAG)-sfGFP-His was sent for 
sequencing to confirm before its expression. Then, pGEX-2T-GST-hp53(K372TAG)-
sfGFP-His, together with pEVOL-AcdKRS, is used to cotransform E. coli BL21(DE3) 
cells to express the p53-K372AcdK. The transformed cells were placed to plate for o/n, 
and single colony was picked and let to grow in the 5 mL 2YT medium. The seed culture 
was then used to inoculate 500 mL of 2YT media. 0.2% arabinose, 1 mM IPTG and 2 mM 
AcdK were added to induce the expression of p53-K372AcdK after OD reached 0.8. The 
expressed protein p53-K372AcdK was purified by Ni-NTA followed by the glutathione 
affinity resin and confirmed by SDS-PAGE (Figure 17B). 
 
Figure 17 The expression of hp53 with AcdK incorporated. (A) the plasmid for the 
expression of hp53; (B) SDS-PAGE for the GST-p53-sfGFP expression.  
 
3.10.3 The conversion of hp53-K372AcdK to Kme2 
After we get purified hp53-K372AcdK at hand, we then carried out the Staudinger 
reduction followed by the reductive amination to generate desired p53 with mono- or 
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dimethylation at K372 site (p53-K372me and p53-K372me2). The purified protein was 
dialyzed to PBS buffer pH 7 to remove any small molecules such as glutathione or 
imidazole. After been incubated with 5 mM TCEP for 2 h, the reductive amination was 
carried out by adding 100 mM monomethylamine or dimethylamine then NaCNBH3 and 
let to stay at 37 oC for 8 h to generate p53-K372me or p53-K372me2, respectively. The 
formation of p53-K372me and p53- K372me2 were both similarly confirmed by western 
blot analysis with the anti-p53-K372me antibody and pan-anti-Kme2 antibody, 
respectively, while the WT p53 was also used as a control with no band detected (Results 
combined in Figure 18).  
 
3.11 The expression of Tip60 and enzymatic assay 
We got the plasmid pCIN4-FH-TIP60 containing the gene for Tip60 fused with 
GST at its N-terminus from Dr. Wei Gu’s group at Columbia University.  
 
3.11.1 The expression of Tip60 
It was used to transform E. coli BL21(DE3) cells. A single colony was picked for 
the setting up of 10 mL seed culture, and the seed culture was used to inoculate 1 L LB 
medium with 100 µg/mL Amp for expression. The transformed cells were grown at 37 oC 
in the LB medium to OD600 around 0.4-0.6. The temperature was changed to 16 oC at that 
moment, and the expression of GST-Tip60 was induced with the addition of 0.7 mM IPTG. 
Next, cells were let to grow continuously at 16 oC for 12 h. After the expression, cells 
were collected and washed with 100 mM Tris lysis buffer pH 7.5 containing 1 mM PMSF 
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and 10 µg/mL DNase I. and sonicated. The cell pallet was stored at -80 oC for purification. 
30 mL 100 mM Tris lysis buffer pH 7.5 with 1 mM PMSF and 10 µg/mL DNase I was 
used to resuspend the cell pallet.  The expressed GST-Tip60 was enriched in glutathione 
resins and eluted by 10 mM glutathione in 50 mM Tris buffer pH 8. The purified protein 
was detected by SDS-PAGE (Figure 18A). 
 
Figure 18 The expression of Tip60 and its enzymatic assay. (A) SDS-PAGE for the 
expression of GST-Tip60; (B) Tip60 assay for the cross-talk between p53-K372 
methylation and acetylation; (C) quantification of cross-talk between p53-K372 
methylation and acetylation. Adapted with permission from [87]. 
 
3.11.2 The setting up of Tip60 enzymatic assay 
Then, we started to test the Tip60 enzymatic assay on all three p53 protein varines 
with or without methylation. Each of the proteins was incubated with Tip60 with the 
existence of acetyl-CoA, followed by the Western blot analysis by an anti-p53-K120ac 
antibody. The result showed that Tip60 catalyzed the acetylation at K120 site for all three 
p53 protein varians, but the acetylation level was significantly enhanced by K372 
methylation (Figure 18B). Quantitative analysis showed both mono- and dimethylation at 
K372 could increase the acetylation at K120 site by 2.5 to 3 folds, and this result provides 
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a first evidence proofing the direct cross-talk of p53 K372 methylation to boost the 
acetylation of p53 K120 by Tip60 (Figure 18C). 
 
3.12 Summary 
To summary, we have demonstrated a novel synthetic method with the 
combination of noncanonical amino acid incorporation via amber suppression with a two-
step bioorthogonal reaction for the expedient preparation of proteins with site-specific 
lysine dimethylation incorporated. Both of the reactions, Staudinger reduction and 
reductive amination, are with site-specificity, convenience, and good bio-compatibility, 
and thus this strategy is applicable for the synthesis of proteins with site-specific lysine 
mono- or di-methylation for further biological studies.  Besides two types of methylation 
mentioned above, this approach is theoretically applicable for any lysine alkylation PTMs, 
such as the rare hypusine found in eukaryotic translation initiation factor protein 5A 
(eIF5A)[94] and  carboxymethyl-lysine (CML) during the metabolic of glycoproteins[95]. 
Since there are only three levels of Lys methylation, it provides less challenging 
for the chemical biologist comparing with Lys acylation discussed in the next part. We 
have showed the accessibility of our method to Kme1 and Kme2, notwithstanding, the 
synthetic study of tri-methyllysine from protein chemistry or amber codon suppression 
point of view is still in abysmal ignorance. Several known examples of protein preparation 
with Lys tri-methylation are from chemical total synthesis. Our AcdK system is not 
applicable to Kme3, because allysine cannot undergo reductive amination with 
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trimethylamine. To develop synthetic approaches for Kme3 can advance our 
understanding with no doubt. 
One more point worth mentioning is that the intermediate allysine itself is the first 
amino acid example containing an aliphatic aldehyde group incorporated into proteins. 
Due to its natural application as a crosslinking reagent in both elastin and collagen[88], it 
can be a good electrophilic center for other protein functionalization for further protein 
chemical biology studies, such as labeling, bioconjugation, solidification, etc. 
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CHAPTER IV 
THE SYNTHETIC INVESTIGATION OF LYSINE ACYLATION 
4.1 Research background 
Among all the proteinogenic amino acids, Lys is the only one carrying a side chain 
amino group. Due to the wide reactivity of aliphatic amine, large numbers of PTMs 
existing on Lys have been discovered, dramatically outnumbering modifications of other 
amino acids[17]. Acylation as another main group of Lys PTMs has been one of the research 
focuses since the discovery of acetylation in histones. Besides acetylation, two other major 
acylation modifications are biotinylation serving as a cofactor for enzymes, and 
lipoylation for membrane protein or secreted protein anchoring on membrane. 
With the recent development of MS/MS and proteomics, an increasing diversity 
and amount of novel Lys PTMs have been found widespread on cytosolic proteins, 
transcription factors and membrane proteins[96]. In order to shed light on the identification 
and functional study of these PTM associated enzymes such as “writer”, “reader” or 
“eraser”, one of the prerequisites is to prepare sufficient amount of native proteins with 
Lys acylation modifications installed at specific sites for further functional studies. Similar 
to Lys methylation, the direct extraction and traditionally recombinant protein expression 
can hardly help with modified POIs. Researchers started with the enzymatic synthesis 
approach[5], nonetheless, the enzymes for most of the novel modifications are unexploded 
and promiscuis.  
Many chemical biology strategies have been developed, whose pros and cons have 
been discussed in part 2, and here comes an abridge edition of introduction. NCL-based 
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protein total synthesis and EPL-based protein semi-synthesis can theoretically generate 
native proteins with natural or non-natural structures. However, chemical synthesis is 
generally limited to 200 AAs, and an HPLC purification step is needed that can cause 
protein to denature. In addition, Cys alkylation and Dha based bioorthogonal reactions can 
generate Lys acylation with S-linked or C-linked mimics[6]. However, the products cannot 
perform the same comparing with the native ones. 
Another approach is to apply amber codon suppression for the incorporation of 
proteins with Lys acylations. Initiated by the Chin group, many simple PTMs have been 
successfully incorporated mainly based on the pyrorolysine system, such as Kac, Kpr, 
Kbu, Kcr, and Khib[8]. Although straightforward and convenient, the selection of a PylRS 
mutant necessary to recognize the particular modified Lys can be tedious and does not 
guarantee to be successful. For instance, Lys with charge-containing side chain such as 
succinylation, or large acylation modifications such as lipidation or Ubiquitination is not 
accessible for the direct incorporation strategy. For instance, all our trials for the 
incorporation of malonyllysine, succinyllysine, and glutaryllysine have turned out to be 
failure in the direct selection of PylRS mutants. And therefore, a more robust and versatile 
strategy is needed for the installation of Lys acylation modifications. 
 
4.2 The design and synthesis of AznL 
4.2.1 The design of AznL 
To solve this problem, we designed a novel strategy by coupling the amber-
suppression-based mutagenesis approach with the traceless Staudinger ligation reaction. 
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Our idea stems from the conversion of azide group to different acylation modifications via 
the traceless Staudinger reaction developed by Bertozzi[97] and modified by Raines[98]. As 
a typical bioorthogonol reaction, traceless Staudinger reaction is capable to protein 
modifications. We then proposed that AznL installed in proteins could undergo a multi-
step reaction with phosphinothioester to finally generate different acylated Lys with their 
native structures. One of the key points for this strategy is that by simply changing the 
phosphinothioester reagents, we can theoretically prepare any types of Lys acylation 
PTMs. We decided to use two examples to show the application of our strategy, the 
acetylation and succinylation[99]. Because acetylation is the most widely existing PTM, 
and succinylation is a newly discovered PTM (Figure 19).  
 
Figure 19 The conversion of AznL to Lys acylation via trassless Staudinger ligation 
 
Interestingly, AznL was not a novel ncAA been incorporated into proteins: 
previous reports have shown the installation of AznL at the methionine positions via the 
residue-replacement strategy[100]. By using this strategy, AznL has been incorporated for 
the study of nascent cellular proteomes. However, this strategy fails to meet our 
requirement of site-specific acyllysine incorporation into specific POIs, due to the global 
substitution of Met among the entire proteome. Therefore, we must apply the amber-
suppression mutagenesis method over PylRS system for the AznL incorporation. 
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4.2.2 The synthesis of AznL 
We initialized our project with the synthesis of AznL (10) from a recently reported 
approach. The synthetic procedure of AznL is a modified version from reference[101], 
which contains four steps. 
 
Figure 20 Scheme for the synthesis of AznL 
 
The synthesis of imidazole-1-sulfonyl azide (11): To the solution of sodium azide (1.31 
g, 20.2 mmol) in anhydrous acetonitrile (30 mL) was added sulfuryl chloride solution (97% 
solution, 1.7 mL, 20.4 mmol) dropwise in an ice bath. The mixture was then stirred at r.t. 
for 8 h. Imidazole (2.78 g, 40.9 mmol) was added into the mixture in an ice bath and the 
afforded solution was stirred at r.t. for another 8 h. The mixture of white slurry was 
partitioned with EtOAc/H2O solution and the organic layer was collected and washed with 
H2O, saturated aqueous NaHCO3, and brine, dried over anhydrous sodium sulfate, and 
filtered. Hydrogen chloride solution (1 M in EtOAc, 12 mL, 12 mmol) was added into the 
filtrate in an ice bath. The afforded white suspension was collected by filtration. The filter 
cake was washed with cold ethanol and EtOAc to afford imidazole-1-fulfonyl azide 
hydrochloride (11) as the desired product (2.2 g, 52%) in white solid. 1H NMR (D2O, 300 
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MHz) δ 8.88 (br, 1H), 7.87 (br, 1H), 7.44 (br, 1H). MS (Free base + H+): Calc. 174.0, Obs. 
174.0362. 
The synthesis of compound methyl N6-((benzyloxy)carbonyl)-N2-(tert-
butoxycarbonyl)-L-lysinate (12): 9.51 g of Boc-Lys(Cbz)-OH (25 mmol, Sigma-Aldrich) 
was dissolved in dry DMF, followed by the addition of K2CO3 (7.26 g, 52.5 mmol). 3.44 
mL of MeI (55 mmol) was gradually added and was let to stir overnight at 80 oC. Then 
the reaction mixture was quenched by the addition of 50 mL H2O and extracted by EtOAc 
30 mL for 3 times. The EtOAc layers were combined, washed with brine, and dried by 
anhydrous Na2SO4. The crude product was then purified by the silica gel flash column 
chromatography (eluted at 10% EtOAc/hexane) to give an oil product (12) (9.6 g, 97%). 
The synthesis of compound methyl (tert-butoxycarbonyl)-L-lysinate (13): The 
solution of Boc-Lys(Cbz)-OMe (12) (3.9 g, 10 mmol) in methanol (100 mL) was added 
palladium on activated carbon (Pd 10%, 0.6 g, 0.6 mmol). The mixture was stirred at r.t. 
with hydrogen bubbled through where the reaction progress was monitored by the TLC 
analysis. The reaction was terminated as the starting protected amino acid on TLC 
disappeared. Then the reaction mixture was filtered through a celite cake packed on a 
Buchner funnel and the flowed-through solution was concentrated under reduced pressure 
to afford colorless oil that was characterized as the desired product (13). The product was 
directly used in the next step without further purification. 
The synthesis of compound (14): Boc-Lys-OMe (13) (0.81 g, 3.1 mmol) from the 
previous step was dissolved in methanol (20 mL). CuSO4 5H2O (6.8 mg, 0.45 mmol) and 
K2CO3 (888 mg, 6.4 mmol) were added into the solution followed by the addition of 
  69 
imidazole-1-sulfonyl azide hydrochloride (11) (650 mg, 3.1 mmol) into the mixture in an 
ice bath. The resulting mixture was stirred at r.t. for 8 h. After addition of EtOAc (10 mL), 
the diluted mixture was then washed with water, saturated aqueous NaHCO3, brine, dried 
over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The 
crude product was further purified by the silica gel flash column chromatography (eluted 
at 5% EtOAc/hexane) to give a clear oil as the desired product (14) (0.7 g, 79%). 1HNMR 
(CDCl3, 300 MHz). δ 5.09 (d, 1H, J = 1.6 Hz), 4.33 (dd, 1H, J = 1.6, 1.8 Hz), 3.77 (s, 3H), 
3.24 (t, 2H, J = 1.2 Hz), 1.99-1.78 (m, 2H), 1.78-1.58 (m, 2H), 1.58-1.32 (m, 12H). 
The synthesis of AznL (10): The solution of ester from the previous step (14) (0.7 g, 2.4 
mmol) in a 1:1 mixture of methanol and THF (24 mL) was added LiOH aqueous solution 
(0.5 M, 24 mL) and stirred at r.t. The reaction progress was monitored by the TLC analysis. 
After 5 h, the spot representing the starting ester on TLC plate disappeared. The reaction 
mixture was then diluted with EtOAc/H2O. After partition, the organic layer was discarded, 
and the aqueous layer was acidified by the addition of 3M HCl until pH was adjusted to 
3-4. The mixture was than extracted with EtOAc twice. The organic layers were combined, 
washed with brine, dried over anhydrous Na2SO4, and concentrated to afford clear sticky 
oil as the desired product which was subjected directly to next step without 
chromatography purification. 
The afforded acid from the previous step (0.8 g, 2.9 mmol) in dioxane (5 mL) was 
added into a HCl solution (4 M in dioxane, 10 mL). The mixture was stirred at r.t. The 
reaction progress was monitored by TLC. After reaction for 3 h, the HCl solution were 
removed under reduced pressure. The afforded oil was dissolved in minimal amount of 
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water, neutralized with aqueous sodium hydroxide and subjected to the ion exchange 
chromatography (Dowex 50WX4) to afford a pale while solid as the desired product AznL 
(10) (150 mg, 36% for two steps). 1H NMR (D2O, 300 MHz). δ 4.17 (t, 1H, J = 1.4 Hz), 
3.35 (t, 2H, J = 1.2 Hz), 2.10-1.79 (m, 2H), 1.78-1.30 (m, 4H). MS (Aznl+H+): Calc. 173.1, 
Obs. 173.1040. (Figure 21) 
 
Figure 21 1HNMR spectrum of AznL 
 
4.3 The selection and screening of AznL 
4.3.1 The selection of AznL 
With enough amount of AznL at hand, we started to identify a specific PylRS 
mutant for AznL. We use the same approach for the generation of a PylRS mutant library 
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with randomization at five active site residues, Y306, L309, C348, Y384, and W411 as 
for AcdK. The DNA library was then cloned into a pBK plasmid.  
A double-sieve selection was carried out with an alternative combination of three 
rounds of positive and two rounds of negative selections, with similar procedure as 
described for AcdK. Final positive selected colonies grew on LB plates with 102 µg/mL 
Cm, 25 µg/mL Kan, 12 µg/mL Tet, and with or without 1 mM AznL to get several mutant 
candidates.  
 
4.3.2 The selection result 
After the selection processes, we again carried out the screening by the 
visualization of GFPUV expression, similar to the AcdK screening. The clones picked after 
the third positive selection was let to grow on LB plate with 102 µg/mL Cm, 25 µg/mL 
Kan, and 12 µg/mL Tet but with or without 1 mM AznL. By measuring the fluorescent 
intensity of GFPUV expression, we can select a best colony from 6 candidates after the 
third positive selection.  
 
Figure 22 Screening of the clones after the third positive selection on LB plates. The 
expression of GFP can be seen on the plate with either 1 mM or 5 mM AznL but not the 
one without. 
 
0 mM 1 mM 5 mM
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From Figure 22, the mutant with the best amber suppression efficiency in E. coli 
was identified as Y306L/C348I/Y384F. The gene mutant corresponding to this PylRS 
mutant noted as AznLRS together with the tRNAPyl was incorporated into pEVOL plasmid 
as pEVOL-AznLRS-PylT and was then used to transform the E. coli BL21(DE3) cells for 
the expression of sfGFP with an amber codon at the D134 site. 
 
Table 1 The mutation sites for the selected PylRS candidates 
MUTANT NO. LABEL MUTATION SITES 
1 AznLRS1 306L309L348I384F411W 
2 AznLRS3 306F309M348M384F411W 
3 AznLRS4 306L309L348V384F411F 
4 AznLRS9 306L309L348L384F411W 
5 AznLRS20 306L309L348I384F411W 
6 AznLRS45 306L309L348I384F411W 
 
4.4 The expression and purification of sfGFP-D134AznL 
4.4.1 The incorporation of AznL 
The selected plasmid pEVOL-AznLRS-PylT together with pBAD-sfGFP-
D134TAG was used to transform E coli BL21(DE3) cells. After picking up the single 
colony for seed culture, cells were grown in the 250 mL LB medium. The expression was 
induced with the addition of with 1 mM IPTG, 0.2 % arabinose, and 5 mm AznL when 
OD600 reached 0.6. After another 8 h growing, the cells were collected with centrifuging 
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(4k 20 min, 4 oC), washed, and fully resuspended with a lysis buffer (50 mM NaH2PO4, 
300 mM NaCl, 10 mM imidazole, pH 7.5). The cells were sonicated under ice/water bath 
for 3 times (4 min each time with an interval of 4 min). Then the cell lysate was centrifuged 
(10k 40 min, 4 oC), and the precipitate was removed. The cell lysate was pour into 1 mL 
Ni SepharoseTM 6 Fast Flow column (GE Healthcare) column, and the flow-through was 
removed. 30 mL of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 
7.5) was used to wash the resin. 12 mL elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM imidazole, pH 7.5) was used to elute the protein. All the eluted fractions were 
collected and concentrated by Amicon Ultra-15 Centrifugal Filter Device (10k MWCO, 
Millipore), and buffer was exchanged to 20 mM phosphate buffer pH 8.5. Fast protein 
liquid chromatography (FPLC) Q-Sepharose anion exchange column was used to further 
purify the sfGFP-D134AznL. Buffer A is 20 mM phosphate pH 8.5 buffer, while buffer 
B 20 mM phosphate pH 8.5 buffer containing 1 M NaCl. The wash with 10 column volume 
(CV) of mobile phase containing 5 % B was followed by the elution of a gradient from 5 % 
to 50 % B in 10 CV mobile phase. The elution samples were collected and again 
concentrated by Amicon Ultra-15 Centrifugal Filter Device (10k MWCO, Millipore). The 
purified protein was confirmed by SDS-PAGE (Figure 23A). The buffer was further 
exchanged to 200 mM phosphate pH 6.5 buffer for the further Staudinger reaction. Then 
the expression yield of full-length sfGFP-D134AznL was about 20 mg/L. The expression 
of WT sfGFP followed the similar procedure without the addition of AznL for induction, 
which will be further used as negative control for the reaction. 
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Figure 23 The expression of sfGFP-D134AznL (A) Coomassie staining of SDS-PAGE 
analysis for sfGFP-D134AznL; (B) ESI-MS of sfGFP-D134AznL; (C) fluorescence 
labeling of sfGFP-D134AznL with azido-dye. Adapted with permission from [99]. 
 
The purified sfGFP-D134AznL was analyzed by ESI-MS showing one major peak 
at 27866 Da and one minor peak at 27735 Da, which agrees with the theoretical molecular 
weights of full-length sfGFP with AnzL installed at its 134 position and its N-terminal 
methionine cleavage product (Figure 23B). Notably, some side peaks in Figure 23B are 
representing some impurities not fully known. 
 
4.4.2 The fluorescence labeling of sfGFP-D134AznL 
The existence of the azide functionality in sfGFP was further confirmed by its 
selective labeling with an alkyne-fluorescein dye. The dye was synthesized and donated 
by Erol Can Vatansever from my lab. The fluorescent labeling of sfGFP-D134AznL was 
carried out according to standard CuAAC procedure[102]. 50 µM of CuSO4 was mixed with 
300 µM of BTTAA, followed by the addition of 500 µM alkyne-fluorescein, and 15 µM 
of sfGFP-D134AznL (all the mentioned concentrations were final concentrations). The 
reaction was initialized by the addition of ascorbate stock solution in PBS to a final 
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concentration of 2.5 mM. The same reaction was carried out for wild type sfGFP. The 
reaction was allowed to be incubated at 25 oC for 4 h followed by the SDS-PAGE analysis. 
After the fluorescence detection, the gel was then stained by Coomassie blue (Figure 23C). 
These combined results validated the specificity of AznLRS toward AznL and the 
selective incorporation of AznL at the amber codon site. 
 
4.5 The expression and purification of Ub-K48AznL, Ub-K48ac, and WT-Ub 
4.5.1 The DNA and protein sequence of Ub 
DNA sequence: Ub-K48TAG-His6 
atgcaaatattcgtgaaaaccctaactggtaagaccatcactctcgaagtggagccgagtgacaccattgagaatgtcaaggca
aagatccaagacaaggaaggcatccctcctgaccagcagaggttgatctttgctgggtagcagctggaagatggacgcaccct
gtctgactacaacatccagaaagagtccaccctgcacttggtccttaggctgagaggaggacatcaccatcaccatcactaa 
 
Protein sequence: Ub-K48AznL-His6 
MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAG(Aznl)QLEDG
RTLSD YNIQKESTLHLVLRLRGGHHHHHH 
 
4.5.2 The expression of Ub-K48AznL 
Although we first tested our AznL installation into sfGFP, we decided to change 
to ubiquitin (Ub) as model proteins for three purposes. Ub as a smaller protein with only 
76 AAs is easier to characterize with MALDI-TOF instead of ESI. The wider solubility of 
  76 
Ub makes it possible for higher percentage of organic solvent during chemical conversions. 
Last but not the least, sfGFP is supposed to be one of the most stable proteins in nature; 
notwithstanding, we sometimes observer an unrecognizable chopping-off of a peptide 
after long time storage with a remaining protein of 26 kDa molecular weight. 
The plasmid of pEVOL-AznLRS-PylT mentioned before was used to co-
transferred E. coli BL21(DE3) cells together with pET-Ub-K48TAG. The cells were 
placed on LB agar plate containing 100 µg/mL Amp and 34 µg/mL Cm. A single colony 
was picked, followed by the growth in a 5 mL LB medium culture for o/n. The overnight 
culture was used to inoculate 250 mL 2YT medium with the same concentration of Amp 
and Cm. Cells grew in a 37 oC shaker for 3 h until OD600 reached 0.6. The protein 
expression was induced by the addition of 1 mM IPTG, 0.2% arabinose, and 5 mM Aznl. 
After another 8 h incubation, the cells were collected (4k 20 min, 4 oC), washed, and fully 
resuspended with PBS. The sonication of cells underwent under ice/water bath for 3 times 
(4 min each time with an interval of 4 min). Then the cell lysate was centrifuged (10k 40 
min, 4 oC), and the precipitate was removed. The supernatant was adjusted pH to 3.5 with 
acetic acid and was incubated for 20 min before centrifuging (10k 40 min, 4 oC). After the 
removal of precipitation, 1 mL Ni SepharoseTM 6 Fast Flow column (GE Healthcare) was 
added to the supernatant, and the mixture was loaded to a column to remove the flow-
through. 50 mL of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 
7.5) was used to wash the resin in three batches. Around 6 mL of elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 7.5) was used to elute the target protein. 
All the eluted fractions were collected and concentrated by Amicon Ultra-15 Centrifugal 
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Filter Device (3.5k MWCO, Millipore), and buffer was exchanged to 200 mM phosphate 
buffer pH 6.5 for the further traceless Staudinger ligation.  
 
4.5.3 The expression of WT-Ub and Ub-K48AcK 
WT Ub with a N-terminal 6×his tag was also expressed in a 1 L 2YT culture with 
the addition of 100 µg/mL Amp. Cells were let to grow in a 37 oC shaker (250 r.p.m.) for 
3 h until OD600 reached 0.6. The protein expression was induced by the addition of 0.8 
mM IPTG as the final concentration and let to incubate for another 8 h. Next, cells were 
collected, sonicated and the protein was purified with a similar procedure as the 
purification of Ub-K48AznL. For the expression of Ub-K48ac, the pEVOL-AcKRS-PylT 
was used instead, while 5 mM of AcK was provided while induction. All the other 
expression and purification steps remain the same as Ub-K48AznL. 
 
4.6 The synthesis of (diphenylphosphino)methanethiol thioesters 
We started with the synthesis of both (diphenylphosphino)methanethiol thioesters. 
The procedure design and synthesis were carried out by Dr. Yadagiri Kurra. 
 
4.6.1 The synthesis of (diphenylphosphino)methanethiol acetate (dPPMT-Ac) 
 
Figure 24 Scheme for the synthesis of dPPMT-Ac 
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The synthesis of Compound (chloromethyl)diphenylphosphine oxide (16): 
Chloromethylphosphonic dichloride (2 g, 12 mmol) was dissolved in freshly distilled THF 
(30 mL). A solution of phenylmagnesium bromide (1.0 M) in THF (24 mL, 24 mmol) was 
added dropwise over 30 min. The resulting mixture was stirred at reflux for 24 h. The 
reaction was then quenched by the addition of water (20 mL), and solvent was removed 
under reduced pressure. The residue was taken up in CH2Cl2 and washed once with water 
(50 mL) and once with brine (50 mL). The organic layer was dried over anhydrous MgSO4 
and filtered, and solvent was removed under reduced pressure. The residue was purified 
by flash chromatography (silica gel, 3% MeOH in CH2Cl2). Phosphine oxide (16) was 
isolated as a white solid in 63% yield. 1HNMR (CDCl3, 300 MHz) δ 7.84-7.79 (m, 4H), 
7.60-7.59 (m, 2H), 7.55-7.49 (m, 4H), 4.05 (d, 2H, J= 4.2 Hz). 31P NMR (CDCl3, 200 
MHz) δ 28.3.  
The synthesis of Compound S-((diphenylphosphoryl)methyl) ethanethioate (17). 
Phosphine oxide 16 (1.2 g, 4.8 mmol) was dissolved in DMF (20 mL). Potassium 
thioacetate (0.829 g, 5.76 mmol) was then added, and the reaction mixture was stirred 
under Ar(g) for 18 h. The solvent was then removed under reduced pressure. The resulting 
oil was purified by chromatography (3% v/v MeOH in CH2Cl2). Phosphine oxide 15 was 
isolated as a clear, colorless oil in 70 % yield. 1HNMR (CDCl3, 300 MHz) δ 7.78-7.74 
(m, 4H), 7.54-7.53(m, 2H), 7.49-7.45 (m, 4H), 3.77 (d, 2H, J = 4.1 Hz), 2.25 (s, 3H). 
13CNMR (CDCl3, 75MHz) δ 193 (d), 132.3, 132.3, 131.5, 131.1, 131.0, 130.7, 128.7, 
128.6, 30.0, 27.6 (d). 31P NMR (CDCl3, 200 MHz) δ 28.9.  
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The synthesis of Compound S-((diphenylphosphaneyl)methyl) ethanethioate 
dPPMT-Ac (15). Phosphine oxide 17 (1.06 g, 4 mmol) was dissolved in anhydrous 
chloroform (10 mL). Trichlorosilane (8 mL, 90 mmol) was added, and the resulting 
solution was stirred under Ar(g) for 72 h. The solvent was then removed under reduced 
pressure. (CAUTION: Excess trichlorosilane in the removed solvent was quenched by the 
slow addition of saturated sodium bicarbonate in a well-ventilated hood.) The residue was 
purified by flash chromatography (silica gel, 3 % v/v MeOH in CH2Cl2). Phosphine 7 
was isolated as a white solid in 65%% yield. 1HNMR (CDCl3, 300 MHz) δ 7.45-7.41 (m, 
3H), 7.40-7.33(m, 7H), 3.52 (t, 2H, J = 1.8, 3.3 Hz), 2.29 (s, 3H). 13CNMR (CDCl3, 
75MHz) δ 193, 136.8, 136.6, 132.8, 132.6, 131.0, 129.1, 128.6, 128.5, 30.2, 25.9 (d). 
31PNMR (CDCl3, 200 MHz) δ -15.33. All the 1HNMR, 3CNMR and 31PNMR spectra of 
dTTMP-Ac are listed at the end of the Chapter (Figure 34). 
 
  80 
4.6.2 The synthesis of (diphenylphosphino)methanethiol succinate (dPPMT-Su) 
 
Figure 25 Scheme for the synthesis of dPPMT-Su 
 
The synthesis of 4-(tert-butoxy)-4-oxobutanoic acid (19): To a mixture of succinic 
anhydride (3 g, 0.3 mol), N-hydroxysuccinimide (1 g, 0.009 mol), and DMAP (0.35 g, 
0.003 mol) in toluene (15 mL) were added tert-butyl alcohol (3.5 mL, 0.037 mol) and Et3N 
(0.009 mol, 1.25 mL). The suspension was refluxed for 24 h. The solution was cooled and 
diluted with EtOAc (15 mL). The reaction mixture was washed with 10% citric acid and 
brine, dried over Na2SO4, and concentrated to give a brown oil. The oil was recrystallized 
with ether and petroleum ether at -20 °C to give the desired product 8 as a white crystal 
(4.0 g, 78%).1H NMR (CDCl3, 300 MHz): δ 2.62 (t, 2H, J = 3.3 Hz), 2.54 (t, 2H, J =1.2 
Hz), 1.44 (s, 9H), 13CNMR (CDCl3, 75MHz): 178.5, 171.4, 81.0, 30.0, 29.1, 28.0. 
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The synthesis of phosphine oxide diphenylphosphine oxide (20): A 250 mL round 
bottom flask equipped with an addition funnel was evacuated and Ar filled for 3 times, 
charged with 50 mL 1 M PhMgBr/THF (71.7 mL, 71.7 mmol, 3.3 eq.), and the solution 
cooled to 0 oC under Ar. A solution of 3 g diethylphosphite (21.7 mmol, 1.0 eq) in 10 mL 
THF was then added dropwise over 15 min. The mixture was let stand for 15 min at 0 oC, 
then the bath was removed, and the mixture was stirred for two hours at ambient 
temperature and then cooled again to 0 oC. 75 mL 0.1 N HCl was added dropwise over 20 
min, then 75 mL MTBE was added, and the mixture was filtered through a celite pad 
followed by washing the pad with CH2Cl2. The filtrate phases were separated, and the 
organic phase combined with the first organic phase, dried by MgSO4, and the solvents 
removed in vacuo. The residue was purified by flash column chromatography to give 20 
(3.0 g, 70%) 1H NMR (500 MHz, CDCl3) δ: 8.87 (s. 1H), 7.73-7.50 (m, 4H), 7.49-7.45 
(m, 6H). 13C NMR (75 MHz, CDCl3) δ: 132.5, 132.5, 130.6, 130.5, 128.9, 128.7. 
31PNMR (500MHz, CDCl3): δ: 21.4. 
The synthesis of Phosphine-Borane Complex (21): A solution of phosphine oxide 20 
(2.00 g, 9.90 mmol) in anhydrous CH2Cl2 (30 mL) was added dropwise slowly to a 
solution of DIBAL (1 M in CH2Cl2, 39.6 mL, 39.6 mmol) under Ar(g) in a flame-dried 
three-neck round-bottom flask. The resulting solution was stirred for 20 min, and then 
cooled to 0 °C with an ice bath. The solution was then diluted with CH2Cl2 (30 mL), and 
a sparge needle of Ar(g) was allowed to blow through the solution for 5 min. A solution 
of 2 N NaOH (20 mL) was added dropwise slowly to the reaction mixture (Caution of gas 
evolution!) followed by a saturated solution of Rochelle’s salt (20 mL) to dissipate the 
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emulsion that forms. The resulting biphasic solution was transferred to a separatory funnel, 
and the organic layer was separated, dried over anhydrous MgSO4, filtered, and 
concentrated under reduced pressure. (1.8 g 100%). Borane-dimethylsulfide (3 M solution 
in THF, 6.45 mL, 19.35 mmol) was added to a round-bottom flask with freshly distilled 
THF (20 mL). To this solution, the crude diphenylphosphine (1.8 g, 9.67 mmol) was added 
in one portion. The solution was stirred under nitrogen for 2 h and was quenched slowly 
with ice (~10 g). The resulting solution was diluted with brine (20 mL) and extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 10 mL), 
dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure 
and the crude oil was purified by flash chromatography to yield 21 (1.1 g, 60% yield). 1H 
NMR (500 MHz, CDCl3) δ: 7.73-7.66 (m. 4H), 7.54-7.45 (m, 6H). 31PNMR (500MHz, 
CDCl3): δ: 22.1. 
The synthesis of diphenylphosphino(borane)methane alcohol (22): 21 (1.0 g, 5.0 mmol) 
was dissolved in a mixture of aqueous formaldehyde (37% w/w, 5 mL) and THF (10 mL). 
To this solution, KOH (700 mg, 10.0 mmol) was added. The solution was stirred for 2 h, 
and the volatile solvent was removed under reduced pressure. The resulting aqueous 
solution was extracted with EtOAc (3 x 10 mL), washed with brine (1 x 10 mL), dried 
over sodium sulfate, filtered, and the solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography to yield 22 as a colorless liquid (0.861 
g, 70%). 1H NMR (CDCl3, 300 MHz): δ 7.76-7.72 (m, 4H), 7.55-7.53(m, 2H), 7.50-7.47 
(m, 4H), 4.45 (s, 3H), 2.05 (br, 1H), 1.46-0.52 (m, 3H); 13C NMR (CDCl3, 75 MHz) δ 
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132.8, 132.7, 131.7, 131.7, 129.0, 128.9, 126.9, 126.4, 60.5, 60.2. 31P NMR (CDCl3, 300 
MHz) δ 25.7. 
The synthesis of diphenylphosphino(borane)methyl methanesulfonate (23): 22 (1.1 g, 
5.0 mmol) was dissolved in freshly distilled methylene chloride (10 mL), followed by 
addition of trimethylamine (1.4 mL, 10.1 mmol). The solution was cooled to 0 °C with 
ice-water bath. To this solution, methanesulfonyl chloride (580.0 µL, 7.4 mmol) was 
added dropwise. The solution was stirred under nitrogen for 15 h. The solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography 
(3:1 Hexane:EtOAc) to yield 23 as a white solid (1.0 g, 3.9 mmol, 70%). 1H NMR (CDCl3, 
300 MHz) δ 7.76-7.72 (m, 4H), 7.59-7.57 (m, 2H), 7.53-7.49 (m, 4H), 4.91 (d, 2H, J=1.2 
Hz,), 2.89 (s, 3H). 31P NMR (CDCl3, 300 MHz) δ 18.2. 
The synthesis of diphenylphosphino(borane)methanethiol acetate (24): Potassium 
thioacetate (0.737 g, 5.12 mmol) was added to a solution of 12 (0.8 g, 2.58 mmol) in 
anhydrous DMF (15 mL) under Ar(g). The resulting solution was stirred overnight at room 
temperature, after which the solvent was removed under reduced pressure. The residue 
was dissolved in EtOAc (20 mL), and the resulting solution was washed with water and 
brine. The combined organic extracts were dried over anhydrous MgSO4, filtered, and the 
solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography (4:1 hexanes:ethyl acetate) to yield 24 as a white solid (0.487 g, 65%). 
1H NMR (CDCl3, 300 MHz) δ 7.71-7.67 (m, 4H), 7.51-7.49 (m, 2H), 7.46-7.43 (m, 4H), 
3.72 (d, 2H, J =4.5 Hz), 2.24 (s, 3H). 13C NMR (CDCl3, 75 MHz) δ 193.2, 132.4, 132.4, 
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131.8, 131.7, 128.9. 128.8, 127.8, 127.3, 30.0, 23.9 (d).31P NMR (CDCl3, 300 MHz) δ 
19.0 (d). 
The synthesis of diphenylphosphino(borane)methanethiol-mono-t-butyl succinate 
ester (26): 24 (0.4 g, 1.38 mmol) was dissolved in freshly distilled methanol (5 mL), 
followed by addition of NaOH (66 mg, 1,66 mmol). After stirring under nitrogen for 10 
min, the solution was neutralized by 1 N HCl, and was extracted with EtOAc (2 × 30 mL). 
The combined organic layers were washed by brine (1 × 10 mL), dried over sodium sulfate, 
filtered, and concentrated under reduced pressure to obtain 25. The crude thiol of 25 was 
dissolved in freshly distilled CH2Cl2 (10 mL), followed by the addition of 19 (0.352 g, 2.0 
mmol), 1,3-dicyclohexylcarbodiimide (0.5 g, 2,42 mmol), and cat. N,N’-dimethyl-4-
aminopyridine. The solution was stirred under nitrogen for 4 h, and the solution was 
filtered through a pad of celite. The solvent was removed under reduced pressure. The 
crude product was purified by flash chromatography (3:1 Hexane:EtOAc) to yield the 
thioester 26 as a colorless oil (0.33 g, 60%). 1H NMR (CDCl3, 300 MHz) δ 7.72-7.68 (m, 
4H), 7.53-7.45 (m, 6H), 3.75 (d, 2H, J = 3.9 Hz), 2.75 (t, 2H, J = 3.9 Hz), 2.48 (t, 2H, J = 
3.3 Hz), 1.43 (s, 9H). 13C NMR (CDCl3, 75 MHz) δ 195 (d), 170.6, 132.5, 132.4, 131.8, 
131.7, 128.9, 128.8, 127.8, 127.3, 38.4, 30.3, 28.0, 23.5 (d). 31PNMR (CDCl3, 75 MHz) 
δ 41.5. 
The synthesis of diphenylphosphinomethanethiol-mono-t-butyl succinate ester (27): 
Phosphine-borane 26 (0.25 g, 0.621 mmol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) 
(0.139 g mg, 1.24 mmol) was dissolved in freshly distilled toluene (2 mL). The solution 
was submerged in an oil-bath pre-heated to 60 °
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for 1 h. After cooling to room temperature, the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography (4:1 Hexane:EtOAc) 
under nitrogen to yield 27 as a colorless oil (0.168 g, 70%). 1H NMR (CDCl3) δ 7.46-7.43 
(m, 4H), 7.37-7.36 (m, 6H), 3.55 (d, 2H, J = 2.1 Hz), 2.80 (t, 2H, J = 4.2 Hz), 2.55 (t, 2H, 
J = 4.5 Hz), 1.45 (s, 9H). 13C NMR (CDCl3, 75MHz) δ 196 (d), 170.9, 136.8, 136.7, 
132.8, 132.6, 129.1, 128.6, 128.5, 80.9, 38.5, 30.5, 28.0, 25.6, 25.4 (d). 31P NMR (CDCl3, 
300 MHz) δ - 15.3. 
The synthesis of diphenylphosphinomethanethiol-succinic acid (18): To a solution of 
ester 27 (0.15 g, 0.45 mmol) in CH2Cl2 (3 mL) was added TFA (3 mL). After being stirred 
at r.t. for 1 h, the reaction mixture was concentrated in vacuum to give a colorless oil 18 
as the final product (0.098 g, 73%). 1HNMR (CD3OH, 300 MHz) δ 7.44-7.42 (m, 4H), 
7.41-7.36 (m, 6H), 3.56 (d, 2H, J=2.4Hz), 2.82 (t, 2H, J =4.2Hz), 2.58 (t, 2H, J=4.2Hz). 
13CNMR (CDCl3,75 MHz) δ 196.9 (d), 174.0, 136.8, 132.5, 132.3, 128.8, 128.3, 128.2, 
37.8, 28.4, 24.8 (d). 31P NMR (CDCl3, 300 MHz) δ - 14.9. All the 1HNMR, 3CNMR and 
31PNMR spectra of dTTMP-Su are listed at the end of the Chapter (Figure 35). 
 
4.7 Methodology investigation on Ub-K48AznL  
4.7.1 Reaction setting up of dPPMT-Ac 
With the synthesized diphenylphosphinothioester reagents at hand, we started to 
investigate our methodology over Ub-K48AznL as our model protein in a time-dependent 
view (Figure 26A). Because the traceless-Staudinger ligation reaction has been known as 
a multi-step reaction with a complicated mechanism[103], we decided to elongate the 
  86 
reaction to two days. Around 5 mg of dPPMT-Ac was dissolved in pure DMSO to a final 
concentration of 100 mM as the stock solution. The Ub-K48AznL, wild type Ub, and Ub-
K48ac were all prepared in 200 mM phosphate buffer pH 6.0 with concentrations between 
10 and 20 µM. The phosphine reagents in DMSO stock solution were slowly added into 
the Ub-K48AznL (~20 µM) solution to reach to a final concentration of 5 mM. Reactions 
were gently pipetted to make solutions well mixed, and potential precipitations were 
removed by centrifuging. Then, the reaction mixture was let to incubate at 37 oC for one 
to two days. A same amount of WT Ub with the addition of same amount of phosphine 
reagent was used as the negative control, while Ub-K48ac without phosphine was used as 
the positive control. Samples of reaction mixtures were taken 12 h intervals, followed by 
the adidition of 5 µL azidoethanol to each sample as a quencher, and then diluted with 10× 
PBS buffer. The quenched samples were centrifuged at 14K for 5 min to remove any 
precipitations, dialyzed over 10× PBS buffer for 3 times, and then concentrated to small 
volumes.  
 
4.7.2 Reaction characterization  
Different samples were taken with a time interval of 12 h. After mixing with a SDS 
loading buffer, final samples were applied to two 15 % SDS-PAGE gel separately. The 
first gel was stained with Coomassie blue and then directly applied for imaging. The 
second gel was transferred to a nitrocellulose membrane for Western blot analysis. The 
pan anti-Kac antibody from PTM BioLabs Inc. was first applied and then followed by 
blotting with secondary antibody and visualization. The result showed that an increased 
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acetylation level with the elongation of reaction time (Figure 26B). The reaction is not 
close to completion until at the time point of 48 h, since the acetylation level was not 
significantly higher than the one at 36 h. The negative control WT Ub did not have any 
detectable acetylation band, in contrast to the intense acetylation band for the Ub-
K48AznL reaction group.  
We further applied MALDI-TOF-MS to exam the product from Ub-K48AznL to 
its corresponding acetylation product Ub-K48ac. Reaction sample after 48-h incubation 
was applied to Ziptip (Reversed-phase, pipette tips for sample preparation, Millipore 
Corporation) sample preparation, followed by sending to MALDI-TOF-MS (Applied 
Biosystems Voyager-DE STR) with data explorer software from the same company. The 
spectrum showed two main peaks at 9386 and 9428Da, suggesting the corresponding 
traceless Staudinger ligation product Ub-K48ac and a side product Ub-K48 with native 
Lys, whose theoretical molecular weights are 9387 and 9429 Da, respectively (Figure 
26C). The generation of side-product will be further discussed in the next part, while some 
other peaks are representing some unknown impurities or potential side reactions not fully 
studied. We can see from the quantification that the desired product Ub-K48ac has slightly 
higher percentage over the by-product WT Ub in the final product mixture.  
To confirm the site-specificity of the reaction, the 48-h reaction product was 
trypsinized and applied to the MS/MS analysis. The K48ac-containing peptide fragment 
could be clearly observed, indicating the acetylation at K48 site (Figure 26D). 
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Figure 26 Methodology examination on UbK48AznL (A) the structure of dPPMT-Ac; 
(B) the gel-based time dependent assay for Lys acetylation; (C) MALDI-TOF of 
UbK48AznL after traceless Staudinger acetylation reaction for 48 h; (D) MS/MS analysis 
of UbK48AznL after traceless Staudinger acetylation reaction for 48 h. Adapted with 
permission from [99]. 
 
4.7.3 Result analysis  
Although as thioester, the phosphinothioester did not show much non-specific 
interaction with native Lys to generate Kac everywhere, due to the nature of aliphatic 
thioester. From another point of view, although traceless Staudinger ligation owns a very 
slow kinetics, the Western blot result together with MS/MS spectum shows a much slower 
non-specific intermolecular S-to-N acyl transfer between dMMPT-Ac and free Lys on Ub. 
For the generation of native Lys peak, we need to consider about the mechanism 
of traceless-Staudinger ligation reaction, because it has been noted that phosphinothioester 
can reduce azide back to amine due to its intrinsic reductive nature[104]. 
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Figure 27 Mechanism of traceless Staudinger ligation reaction on proteins 
 
To start with, the phosphine (III) of the phosphinothioester attacks the terminal 
azide nitrogen atom, and with the leaving of the nitrogen gas, a key N-P ylide intermediate 
forms. The nitrogen with partial negative charge will attack the adjacent carbonyl group 
of the thioester to form an amide bond, which can undergo water attacking to give out the 
final acylated product (Figure 27). However, the N-P ylide intermediate can directly 
undergo hydrolysis to release native Lys side chain. Therefore, the overall result for the 
side reaction is to reduce the azide group back to an amino group, which shares exactly 
the same process as other trialkylphosphine reagents such as TCEP. Although this is 
inevitable process, theoretically we should be able to separate the Lys from the acylated 
products by using an immunoaffinity column with acylated Lys specific antibody. But for 
this research, we did not take further efforts for the product purification, because the native 
Lys will not give out any signal for enzymatic deacylation assay. 
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4.8 Methodology examination and optimization for Lys succinylation  
4.8.1 Reaction test of dPPMT-Su 
Encouraged by the result of acetylation, we decided to move ahead to succinylation, 
with the synthesized dPPMT-Su at hand (Figure 28A). Around 5 mg of dPPMT-Su and 
was dissolved in DMSO solution to reach 100 mM as stock solution. The Ub-K48AznL 
and WT Ub in 200 mM phosphate buffer pH 6.0 with was added with the phosphine 
reagents in DMSO stock solution slowly to reach to a final concentration of 5 mM. 
Reactions were gently pipetted to make solutions well mixed and then let to stand at 37 
oC. A same amount of WT Ub with the addition of same amount of phosphine reagent was 
used as the negative control. Samples of reaction mixtures were taken 12 h intervals, 
followed by mixturing with 5 µL azidoethanol to each sample as a quencher. The quenched 
samples were centrifuged at 14K for 5 min to remove any precipitations, dialyzed over 
10× PBS buffer for 3 times, and then concentrated to small volumes. The samples were 
mixed with a SDS loading buffer, and then applied to two 15 % SDS-PAGE gel separately. 
The first gel was stained with Coomassie blue and then directly applied for imaging. The 
second gel was transferred to a nitrocellulose membrane for Western blot analysis. The 
pan anti-Ksu antibody from PTM BioLabs Inc. was first applied and then followed by 
blotting with secondary antibody and visualization. The result showed that a band with 
increased intensity with the elongation of reaction time. However, the negative control 
WT Ub showed a strong succinylation band as well after mixing with dPPMT-Su (Figure 
28B). 
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Figure 28 Methodology examination and optimization of Lys succinylation (A) the 
structure of dPPMT-Su; (B) the gel-based time dependent assay for Lys succinylation; (C) 
the potential side reaction of non-specific Lys succinylation; (D) the structure of dPPMT-
NB-Su. Adapted with permission from [99]. 
 
4.8.2 Result analysis 
From the result above, we found that the dPPMT-Su showed a very strong non-
specific acylation reaction to provide succinylation over native Lys residues. The first 
explanation comes from an increased electrophilicity of the succinyl thioester due to the 
electrowithdrawing effect of the second carboxyl group comparing with the acetyl group. 
However, even though the activity of the thioester bond increases, we cannot expect such 
high level of by product formation.  
Then we proposed another potential mechanism. Different from the dPPMT-Ac, 
the dPPMT-Su owns a free carboxyl group on the side chain of succinyl part. This free 
carboxyl group can attack the thioester warhead followed by the hydrolysis to generate 
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succinyl anhydride. This reaction has been shown to undergo in aqueous condition with 
neutral pH, especially during long-time storage. Succinic anhydride is a very active 
compound that can label Lys without any selection (Figure 28C). One simple way to 
overcome it is to provide an orthogonal protecting group over the free carboxyl group, 
which can be efficiently removed after traceless Staudinger ligation reaction. Therefore, 
we decided to choose the O-nitrobenezyl photocaging group (Figure 28D). 
 
4.8.3 The synthesis of photocaged (diphenylphosphino)thiol succinate 
We have decided to use the O-nitrobenezyl protecting group (NB) to protect the 
free carboxyl group, and thus we labeled our new dPPMT-Su edition as dPPMT-NB-Su.  
 
Figure 29 Scheme for the synthesis of dPPMT-NB-Su 
 
The synthesis of 4-((2-nitrobenzyl)oxy)-4-oxobutanoic acid (29): O-nitrobenzyl 
alcohol (4.0 g, 26.12 mmol), succinic anhydride (5.23 g, 52.24 mmol), and DMAP (1.60 
g, 13.06 mmol) were dissolved completely in dried CHCl3 (86 mL) and refluxed under a 
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nitrogen atmosphere for 24 h. After removing partially CHCl3 under reduced pressure, the 
mixture was washed three times with 10 % HCl and then extracted with saturated NaHCO3 
solution. The basic aqueous phase was washed with ether and acidified to pH 5.0 with 10% 
HCl. The white solid precipitate was collected and dried in vacuo at 40 °C overnight to 
give 29 (6.08 g, 92%). 1H NMR (CDCl3): δ 8.09 (dd, 1H, J = 0.4, 1.8 Hz), 7.66−7.59 (m, 
2H), 7.50-7.47 (m, 1H), 5.55 (s, 2H), 2.76-2.72 (m, 4H). 
The synthesis diphenylphosphino(borane)methanethiol-2-nitrobenzylsuccinate ester 
(30): 25 (0.4 g, 1.38 mmol) from the synthesis of dPPMT-Ac was dissolved in freshly 
distilled methanol (5 mL), followed by addition of NaOH (66 mg, 1,66 mmol). After 
stirring under nitrogen for 10 min, the solution was neutralized by 1 N HCl, and was 
extracted with EtOAc (30 mL) twice. The combined organic layers were washed by 10 
mL brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The crude thiol (14) was dissolved in freshly distilled CH2Cl2 (10 mL), followed by 
addition of 18 (0.408 g, 1.58 mmol), DCC (0.4 g, 0.97 mmol), and cat. N,N’-dimethyl-4-
aminopyridine. The solution was stirred under nitrogen for 4 h, and the solution was 
filtered through a pad of celite. The solvent was removed under reduced pressure. The 
crude product was purified by flash chromatography (3:1 Hexane:EtOAc) to yield the 
thioester 30 as a colorless oil (0.432g, 65%). 1HNMR (CDCl3, 300MHz) δ 8.10 (t, 1H, J 
= 1.2 Hz), 7.85-7.83 (m, 1H), 7.82-7.80 (m, 4 H), 7.69-7.43 (m, 8H), 5.61 (s, 2H), 3.73 (d, 
2H, J = 1.2 Hz), 2.85 (t, 2H, J = 4.2 Hz), 2.67 (t, 2H, J = 4.2 Hz). 13CNMR (CDCl3, 75 
MHz) δ 195 (d), 170, 147.4, 133.9, 132.4, 132.4, 132.0, 131.8, 131.4, 131.3, 129.0, 128.9, 
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128.9, 128.8, 128.7, 128.6, 127.6, 127.2, 125.0, 63.3, 37.9, 29.0, 23.6 (d). 31P NMR 
(CDCl3, 300 MHz) δ 40.4; 
The synthesis of diphenylphosphinomethanethiol-2-nitrobenzylsuccinate ester (28): 
30 (0.2 g, 0.41 mmol) and DABCO (0.139 g mg, 1.24 mmol) was dissolved in freshly 
distilled toluene (2 mL). The solution was submerged in an oil-bath pre-heated to 60 °C. 
The solution was stirred under argon for 1 h. After cooling to r.t., the solvent was removed 
under reduced pressure. The crude product was purified by flash chromatography (3:1 
Hexane:EtOAc) under nitrogen to yield 28 as a colorless oil (0.15 g, 80%). 1HNMR 
(CDCl3) δ 8.10 (dd, 1 H, J = 0.6, 4.8 Hz), 7.66-7.63 (m, 2H), 7.46-7.42 (m, 5H), 7.36-
7.34 (m, 6H), 5.52 (s, 2H), 3.53 (d, 2H, J= 2.1 Hz), 2.89 (t, 2H, J = 4.2 Hz), 2.73 (t, 2H, J 
= 4.2 Hz). 13CNMR (CDCl3, 75 MHz) δ 196 (d), 171. 2, 147.4, 136.7, 136.6, 133.8, 132.8, 
132.6, 131.9, 129.2, 128.9, 128.8, 128.7, 128.6, 128.5, 120.0, 63.2, 38.1, 29.1, 25.7 (d). 
31P NMR (CDCl3, 300 MHz) δ - 15.1. All the 1HNMR, 13CNMR and 31PNMR spectra of 
dTTMP-NB-Su are listed at the end of the Chapter (Figure 36). 
 
4.8.4 Reaction test of photocaged succinyl diphenylphosphinothioester 
With dPPMT-NB-Su at hand, the reaction setting up is exactly the same as the 
non-protected edition, which WT-Ub was still used as a negative control (Figure 30A). 
After incubated under 48 h, the reaction mixture was quenched. The quenched samples 
were treated with UV light at 365 nm wavelength for 30 min on ice bath. After mixing 
with a SDS loading buffer, final samples were applied to two 15 % SDS-PAGE gel 
separately. The first gel was stained with Coomassie blue and applied for imaging. The 
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second gel was then transferred to nitrocellulose membrane for the Western blot analysis. 
The pan-anti-Ksu antibody from PTM BioLabs Inc. was first applied and then followed 
by the blotting with secondary antibody and visualization. To our surprise, the control 
reaction with wild type Ub did show detectable lysine succinylation in a very low level 
(Figure 30B). Although we did not observe any side reaction with dPPMT-Ac, it is 
possible that the electronwithdrawing inductive effect of the photocaged carbonyl group 
in dPPMT-NB-Su actually still plays a role in the activation of its thioester. Therefore, the 
non-specific S-to-N acyl transfer becomes more favored, and a succinylation over native 
Lys side chain was then observed.  
To further confirm the formation of Ub-K48su, the sample after 48-h incubation 
and UV treatment was treated with Ziptip as mentioned above and then sent for MALDI-
TOF-MS analysis. In the spectrum, two major peaks showed up as one at 9388 Da and 
another at 9488 Da, agreeing with the MW of the corresponding WT Ub and Ub-K48su, 
respectively (Figure 30C). Interestingly, the side product with native Lys is a little more 
abundant than the desire product of Ub-K48su, which does not agree with the increased 
electrophilicity of the succinyl carbonyl group. We explain it as an increased steric effect 
interrupting the attacking of the N-P yelid to the thioester, due to the introduction of the 
photo caging group at the side chain carbonyl group. Notably, some side peaks in Figure 
30C are representing some potential side reactions not fully studied. 
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Figure 30 Methodology examination of Lys succinylation via dPPMT-NB-Su. (A) the 
structure of dPPMT-NB-Su; (B) the gel-based time dependent assay for Lys succinylation; 
(C) MALDI-TOF of UbK48AznL after traceless Staudinger succinylation reaction for 48 
h; (D) MS/MS analysis of UbK48AznL after traceless Staudinger succinylation reaction 
for 48 h. Adapted with permission from [99]. 
 
Next, the final product was trypsinized and sent for MS/MS analysis to confirm 
the succinylation at the K48 position. A peptide fragment containing K48su was 
detected, showing the succinylation at K48 (Figure 30D).  
 
4.9 The expression of histone H3-K4Aznl, WT-H3, and H4-His6-SUMO  
4.9.1 The DNA and protein sequence of histone H3 
DNA sequence: WT-H3(C110A): 
gctcgcaccaaacagactgctcgtaagtccactggcggtaaagcgccgcgtaaacagctggcaaccaagatggcgcgtaaa
agcgctccagctactggcggcgtgaagaagccgcaccgttatcgcccgggtactgtggctctgcgtgaaatccgccgctacc
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agaaaagcaccgaactgctgattcgcaaactgccatttcaacgtctggttcgcgaaattgctcaggatttcaaaaccgacctgcg
cttccagtctagcgctgtgatggcactgcaagaggcgtctgaggcatatctggttggcctgttcgaagataccaacctgtgcgca
atccatgcaaagcgtgtaaccattatgccgaaagacatccaactggctcgtcgtatccgtggtgagcgtgcgtga 
 
Protein sequence: His6-TEV-H3-K4AznL(C110A): 
MGSSHHHHHHSQDPENLYFQART(AznL)QTARKSTGGKAPRKQLATKAARKSA
PATGGVKKPHRYRPGTVALREIRRYQKSTELLIRKLPFQRLVREIAQDFKTDLRF
QSSAVMALQEASEAYLVGLFEDTNLAAIHAKRV TIMPKDIQLARRIRGERA 
 
4.9.2 The purification of H3K4AznL 
Encouraged by the acetylation and succinylation result on Ub, we decided to move 
ahead to histone succinylation and other higher structures such as tetramer or nucleosome. 
In other methodology for PTM study, different histone variants with site-specific Lys 
PTMs must be prepared separated and then assembled to tetramer. By combine our AznL 
incorporation and traceless Staudinger ligation reaction, we can install a large variety of 
Lys acylation modifications into proteins by simply changing the acyl group in the 
phosphinothioester reagent we use, in a “one-size-fits-all” manner. And we started our 
methodology investigation over histone H3 with amber codon at K4 position.  
The plasmid of pEvol-PylT-AznLRS mentioned before was used together with 
pETduet-H3K4TAG to co-transform E. coli BL21(DE3) cells. The cells were placed on 
LB agar plate containing 100 µg/mL Amp and 34 µg/mL Cm. A single colony was picked, 
followed by the growth in a 5 mL LB medium for o/n. The overnight culture was further 
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inoculated into a 250 mL 2YT medium with the same concentration of Amp and Cam. 
Cells were grown in a 37 oC shaker (250 r.p.m.) for 3 h until OD600 reached 0.6. The 
protein expression was induced by the addition of 1 mM IPTG, 0.2 % arabinose and 5 mM 
AznL. After another 8 h incubation, the cells were harvested by centrifugation (4k 20 min, 
4 oC), washed, and fully resuspended in a 40 mL lysis buffer (20 mM Tris-HCl, 500 mM 
NaCl, 0.1% Triton X-100, 0.1% NaN3, pH 7.5). The sonication of cells underwent under 
ice/water incubation for 3 times (4 min each time with an interval of 4 min). Then the cell 
lysate was centrifuged (6k 20 min, 4 oC), and the supernatant was removed. The precipitate 
was washed with 30 mL lysis wash buffer (20 mM Tris-HCl, 500 mM NaCl, 0.1% NaN3, 
pH 7.5) twice. The supernatant was removed again, and the inclusion body was dissolved 
in 6 M urea histone solublization buffer (6 M urea, 20 mM Tris, 500 mM NaCl, pH 7.5). 
The solution was centrifuged at 10 k for 40 min to remove all the precipitate. The 
supernatant was loaded to 1 mL Ni SepharoseTM 6 Fast Flow column (GE Healthcare) and 
the flow-through was removed. 15 mL of wash buffer (6 M urea, 20 mM Tris, 500 mM 
NaCl, 20 mM imidazole, pH 7.5) was used to wash the protein-bound resin in three batches. 
Around 6 mL elution buffer (6 M urea, 20 mM Tris, 500 mM NaCl, pH 7.5) was used to 
elute the target protein. All the eluted fractions were then collected and concentrated by 
Amicon Ultra-15 Centrifugal Filter Device (3 k MWCO, Millipore), and buffer was 
exchanged to histone solublization buffer for the further traceless Staudinger ligation 
reaction.  
Both WT histone H3 and H4 proteins with N-terminal his6 tags were expressed in 
a 1 L 2YT media with the addition of 100 µg/mL Amp. Cells were let to grow in a 37 oC 
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for 3 h until OD600 reached 0.6. The protein expression was induced by the addition of 0.8 
mM IPTG. After incubated for 8 h, cells were collected and sonicated. The further 
purification processes were the same as the purification of H3-K4AznL. 
 
4.10 General process of time-dependent traceless-Staudinger ligation reaction of 
H3K4AznL  
4.10.1 The setting up of time-dependent Succinylation assay 
The setting up of traceless Staudinger ligation reaction for H3K4AznL was similar 
to the setting up of Ub, except for H3K4su, the degassed histone solublization buffer with 
6 M urea at pH 6.0 instead of a PBS buffer was used when it was necessary. The 
photocaged phosphine reagents dPPMT-NB-Su in DMSO stock solution were added to 
reach to a final concentration of 5 mM. Reactions were gently pipetted to make solutions 
well mixed and then let to incubate at 37 oC. A same amount of WT H3 with the addition 
of same amount of phosphine reagent was used as the negative control. Samples of 
reaction mixtures were taken with a 12 h interval, followed by the addition of 5 µL of 
azidoethanol to each sample as the quencher. The quenched samples were centrifuged at 
14K for 5 min to remove any precipitations, dialyzed over PBS with 6 M urea for 3 times, 
and then concentrated to small volumes. The dialyzed samples were treated with UV light 
at 365 nm for 30 min and applied to two 15 % SDS-PAGE gel separately. The first gel 
was stained with Coomassie blue and applied for imaging. The second gel was further 
transferred to nitrocellulose membrane for Western blot. The pan-anti-Ksu antibody from 
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PTM BioLabs Inc. was first applied and then followed by the blotting with secondary 
antibody and visualization (Figure 31A).  
 
4.10.2 The MS/MS analysis of H3K4AznL 
We further confirmed K4 succinylation with the MS/MS analysis, which clearly 
showed a Ksu-containing peptide fragment at K4 position (Figure 31B). Liquid 
Chromatography-tandem Mass Spectrometry (LC-MS/MS) was applied to identify the 
specific modifications to Ub-K48 and histone H3-K4 proteins. The protein digestion, LC-
MS/MS analysis, and data analysis were conducted following the method described 
previously. 10 µg of each protein was used for the analysis. Briefly, protein sample was 
denatured by 8 M urea dissolved in Tris buffer (50 mM Tris-HCl, 10mM CaCl2, pH 7.6), 
supplemented with 5 mM dithiothreitol (DTT) for reduction of potential disulphide bonds. 
The denatured protein was diluted into a final concentration of 1 M urea with the same 
Tris buffer, followed by peptide digestion. Ubiquitin was digested by Mass Spectrometry 
Grade Trypsin Gold (Promega, Madison, WI) with 1:50 w/w at 37 °C overnight, while 
histone H3 was digested by chymotrypsin (Promega, Madison, WI) at 25 °C. The digested 
peptides were then cleaned up using a Sep-Pak Plus C18 column (Waters Corporation, 
Milford, MA), followed by loading onto a biphasic 2D reversed phase (RP)/strong cation 
exchange (SCX) capillary column with a pressure cell. The column was then washed with 
100% aqueous solvent (99.9 % H2O, 0.1 % formic acid) for 5 min, followed by a 1-hour 
wash by ramping up the solvent to 100% organic solvent (0.1 % formic acid, 80% 
acetonitrile). This was
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peptides were eluted and separated in a 15-cm-long 100 µm-ID C18 capillary column 
connected to the 2D column. LTQ ion trap mass spectrometer (Thermo Finnegan, San 
Jose, CA) was used to analyze the peptides. The full scan was set to the range of 300-1700 
m/z, in which the top 5 abundant peptides in each scan were subjected to collision induced 
dissociation (CID) fragmentation for tandem mass spectrometry (MS/MS) analysis. 
Peptide identity was processed by the in-house pipeline as described previously. Peptide 
searching was based on ProLuCID (version 1.0) search algorism. For the peptide 
modification search, mass increase was added in order to identify the modified peptides. 
More specifically, 42.0367 was added for lysine acetylation modification, and 100.0648 
was added for lysine succinylation modification. 
  
Figure 31 Preparation of histone with Lys succinylation via dPPMT-NB-Su (A) the 
gel-based time dependent assay for succinylation of H3; (B) MS/MS analysis of H3 
succinylation product. Adapted with permission from [99]. 
 
4.11 The assembly of H3K4su-H4 tetramer 
4.11.1 The preparation of H3K4su 
Since the time-dependent assay showed a successful conversion of H3K4AznL to 
H3K4su, we wanted to further test whether the product we have could be directly used as 
substrate for enzymatic assays. As mentioned in the previous parts, lysine succinylation 
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reverses the charge state of lysine, and thus its occurrence in histones can play a significant 
role to impact the interactions between the histone octamer and its associated DNA. 
Therefore, we decided to use the approach we developed to synthesize histone H3 with 
succinylation at K4 and further assembly it into tetramer with WT H4 as a substrate for 
enzymatic desuccinylation test. AznL was incorporated into H3 as H3K4AznL, followed 
by the reaction with dMMPT-NB-Su similarly as the setting up of time-dependent assay 
described above. The product after UV radiation was dialyzed and confirmed with 
Western blot analysis showing a strong band with the pan-anti-Ksu antibody. WT H3 was 
again used as negative control resulting in a very low level of lysine succinylation. After 
concentrating to lower volume, the reaction product was then treated with UV light for 30 
min, followed by a second dialysis against histone solubilization buffer pH 7.5 for 3 times. 
The solution was concentrated again down to 100 µl and stored for the next step.  
 
4.11.2 The assembly of H3K4su-H4 tetramer 
After confirming the succinylation site, we directly used the product after 48-h 
incubation and UV-treatment to assemble an H3K4su-H4 tetramer as a substrate to test 
Sirt5 activity (Figure 32A). Both histone proteins H3 and WT H4-SUMO with a N-
terminal His6 tag were dissolved in the histone solubilization buffer (6 M urea, 20 mM 
Tris, 500 mM NaCl, pH 7.5) with equimolar ratios. The protein mixture was sequentially 
dialyzed against 500 mL refolding buffer 1 (20 mM Tris, 2 M NaCl, pH 7.5) for 30 min 
once, 500 mL refolding buffer 2 (20 mM Tris, 1 M NaCl, pH 7.5) for 30 min once, and 
500 mL refolding buffer 3 (20 mM Tris, 500 mM NaCl, pH 7.5) for 30 min twice with 
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Slide-A-Lyzer MINI Dialysis devices (3,500-Da cutoff). After the dialysis process to 
refold, tetramers were put into a microcentrifuge tube and let to spin down by 14000 rpm 
for 1 min to remove all the possible precipitation during the refolding process. The 
tetramer product was measured with a concentration of about 16 mg/mL. SDS-PAGE gel 
was used to confirm the tetramer folding showing both bands of H3 and H4, and the 
tetramer was confirmed with SDS-PAGE and then stored on ice for further usages (Figure 
32B). 
 
Figure 32 Preparation of H3K4su-H4 tetramer (A) scheme of the assembly of H4-
H3K4su tetramer; (B) SDS-PAGE analysis of H4-H3K4su tetramer. 
 
4.12 Sirt5 enzymatic assay 
4.12.1 The expression of Sirt1 and Sirt5 
Sirtuin 5 (Sirt5) is a NAD-dependent histone deacylase family enzyme, which has 
been reported to remove succinylation from histones and regulate chromatin functions[105]. 
However, previous research has been based only on histone N-terminal peptides, and no 
evidence has been shown whether Sirt5 performs active over histone or other higher 
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organizations such as tetramer, octamer, or nucleosome. Therefore, we would like to apply 
the tetramer we have to show the desuccinylation activity of Sirt5 but no Sirt1. 
Both the Sirt1 and Sirt5 enzymes were expressed according to the procedure 
reported before[106]. Both enzymes were expressed in E. coli BL21(DE3) cells in 1 L LB 
media at 30 oC for o/n, induced by 0.1 mM IPTG. After collecting and sonicating cells, 
the precipitate was removed by centrifugation (6k 20 min, 4 oC). The supernatant was 
purified with the GST resin similar to Tip60. The mixture was directly loaded to a column 
and the flow-through was removed. 50 mL PBS washing buffer (200 mM NaH2PO4, 100 
mM NaCl, pH 7.4) was used to wash the protein-bound resin in three batches. 10 mL of 
elution buffer (15 mM Glutathione in reduced form, 200 mM NaH2PO4, 100 mM NaCl, 
pH 7.4) was used to elute the target protein. After concentration measurement, the 
enzymes were split into different 50 uL portions with the addition of glycerol to a final 
concentration of 40 %. The final enzyme solution was frozen immediately by ethanol-dry 
ice mixture and stored into -80 oC freezer for future usage. 
 
4.12.2 The setting up of Sirt1 and Sirt5 enzymatic assay 
The H3K4su-H4 tetramer was freshly assembled according to Part 10 at 
concentration of about 16 mg/mL or 180 µM. Sirtuin enzyme stock solution was added to 
each sample as the final concentration of 500 nM for Sirt1 or Sirt5. After 4 h incubation 
at 37 oC, the samples were subjected to the SDS-PAGE analysis. SDS-PAGE separated 
proteins were transferred to nitrocellulose membranes for Western blot. The pan anti-Ksu 
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antibody was used for the membrane blotting, followed by the Stripping-off5 of the 
antibody for probing with a generally used anti-H3 antibody (Abcam). 
As shown in Figure 33, when Sirt5 and its cofactor NAD+ were provided to the 
H3K4su-H4 solution, the succinylation was actively removed from H3. On the contrary, 
a control reaction with Sirt1 showed no succinyla- tion removal from H3. These combined 
results unequivocally approve show that Sirt5 but not Sirt1 is a histone desuccinylase. 
 
Figure 33 The setting up of Sirt1 and Sirt5 enzymatic assay of H3K4su-H4 tetramer 
Adapted with permission from [99]. 
 
4.13 Summary 
To summarize, we reported a versatile chemical biology approach for the site-
specific installation of various Lys acylations into proteins. With the combination of ncAA 
and traceless-Staudinger ligation reaction, Lys acetylation and succinylation were 
successfully installed into proteins in a site-specific mannar. Many proteins in many 
different organisms undergoing Lys succinylation are metabolic enzymes. Lys 
succinylation is a recently discovered Lys acylation found and profiled in many different 
species such as E. coli, yeast (Saccharomyces cerevisiae), human cells, mouse liver tissues, 
and even human pathogens as Mycobacterium tuberculosis[107]. These acidic modification 
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modes share one key feature as the reversion of charge states for Lys. Especially happen 
on histone, Lys succinylation can repulsion charge interaction between histone and DNA 
to lossen the core nucleosome structure. It still remains to be studied whether cells choose 
Lys succinylation as a powerful weapon to regulate the chromatin structure and gene 
transcription function, and whether Lys succinylation is regulated by Sirt5.  
To address these interesting questions, we can first install Ksu at a desired position 
in proteins with the new strategy we developed. And with the combination of typical 
biochemistry or chemical biology techniques, we can further study the role of Lys 
succinylation and its regulation. In addition, the strategy provides an avenue to a myriad 
of other novel acylation PTMs. Although we did not carry out any test for the other two 
acidic modificaitons as malonylation and glutarylation in the current study, but we are 
almost certain about it. For fatty acylations not explored here such as myristoylation, the 
method we reported needs to be further improved to increase the reaction yield and water-
solubility. On the one hand, although surprisingly the phosphinothioester reagents 
performed much better than the phosphinophenyloxyl ester, there is still space for the 
optimization of reaction yield by attempting to avoid the hydrolysis side reaction. On the 
other hand, the water-soluble version of phosphinothioester reagents can be applied with 
high concentrations to accelerate the reaction[104]. To design and add different substitution 
groups to both phenyl groups from a physical organic chemistry point of view[108] will be 
a potential way to increase the reaction efficiency and to reduce the side reaction of N-P 
ylide. We are looking forward the advance of new generations of phosphinothioester 
reagents. 
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Figure 34 1HNMR, 13CNMR and 31PNMR of dPPMT-Ac 
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Figure 35 1HNMR, 13CNMR and 31PNMR of dPPMT-Su 
  109 
 
 
Figure 36 1HNMR, 13CNMR and 31PNMR of dPPMT-NB-Su 
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CHAPTER V 
THE SYNTHETIC INVESTIGATION OF LYSINE ACYLATION VIA KAHA 
REACTION 
5.1 Background 
The synthetic study of proteins with site-specific acyllysine installed is of great 
importance to life science study. However, none of the current strategies is ideal or robust 
enough when facing novel Lys PTMs with various structures. Advantages and 
disadvantages have been analyzed in detail for several chemical biology methods in the 
previous parts, such as the enzymatic synthesis, protein total and semi-synthesis, 
bioorthogonal reactions, direct incorporation via amber codon suppression, etc. One new 
pace to provide potential solution is to combine the noncanonical amino acid incorporation 
with protein chemistry. A typical example reported is the installation of AznL for the 
following traceless Staudinger ligation to generate acyllysine. By using this method, our 
group has shown the preparation of different proteins with site-specific Kac and Ksu, such 
as water-soluble protein Ub and non-water-soluble protein histone. The protein product 
can be used for the assembly of H3-H4 tetramer in vitro, and further applied for enzymatic 
assay directly. 
Although as the first installation of Ksu at a specific site into proteins, the approach 
suffers from several disadvantages that may significantly hinder its further usage. Due to 
a slow kinetics of traceless Staudinger ligation reaction, the conversion from AznL to 
acyllysine takes at least 48 h in order to reach decent yield. More importantly, the reductive 
essence of the phosphinothioester reagents used in it can cause the Staudinger reduction 
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as an inevitable side reaction for the generation of native Lys with a free amino group. 
Although Lys may not give out signal under western blot by using PTM antibodies, the 
heterogeneous nature of the product can still raise concern for further biological studies. 
Last but not the least, the synthesis of different acyl phosphinothioester reagents requires 
special expertise, which is time consuming and tedious. Therefore, we are still looking 
forward to the development of new synthetic approaches for the incorporation of 
acyllysine to overcome those challenges. 
 
5.2 The Design of acylation from AcdK 
One direction for the development of protein chemistry is to introduce new 
reactions from organic chemistry exploration or peptide chemistry onto proteins[109]. 
Literature study showed a novel ligation reaction between α-ketoacids and N-
alkylhydroxylamine reported by the Bode group[110], which has been used for the peptide 
ligation under mild aqueous condition[111]. Instead of non-substituted type-I N-
alkylhydroxylamine, type-II N,O-dialkylhydroxylamine or its cyclic derivatives could 
also undergo the so-called KAHA reaction and showed better ligation yield as well as 
higher tolerance against water[112]. They further applied the ligation product with an 
aspartyl aldehyde group for further functionalization, such as reacting with hydroxylamine 
for protein labeling or reductive amination to generate hydroxylamine side chain. The 
product as hydroxylamine-containing side chain can undergo another KAHA ligation with 
external small molecular ketoacids[113]. 
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Inspired by this approach, we came up with a combinatory methodology of KAHA 
ligation with our ncAA technique of AcdK. As previously mentioned, AcdK as an allysine 
precursor can undergo reductive amination to generate Lys alkylation after being 
incorporated into POIs. Kme and Kme2 are both examples to demonstrate the application. 
By simply changing the methylamine to hydroxylamine, we are able to generate a similar 
hydroxylamine-containing side chain to undergo KAHA ligation and finally generate 
acyllysine.  
We expect this new protein chemistry approach to endow several advantages 
comparing with the traceless-Staudinger ligation strategy. First, the α-ketoacid reagents 
used in KAHA are easy-accessible from commercial resources. Second, there is no known 
reported side reaction between ketoacids with the native amino acid side chains. For 
instance, the α-ketoglutarate as the only reactant for Lys succinylation is purchasable from 
Sigma-Alderich, which is also a wildly existing natural product for the transamination 
procedure of glutamate. Similar to the traceless Staudinger ligation approach, we can 
generate theoretically any different acyllysine PTMs by simply changing the α-ketoacid 
moiety. 
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Figure 37 The combination of AcdK incorporation and KAHA ligation reaction for 
the installation of Lys acylation 
5.3 The optimization of AcdKRS plasmid 
5.3.1 The cloning of opt-AcdKRS plasmid 
Before our investigation on protein chemistry part, we hope to optimize the PylRS 
mutant for better incorporation. The selected original plasmid for AcdK, pEvol-non-opt-
AcdKRS, was codon optimized to generate pEvol-opt-AcdKRS. Three site-directed 
mutagenesis procedures are carried out sequentially to introduce three mutations to the 
pEvol-opt-WT-PylRS plasmid as L309T/D348G/Y384F. Phusion DNA polymerase was 
used for the PCR procedure. Next, we make the insertion of L11C into the optimized 
plasmid to be pEvol-opt-AcdKRS-L11C. Finally, a second copy of opt-AcdKRS was 
installed to the pEvol-opt-AcdKRS yielding pEvol-2×opt-AcdKRS. 
Each of the three constructed plasmids, together with pBAD-sfGFP-D134TAG, 
was then used to co-transform E.coli BL21(DE3) cells. A single colony was picked and 
let to grow in 50 mL 2YT culture for 8 h, induced by 1 mM IPTG, 0.2% arabinose and 2 
mM AcdK after OD reached 0.4. The sfGFP from each sample was purified from via 1 
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mL Ni SepharoseTM 6 Fast Flow column (GE Healthcare) and the elution was 
concentrated. The purified protein was analyzed and quantified by SDS-PAGE with 
Commassie staining (Figure 38A). The plasmid pEvol-opt-AcdKRS-L11C shows the best 
expression with an improvement of 15 % comparing with the original non-optimized 
strain, which was further used for protein expression.  
 
Figure 38 The optimization of AcdKRS by the comparison of sfGFP expression with 
different optimized AcdKRS mutants (A) the GFP expression with optimized AcdKRS; 
(B) SDS-PAGE of the expression of Ub-K48AcdK. 
 
5.3.2 The expression of UbK48AcdK 
We decided to test the reaction condition with the AcdK-containing Ub at K48 
position (Ub-K48AcdK). The best optimized plasmid pEvol-opt-AcdKRS-L11C was used 
to co-transform E. coli BL21(DE3) cells together with pEtduet-UbK48TAG with a C-
terminal His6 tag. Ub-K48AcdK was expressed and purified following a similar process 
as Ub-K48AznL (Figure 38B). 
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5.4 Methodology investigation of the reductive amination with hydroxylamine 
After the routine conversion into Ub-K48AlK by incubating with 5 mM TCEP, a 
two-step reductive amination procedure was carried out according to the reported 
literature[113]: Hydroxylamine hydrogencholoride salt was first dissolved in water to make 
100 mM stock solution. 10 mM hydroxylamine was then added to the solution of Ub-
K48AlK. The solution mixture was let to incubate with hydroxylamine for 4 h at 37 oC, 
and then dialyzed to 100 mM oxalic acid buffer pH 2.5 containing 10 mM hydroxylamine. 
Because the reduction process needs to undergo in acidic condition, the pH of the solution 
was measured with micro-pH meter to guarantee the acidity. Then, the reaction solution 
was treated by excess 20 mM NaBH3CN in two batches with an interval of 1 h. Then, the 
final reaction mixture was let to incubate at 37 oC for o/n. After been dialyzed to pure 
water to completely remove the small molecular reactants, the hydroxylated lysine product 
Ub-K48KOH was dried with lyophilizer to give out its powder form for the next step. 
Before that, MALDI-TOF-MS was used to analyze the product, which gave out a single 
peak at 9404 Da, agreeing with the calculated hydroxylated product after reductive 
amination (Figure 39A). Notably, Figure 39A may contain some side peaks that are not 
fully studied. Similar to our previous researches, MS/MS was used to analyze the 
trypsinized product Ub-K48KOH, and a 48KOH containing peptide fragment was detected 
(Figure 39B). 
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Figure 39 The reductive amination of hydroxylamine on UbK48AlK (A) MALDI-
TOF-MS spectrum of product Ub-K48KOH; (B) MS/MS analysis of 48KOH-containing 
trypsinized peptide fragments. 
 
5.5 Methodology investigation of the KAHA ligation reaction with α-ketoglutarate 
5.5.1 The reaction setting up for Lys succinylation 
After the successful conversion of Ub-K48AlK to Ub-K48KOH, we start the 
investigation of KAHA ligation reaction with α-ketoglutarate, and its generation of Ksu 
can be easily compared with the traceless-Staudinger ligation strategy. Because type-I N-
alkylhydroxylamine needs to react under high DMSO condition, the Ub-K48KOH powder 
was directly used for the reaction setting up. A reaction solution was prepared by 
dissolving a final concentration of 200 mM oxalic acid and 200 mM α-ketoglutarate in a 
pH 2.0 solvent mixture with 9:1 DMSO:H2O. Ub-K48KOH in its powder was dissolved in 
the reaction mixture to reach a final protein concentration of ~20 µM, followed by the 
gentle pipetting to make the reaction solution well-mixed. After nitrogen protecting, the 
reaction tube was incubated under 37 oC for 36 h.  
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5.5.2 The reaction working up and charicterization 
The reaction was quenched by a 1:1 volume ratio water dilution, and potential 
protein precipitate was removed by centrifuging at 14K for 5 min. The supernatant was 
then dialyzed to a 20 mM phosphate pH 7 buffer. After mixing the sample with the SDS 
loading buffer, the final product Ub-K48Ksu was analyzed by 15 % SDS-PAGE gel for 
Coomassie blue staining and western blot analysis. The first gel showed clear bands for 
both samples with or without reaction. Pan-anti-Ksu antibody was used to blot the 
nitrocellulose membrane after the protein transfer from gel to membrane. After blotting 
with secondary antibody and visualization, a strong band could be observed for the 
reaction group while none for the one without reaction (Figure 40A). Then, we sent the 
product sample Ub-K48Ksu for MALDI-TOF-MS analysis after the Ziptip (Reversed-
phase, pipette tips for sample preparation, Millipore Corporation) sample preparation 
process., and the result showed a single major peak is 9487 Da, same as the calculated 
molecular weight (Figure 40B). No other significant peaks can be seen besides a slight 
amount of unreacted starting material. The existence of lysine succinylation at K48 site 
was further confirmed by MS/MS analysis (Figure 40C). 
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Figure 40 Methodology examination of Lys succinylation (A) after reacting with a-
ketoglutarate, the protein product Ub-K48Ksu was analyzed by SDS-PAGE and the 
Western blot probed by a pan-anti-succinyllysine antibody; (B) MALDI-TOF-MS 
spectrum of the KAHA reaction product as Ub-K48Ksu; (C) MS/MS analysis of the 
trypsinized 48Ksu-containing trypsinized peptide fragments. 
5.5.3 Analysis 
With the test of succinylation on Ub, we want to compare the KAHA strategy with 
traceless-Staudinger ligation reaction for the purpose of acyllysine installation especially 
for Ksu, the KAHA ligation reaction approach can reach to higher conversion within 
shorter time period. Additionally, multiple advantages stand out for the ketoacid reactant 
used here over the phosphinothioester reagents, such as the easy-accessibility, no side-
reaction, higher stability against water/air for long-term storage, etc. 
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5.6 Methodology investigation of the KAHA ligation reaction with oxoadipic acid 
5.6.1 The reaction setting up for Lys glutarylation 
Encouraged by the result of Lys succinylation initial trial by the KAHA ligation 
reaction approach, we wanted to test another Lys PTM, Lys glutarylation, which has not 
been reported yet. Oxoadipic acid was purchased from Sigma-Alderich as the 
corresponding α-ketoacid reagent, and the reaction was set up according to a similar 
process as described in the previous part. To reach a decent yield for the reaction, we 
carried out a concentration scanning for both oxalic acid and oxoadipic acid. With a 
complicated mechanism for the KAHA ligation reaction[114], the optimized concentration 
for glutarylation is with to dissolve 200 mM oxalic acid and 400 mM oxoadipic acid in 
9:1 DMSO:H2O solvent mixture to ensure a strong acidic reaction condition pH 2.3. The 
Ub-K48KOH was dissolved to the reaction mixture in its powder form and the reaction was 
let to incubate at 37 oC for 36 h under the nitrogen protecting condition.  
 
5.6.2 The reaction working up and characterization 
After being quenched by the water dilution with a 1:1 volume ratio, the reaction 
product was analysed by SDS-PAGE. Western blot analysis probed by pan-anti-Kgl 
antibody showed a strong band for the reaction group while none for the control without 
reaction (Figure 41A). MALDI-TOF-MS was then carried out to test the conversion of 
Ub-K48KOH to Ub-K48Kgl, and the only major peak 9501 Da agreed with the calculated 
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molecular weight of Ub-K48Kgl (Figure 41B). Notably, some minor peaks can be seen 
representing unreacted starting material and unknown impurities.  The product sample Ub-
K48Kgl was trypsinized and then applied for MS/MS analysis. A peptide fragment with 
48Kgl was found to guarantee the site-specific installation of lysine glutarylation (Figure 
41C). 
 
5.7 KAHA ligation reaction on H3K9 
After the success of Lys succinylation and glutarylation on Ub, we wanted to apply 
this KAHA ligation approach to install either Ksu or Kgl into H3K9 forming H3K9Ksu 
or H3K9Kgl, respectively. Both of them have been found on human histone proteins. 
Comparing with the common Lys acetylation, succinylation and glutarylation can reverse 
the charge state of lysine from positive to negative, which can greatly impact the 
interaction between histone octamer and DNA. We have shown the Ksu could be regulated 
by Sirt5, but no direct data provided for Kgl. The products we got from our approach may 
be directly applied for Sirt5 activity assay. 
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Figure 41 Methodology examination of Lys glutarylation (A) After reaction with 
oxoadipic acid, the protein product Ub-K48Kgl was analyzed by SDS-PAGE and the 
Western blot probed by a pan-anti-glutaryllysine antibody; (B) MALDI-TOF-MS 
spectrum of the KAHA reaction product as Ub-K48Kgl; (C) MS/MS analysis of the 
trypsinized 48Kgl-containing trypsinized peptide fragments. 
 
The expression and purification of H3K9AlK was following a similar process as 
described before. To install AcdK into H3K9 position, the optimized plasmid pEvol-opt-
AcdKRS mentioned above was used to co-transform E. coli BL21(DE3) cells, together 
with pETduet-H3K9TAG. After the elution from 1 mL Ni SepharoseTM 6 Fast Flow 
column (GE Healthcare) was collected and concentrated, TCEP was added to a final 
concentration of 5 mM and incubated for 20 min. The final protein H3K9AlK was 
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exchanged to histone reaction buffer (6 M urea, 20 mM Phosphate, pH 7.4) and stored for 
further usage. 
 A similar two-step reaction procedure was then applied to the stored H3K9AlK. 
After been incubated with hydroxylamine solution at 37 oC for 4 h, the reaction buffer was 
then dialyzed to a pH 2.5 100 mM oxalic acid buffer containing 6 M urea and 10 mM 
hydroxylamine. Next, 20 mM NaBCNH3 was added in two batches with an interval of 1 
h, and the final reaction solution was incubated at 37 oC for o/n. The reaction mixture was 
dialyzed to pure water, lyophilized to remove all the solvent and stored as H3K9KOH in 
its powder form. A 9:1 DMSO:H2O reaction solution pH 2.0 with 200 mM oxalic acid and 
200 mM α-ketoglutarate for succinylation, or 400 mM oxoadipic acid for glutarylation 
was used to dissolve H3K9KOH, separately. The reaction mixture was well mixed and let 
to incubate under 37 oC for 36 h under the nitrogen protecting condition. After quenching 
by water and dialyzed to pure water, the reaction solution containing H3K9Ksu or 
H3K9Kgl was applied to SDS-PAGE gel and then Western blot. The pan-anti-Ksu 
antibody or pan-anti-Kgl antibody followed by the anti-H3 antibody from PTM BioLabs 
Inc. was applied. The visualization showed a strong band for the sample after KAHA 
reaction, suggesting the successful installation of Lys succinylation (Figure 42A) and 
glutarylation (Figure 42B) as expected. The histone final products as H3K9su and H3K9gl 
were both saved for the further Sirt5 enzymatic assay. 
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Figure 42 After reaction with oxoadipic acid, the protein product Ub-K48Kgl was 
analyzed by SDS-PAGE and the Western blot probed by a pan-anti-glutaryllysine 
antibody (A) After reaction with a-ketoglutarate, the protein product H3K9Ksu was 
analyzed by the Western blot probed by a pan-anti-succinyllysine antibody and an anti-
H3 antibody; (B) After reaction with oxoadipic acid, the protein product H3K9Kgl was 
analyzed by the Western blot probed by a pan-anti-glutaryllysine antibody and an anti-H3 
antibody. 
 
5.8 Sirt5 assay over H3K9Ksu and H3K9Kgl 
As a member of the NAD-dependent protein deacylase family, Sirt5 is a histone 
deacylase known to remove lysine succinylation over histone peptide substrates. We have 
shown that Sirt5 can catalyze desuccinylation process over the synthetic H3-H4 tetramer 
prepared by traceless-Staudinger ligation approach over AznL. But no enzymatic assay 
results in vitro have been reported for the deglutarylation activity over histone proteins. 
By using our KAHA ligation strategy, we can site-specifically install Ksu and Kgl into 
H3K9 site. The products stored in powder form were dissolved in 20 mM Tris-HCl pH 
7.5 buffer containing 1 mM NAD+ and 1 mM DTT, and 3 µl of Sirt5 enzyme stock solution 
was added to each sample to reach a final concentration of 540 nM. The reaction mixture 
was let to incubate at r.t. for 4 h, and then applied to SDS-PAGE and western blot with 
pan-anti-Ksu antibody, pan-anti-Kgl antibody or anti-H3 antibody. After visualization, 
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lysine succinylation and glutarylation can both be removed completely from H3K9 
(Figure 43A&B), which agrees with the previous reports for lysine glutarylation. 
 
Figure 43 Sirt5 enzymatic assay over H3-H4 tetramer (A) Desuccinylation of the 
H3K9Ksu by incubating H3K9Ksu with or without 0.5 µM Sirt5 in the presence of 1 mM 
NAD+ and 1 mM dithiothreitol (DTT) for 4 h. After reaction, proteins were analyzed with 
western blot analysis by a pan-anti-succinyllysine antibody and anti-H3 antibody; (B) 
Desuccinylation of the H3K9Kgl under the same condition. After reaction, proteins were 
analyzed with western blot analysis by a pan-anti-Kgl antibody and anti-H3 antibody. 
 
5.9 Other Lys acylation strategies investigation based on AcdK 
In this part, several trial-and-error tests will be briefly discussed for a similar goal 
of methodology development for Lys acylation. Due to limited time and space, these 
unfinished projects will be briefly summarized mainly as proof of concepts. We feel them 
helpful because they are meaningful extension of our AcdK system based on rational 
design. 
 
5.9.1 The succinylation analogs  
Although with the traceless Staudinger ligation reaction we can generate Lys 
acidic PTMs such as succinylation, the yield is not good due to the inevitable Staudinger 
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reduction. Additionally, the reaction in 40 % DMSO may raise the concern of protein 
unfolding. Another design was inspired by the high efficiency of reductive amination over 
hydroxylamine and its derivatives. After the conversion from AcdK to allysine, the protein 
can undergo reductive amination reaction to generate acidic PTM analogs, more 
specifically, n = 1 for Kmal, n = 2 for Ksu, and n = 3 for Kgl. 
 
Figure 44 Scheme for the installation of acidic PTM analogs 
 
O
H2N CO2H
HN
O
O
N3 Protein expression
NH2
n
NH2
n
HN
O
O
N3
HN O O
O
H2N
O O
O
NH2
n
n HN O
O
NH2
n
n
O
Reductive amination
n
  126 
 
 
Figure 45 1HNMR and 13CNMR of 2-(aminooxy)acetate 
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The 2-(aminooxy)acetate (n = 1) was synthesized according to a modified protocol, 
which is omit here. After been analyzed by 1HNMR (300 MHz, D2O) with δ 4.067 (s, 2H), 
and 13C NMR (75 MHz, D2O) with δ: 170.5, 69.6, the product was applied for reductive 
amination reaction with UbK48AlK, which is further confirmed with MALDI-TOF 
(Figure 46A). Then we loaded the sample after reaction to SDS-PAGE followed by the 
Western blot analysis (Figure 46B). All the trials of Western blot by pan-anti-Kmal 
antibody turned out to be failure. However, to our surprise, a clear band could be detected 
by pan-anti-Ksu antibody. 
 
Figure 46 Reductive amination investigation of acidic PTM analog (A) the MALDI-
TOF of the product after reductive amination with 2-(aminooxy)acetate; (B) Western blot 
analysis of the product after reductive amination with 2-(aminooxy)acetate. 
 
5.9.2 The KAT reaction strategy  
The KAHA ligation reaction discussed in this Chapter can generate theoretically 
any acylation modifications. However, the reaction needs near pure DMSO solution with 
a slow kinetics. Inspired by the Bode group for the newly discovered potassium 
acyltrifluoroborate (KAT) amide formation reaction[115] and its related reaction[116], we 
  128 
proposed an alternative as below (Figure 47). By replacing the type I hydroxylamine with 
acyl hydroxylamine, the reaction can undergo in water/butanol solvent mixture with a very 
fast kinetics. 
 
Figure 47 Scheme for the Lys acylation installation with KAT reaction 
 
To start with, N-((aminooxy)carbonyl)-N-ethylethanamine was synthesized 
according to a protocol not mentioned here. The product was analyzed by 1HNMR (300 
MHz, CDCl3) with δ 6.13 (s, 2H), 3.25 (m, 4H), 1.07 (m, 6H), and 13C NMR (75 MHz, 
CDCl3) with δ: 170.5, 42.4, 40.9, 28.0, 26.4 (Figure 48). Surprisingly, the product N-
((aminooxy)carbonyl)-N-ethylethanamine for reductive amination was very unstable. 
After the deprotection of pthalimide group, the product is prone to degradation even under 
r.t. to release diethylamine. And therefore, the trials of reductive amination with 
UbK48AlK turned out to be hydroxylamine addict due to the removal of the acyl group. 
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Figure 48 1HNMR and 13CNMR of N-((aminooxy)carbonyl)-N-ethylethanamine 
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5.9.3 The N-O band cleavage strategy  
The two rest approaches are all based on NCL as the most widely used reaction in 
protein chemical biology field. Inspired by the N-O cleavage reaction developed by the 
Chatterjee group[117], we came up with the tendon reaction strategy. The UbK48AlK will 
first undergo reductive amination with 2-(aminooxy)ethanethiol to generate a γ-thiol 
group to facilitate the NCL with theatrically any acyl thioester. By using the 4-
mercaptophenylacetic acid (MPAA), the N-O bond can be selectively cleaved to release 
native amide structures (Figure 49). 
 
Figure 49 Scheme of the Lys acylation installation with N-O cleavage strategy 
 
We first synthesized 2-(aminooxy)ethanethiol with started pthalimide protection 
strategy. The product was then analyzed by 1HNMR (300 MHz, D2O) with δ 4.03 (t, 2H), 
2.65 (t, 2H), and 13CNMR (75 MHz, CDCl3) with δ: 76.1, 21.3 (Figure 50). The reductive 
amination was carried out with Ub-K48AlK and desired product can be produced. 
However, further optimization of the N-O cleavage is still needed after NCL. 
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Figure 50 1HNMR and 13CNMR of 2-(aminooxy)ethanethiol 
 
  132 
5.9.4 The auxiliary group-assisting strategy  
Another approach we came up with is to use an auxiliary group for to assist the 
NCL, which can be further removed by UV irradiation[118]. After the removal of TCEP for 
the conversion of AcdK to AlK, the amino compound with disulfide bond synthesized by 
Dr. Xinqiang Fang was used to do the reductive amination in water/DMSO solvent 
mixture. The disulfide bond was then cleaved by 10 mM TCEP to release the warhead for 
NCL. After undergoing NCL with different acyl thioester, the O-nitrophenol group can be 
removed under UV light for 1 h on ice (Figure 51). 
 
Figure 51 Scheme for the Lys acylation installation with the auxiliary group-
assisting strategy 
 
MALDI-TOF showed the desired reductive amination reaction as the peak of 9656 
Da with about 60 % yield (Figure 52A). Then, we carried out the NCL with different acyl 
thioester. Both acetyl thioester and propionyl thioester synthesized by Dr. Xinqiang Fang 
were used for NCL. However, due to a long procedure with multiple reaction steps 
followed by dialysis after each reaction, a significant loss of final product made it hard to 
be visualized on MALDI-TOF. Both Western blot analysis showed a strong band only 
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with both reductive amination and NCL (Figure 52B). MS/MS further confirmed the 
existence of K48ac after the reaction (Figure 52C).  
 
Figure 52 Methodology investigation of the Lys acylation installation with the 
auxiliary group-assisting strategy (A) MALDI-TOF of reductive amination; (B) 
Western blot for the acetylation and propionylation; (C) MS/MS of acetylation product. 
 
5.9.5 The Ub cleavage with TCEP  
During the TCEP treatment of Ub with Cys mutations, I observed an unknown 
phenomenon (Figure 53). By incubating 20 mM TCEP with either UbK48C or UbK11C, 
a cleavage around the Cys position could be observed from MALDI-TOF. For UbK48C, 
the cleavage happened on both the C-site and N-site of Cys to completely eliminate Cys 
in between (Figure 54A&B). For UbK11C, the cleavage was not complete. Additionally, 
with a very complicated mechanism, the cleavage can also happen at the carbon-carbon 
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bond to leave a formylation instead of a free N-terminal amine. For UbK11C, a cleavage 
at the T12 site is also cleaved incompletely (Figure 54C&D). For both K11 and K48 sites, 
it happened to be -GC- sequence, which has been known in equilibrium with its thioester 
form[119]. When we extended the test to K27 and K29 sites, a similar cleavage process 
happened with different yields. 
 
Figure 53 Scheme for Ub with Cys mutations cleaved by TCEP 
 
We varied the reaction condition including reaction pH, buffer conponents, and 
temperature, but no change had been observed. However, with a decreased concentration 
of TCEP, the reaction yields significantly dropped. At a concentration of 5 mM, almost 
no reaction can be observed. We originally thought about a radical mechanism. However, 
the addition of 10 mM DTT could not protect the peptide to be chopped.  
N
H
OHS H
N
O
O
OH
H
N
O
H2N
H2N
HS
O
OH
  135 
 
Figure 54 MALDI-TOF of Ub with Cys mutations cleaved by TCEP (A) UbK48C 
with His6 tag as MW 10044 Da before reaction (…FAG-C-QLE…); (B) UbK48C with 
His6 tag was cleaved by 20 mM TCEP to generate fragment 1 4716 Da (QLE…), and 
fragment 2 5244 Da (…FAG), and the Cys was eliminated; (C) UbK11C without His6 tag 
as MW 8542 Da before reaction (…LTG-C-TIT…); (D) UbK11C without His6 tag was 
partially cleaved by 20 mM TCEP to generate fragment 3 MW 7319 Da (TIT…) and a 
cleavage at T site to generate fragment 4 MW 7218 Da (IT…), while the C-terminal 
fragment was too small to be detected. 
 
5.10 Summary 
To summarize, with the combination of amber codon suppression and KAHA 
ligation reaction, a novel approach has been reported for the site-specific lysine acylation 
in POIs. The goal of Lys succinylation and glutarylation have been achieved with this 
approach in both ubiquitin as a water-soluble protein and histone proteins from inclusion 
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body. The acylated protein products can be directly applied for further enzymatic 
desuccinylation or deglutarylation assays.  
Ksu and Kgl are recently discovered new lysine acylation types, which have been 
shown widely existing in the proteomes of several different species[120], however, their 
related PTM enzymes “Writer, eraser, and reader” are remaining largely unknown. A 
recent paper reported a potential histone H3 succinyltransferase[22], but no literature exists 
for the identification of lysine glutaryltransferase. With the current method in this part, 
many lysine succinylation and glutarylation related questions can be further addressed. 
Additionally, since our “AcdK to allysine” system provides a very important 
chemical biology handle as aliphatic aldehyde group, which can be used to achieve many 
protein chemistry designs. To demonstrate its potential applications, we listed several 
trials or discoveries in the end of this chapter. Although some of them may not work so 
far, we are still looking forward to further optimization or condition screening. We are 
also looking forward to applying more chemical reactions from glass beakers[73] to protein 
contents[109], and to a broader biological substrates[121].  
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CHAPTER VI 
THE CHEMICAL LABELING AND INVESTIGATION OF LYSINE LIPIDATION 
6.1 Background 
Besides the Lys mono-/di-methylation discussed in Part III and Lys acylation in 
Part IV/V, lipidation is another important Lys modification mode widely existing with 
high structural and functional diversity. In this chapter, we hope to apply our ncAA 
technique combining with the chemical biology and biochemistry methods to study Lys 
fatty acylation modes from a proteomic view.  
Lipids we intake can modify our proteome with various structures, such as the C-
terminal phosphatidylethanoiaminylation and S-farnesylation. Another main group of 
protein lipidation is fatty acylation, which can divided as N-terminal modification, N-
modification on Lys, S-modification on Cys, O-modification on Ser or Thr four groups 
(Figure 55A). 
In dally diet, we absorb a high amount of fatty acids from all kinds of food, 
including livestock and poultry meats, eggs, fruits, vegetables, nuts, milk and other dairy 
products, etc[122]. Dietary fatty acids are saturated or unsaturated aliphatic acids with short, 
medium, and long hydrocarbon chains. Typically, the fatty acids in food mentioned above 
are rich in fatty acids with variable total carbon number from 3 to 23. As a main family of 
lipids, fatty acids with long hydrocarbon chains own carbon atoms in low oxidation states 
and thus with very high energy comparing with other biomolecules such as saccharin and 
protein[42].  
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After being taken into human body, some of the dietary fatty acids are used as 
building blocks for many cellular lipids and membrane, while others are processed 
different metabolic degradation to release the energy for the synthesis of other intracellular 
energy carrier molecules such as ATP. As a main source with highly condensed energy, a 
sophistic metabolic network has been established to gradually degrade dietary fatty acids 
into smaller components and release the energy inside. For long chain fatty acids with 
even carbon number, they will be first converted into corresponding fatty acyl-CoA 
enzymatically to further undergo β-oxidation pathway repeatedly to produce acetyl-CoA, 
which will then enter the tricarboxylic acid (TCA) cycle as a key intermediate (Figure 
55B). Also known as the Krebs cycle, TCA has been regarded as the hub of cellular 
metabolism. For fatty acids with odd carbon number, a final residual propionyl-CoA will 
generate, which is then converted to succinyl-CoA and enters the TCA cycle and be 
metabolically degraded. Specially, acetic acid and propanoic acid, as two small fatty acids, 
are directly converted to acetyl-CoA and propionyl-CoA by their corresponding acyl-CoA 
synthetases to enter TCA cycle, respectively.  
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Figure 55 Protein fatty acylation and fatty acid metabolism (A) examples of protein 
lipidation; (B) b-oxidation pathway for fatty acid metabolism. 
 
During the β-oxidation pathway, many different acyl-CoA intermediates generate 
during the metabolic degradation of fatty acids. These intermediates with a large variety 
of structures are high-energy labile thioesters that can undergo nucleophilic acyl 
substitution reactions with nucleophiles on proteins such as amino group, hydroxyl group, 
and thiol group. These nucleophilic attacking processes can be either enzymatically or 
chemically to potentially introduce diverse protein fatty acylation modes. Although the β-
oxidation pathway and the TCA cycle generally happen in mitochondria, these attacking 
reactions between fatty acyl-CoAs and protein nucleophiles are not just in mitochondria, 
because the fatty acyl-CoA synthetases have been found in different subcellular 
localizations.  
Till now, protein fatty acylation has been discovered mainly on the N-terminal 
amino group and two amino acid residues as Lys and Cys[123]. Recently, some other 
nucleophilic residues are also reported with fatty acylation modifications. Many important 
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proteins have been found to undergo fatty acylation include histones, G proteins, 
transcription factors, and metabolic enzymes, which plays vital regulatory roles in their 
own structures and functions and in epigenetic control of gene expression.  
We will still focus on Lys fatty acylation modifications. Current identified protein 
Lys fatty acylation types include short chain ones as acetylation, propionylation, 
butyrylation, crotonylation, long chain ones as myristoylation, and palmitoylation[124]. 
Many researches have been done for short chain modifications. However, little has been 
known about long chain modifications, and thus many fundamental questions are 
remaining unclear[39]. For instance, since the modification enzymes for acetylation, 
myristoylation, and palmitoylation are using fatty acyl-CoAs, we wonder whether these 
dietary fatty acids and their metabolic intermediates can modify Lys under non-enzymatic 
manner. For fatty acids with different carbon numbers, will they lead to distinct 
modification pattern or different “fatty acylomes”, and how can these modifications be 
regulated and removed? Solving these questions, we can generate more understanding of 
the impact of dietary fatty acids to human life from an epigenetic point of view. 
 
6.2 Previous research and disadvantages 
Although many important questions remaining unclear, not many progresses have 
been made due to the lack of biochemistry approaches to study long chain fatty acylations. 
Even primarily focusing on the saturated fatty acids with the simplest structures, only a 
few methods are available to profile proteins with fatty acylation so far. Small acylation 
modifications such as acetylated proteins can be enriched by pan-anti-Kac antibody for 
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further proteomic analysis[125]. However, concerns exist for the selectivity and specificity 
of antibody prepared with normal injection to animal due to the heterogeneous nature, 
especially for the long chain fatty acids.  
 
6.2.1 Surrogates for acetylation 
In the previous reports, different functionalized fatty acids have been developed as 
fatty acid surrogates, which are applied to profile fatty acylation proteome to improve the 
selectivity[126]. These surrogates generally have certain chemical functionalities for further 
modifications as chemical labeling or bioconjugation formation to add purification tags 
such as biotin for the purpose of acylated protein enrichment. Both azido group and alkyne 
group are most widely used warheads to arm the carbohydrate chains, due to the easy 
handling Staudinger reaction or “Click reaction”[127].  
For small acylation modification type as acetylation, two clickable small molecules 
have been designed and synthesized as 4-pentynoic acid and 3-azidopropionic acid for the 
substrate identification of an important histone acetyltransferase (HAT) family enzyme 
p300. After being added to certain proteins, the terminal-alkyne group on 4-pentynoic 
acid, for instance, can conjugate with Biotin for further pull-down and proteomic 
analysis[128]. Although these two surrogates can be alternative cofactors for p300, their 
structures are quite different from the acetic acid or its CoA conjugate. Another 
acetyllysine surrogate design is the chloroacetyl-CoA as a cofactor for HAT family 
enzyme GCN5 to be added to protein substrates[129]. Although chloroacetic acid can be a 
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better mimic of acetic acid to profile acetylome, its toxicity and high reactivity over thiol 
group raise concern when applying directly to cellular study.  
 
6.2.2 Surrogates for medium and long chain fatty acylation 
With a similar design, terminal alkyne or azide-conjugated long-chain fatty acid 
surrogates have also been developed to study long-chain fatty acylation modifications and 
the corresponding acylomes. The azide-conjugated myristic acid and palmitic acid are 
used as chemical probes for myristoylation and palmitoylation, respectively. After the 
Staudinger ligation reaction (Figure 56A), the proteins with azidofatty acylations are 
conjugated with biotin and visualized with Streptavidin[126]. Although robust and 
effective, these surrogates are still structurally different from native fatty acids, especially 
at the terminal region. Additionally, long chain fatty acids with terminal olefin have also 
been developed to undergo tetrazine labeling for proteomic study (Figure 56B). 
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Figure 56 Surrogates of fatty acids and their corresponding detection strategies (A) 
terminal olefin group labeled by tetrazine; (B) terminal azido group labeled by Click 
reaction or Staudinger ligation; (C) the basic mechanism of dehalogenase enzyme; (D) 
design of terminal chloride labeled by HaloTag protein. 
 
Neither the alkyne nor the azido group can be a good mimic for a methyl group, 
and therefore they are not ideal to mimic native fatty acids for further protein acylome 
analysis about fatty acylation distribution and function. Therefore, we are looking forward 
to developing novel and robust metabolic labeling strategies for the profiling of protein 
fatty acylation. This study can facilitate our understanding of dietary fatty acids and their 
high-energy intermediates that are potentially able to acylate cell proteome in an 
enzymatic or non-enzymatic manner.  
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6.3 Our design and potential advantages 
6.3.1 Project initiation 
As mentioned in the previous part, fatty acids with a terminal chloride atom are 
good surrogates for their native forms. However, the chloroacetic acid together with its 
corresponding chloroacetyl-CoA are not applicable due to the high electrophilicity of its 
α-carbon atom, which will undergo nucleophilic attack in cell. We envisioned that medium 
and long chain fatty acids with terminal chloride atom would not have such a problem 
with the electron withdrawing effect from the adjacent carbonyl group. We realized a 
popular chemical biology tool named as “Halo-tag” technique. This is an enzyme mutated 
from dehalogenase enzyme by changing a key His in the acid-base catalyzing to Phe 
(Figure 56C). Labeling as ω-chlorofatty acids, we can further apply the “Halo-tag” 
technique for the further labeling or bioconjugation formation (Figure 56D). 
 
6.3.2 Advantage analysis 
To start with, we want to compare the ω-chlorofatty acids with other existing fatty 
acids with distinct terminal functional groups. The ω-chlorofatty acids own many 
advantages comparing with their corresponding ω-alkyl fatty acids, ω-azido fatty acids, 
and ω-olefin fatty acids. We can barely divide them into three aspects. As an enzymatic 
procedure, Halo-tag recognize and react with terminal chloride atom with high selectivity, 
high specificity, and fast kinetics with a secondary rate constant of 106 M-1s-1, comparing 
with other typical bioorthogonal reaction such as Click reaction or tetrazine-ene reaction. 
As for selectivity, no side reaction has been reported to for ω-chloro fatty acids in cell, 
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while other alternatives are not as stable. For instance, the ω-azidofatty acids may undergo 
reduction reaction under the reductive condition inside of cell.  
Next, the terminal chloride atom is a good mimic for the methyl group as regard to 
both size and hydrophobicity. The ω-chlorofatty acid with one less carbon number 
comparing with the corresponding natural fatty acid is much similar in topology 
comparing with a terminal alkyne or azide or olephin. We are using myristic acid and its 
four surrogates with different terminal functional groups as example. From the 3D 
structure models in Table 6.1, the ones with either azido group or alkyne group are much 
longer than the native one, while the one with olefin group has a plain topology at its 
terminal region. In addition, surrogates with the terminal alkyne and azide are also 
different in hydrophobicity comparing with the ethyl group they are trying to mimic. 
Therefore, only the ω-chlorofatty acid can be the best analogy to substitute the native fatty 
acid for our further metabolic study. 
 
Table 2 The comparison of fatty acids with different terminal functional groups 
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6.3.3 Introduction to Halo-tag and our strategy 
Halo-tag is one of the most widely used protein tag techniques, in which an 
engineered enzyme was used to react with ω-chlorofatty acids[61]. Starting from a 
haloalkane dehalogenase, the His272 necessary for the acid-base catalyzing mechanism 
was engineered to Phe (Figure 56C), which makes the enzyme covalently bind to the 
chloride containing substrate without falling-off[130]. The modified enzyme was then 
applied for the binding to synthetic ligands with long chlorohydrocabon chains. The 
follow-up research has extended the Halo-tag ligands into any molecules with a long chain 
functionalized with a terminal chloride atom, which makes it better applicable to a wilder 
chemical biology fields. By applying the Halo-tag technique, we can use Halo protein with 
fluorescence labeling or biotin labeling to react with proteins with Lys long chain 
acylation and further visualized them (Figure 56D).  
Since we are trying to study dietary fatty acids and their metabolic intermediates 
with long, medium, and short chain length, we want to confirm whether Halo protein can 
recognize all of them and with what kinds of kinetics. Therefore, we selected four different 
ω-chlorofatty acids with various carbon number as 5-chlorovaleric acid representing short 
chain, 8-chlorooctanoic acid representing medium chain, 11-chloroundecanoic acid and 
13-chlorotridecanoic acid representing long chains. A gel-based kinetics assay will be 
carried out by using florescence labeled Lys derivatives as small molecular probes to react 
with HaloTag protein.  
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6.4 The synthesis of chlorofattyn-acids (n = 4, 7, 10, 12) and FITC-Lys(chloroacyl)-
OMe  
To start with, we need to synthesize the ω-chlorofattyn-acids (n = 4, 7, 10, 12) with 
different carbon numbers. More specifically, we made three different compounds as 8-
chlorooctanoic acid, 11-chloroundecanoic acid and 13-chlorotridecanoic acid, while the 
5-chloropentanic acid is commercially available. To further study the binding and reaction 
kinetics, we want to synthesize the corresponding fluorescein labeled Lys derivatives.  
 
6.4.1 The synthesis of chlorofatty acids 
 
Figure 57 Scheme for the synthesis of 8-bromooctanoic acid 
 
The synthesis of 8-chlorooctanoic acid (31): 8-bromooctanoic acid (1 eq, 22.4 mmol, 5 
g) was dissolved in methanol (2 ml/0.3 mmol), with the addition of LiCl powder (20 eq, 
450 mmol, g). The reaction mixture was allowed to reflux overnight under stirring 
condition, followed by the evaporation of methanol over vacuum. The remaining product 
was extracted by EtOAc/H2O system to the EtOAc layer. The organic phase was then 
collected, washed with Brine, and dried over sodium sulfate anhydrous. After the 
evaporation of EtOAc, an oil product 8-chlorooctanoic acid (31) was generated with 97 % 
yield, which was further verified by NMR. 1H NMR (300 MHz, CDCl3) δ 3.55 (t, 2H, 
OH
O
Br OH
O
Cl
LiCl
MeOH, reflux
31
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J=1.2 Hz), 2.36 (t, 2H, J=1.2 Hz), 1.79-1.34 (m, 10H), 13C NMR (75 MHz, CDCl3) δ 
180.4, 45.0, 34.0, 32.5, 28.8, 28.5, 26.6, 24.5  
 
 
Figure 58 1HNMR and 13CNMR of 8-bromooctanoic acid 
  149 
 
 
Figure 59 Scheme for the synthesis of 11-chloroundectanoic acid 
 
The synthesis of 11-chloroundecanoic acid (32): 11-bromoundectanoic acid (1 eq, 18.9 
mmol, 5 g) was dissolved in methanol (2 ml/0.3 mmol), with the addition of LiCl powder 
(20 eq, 380 mmol, 63 g). The reaction mixture was allowed to reflux overnight under 
stirring condition, followed by the same procedure of extraction by EtOAc/H2O for 2 
times. The EtOAc phase was collected, washed with Brine and evaporated to give out 
yellow solid as 11-chloroundecanoic acid (2) with 95 % yield, which was further verified 
by NMR. 1H NMR (300 MHz, CDCl3) δ 3.50 (t, 2H, J=1.2 Hz), 2.28 (t, 2H, J=1.2 Hz), 
1.76-1.02 (m, 16H), 13C NMR (75 MHz, CDCl3) δ 180.8, 45.4, 34.3, 32.8, 29.6, 29.5, 29.4, 
29.2, 29.0, 27.0, 24.8. 
OH
O
Br OH
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MeOH, reflux
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Figure 60 1HNMR and 13CNMR of 11-chloroundectanoic acid 
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Figure 61 Scheme for the synthesis of 13-chlorotridecanoic acid 
 
Dimethyl 2-(11-bromoundecyl)malonate (34): Sodium methoxide was freshly made by 
the slow addition of 23 ml of methanol into sodium metal (2.3 g, 100 mmol) over ice bath 
and refluxing the solution for 2 h until all the sodium metal dissolved. The sodium 
methoxide generated was then added slowly to a methanol solution of dimethylmalenate 
(1.38 g, 1.2 ml, 1 eq, 10 mmol), followed by the precipitation of a white solid. After more 
methanol was added, the white solid could redissolve to give out a clear solution. Then, 
add this clear solution dropwisely to a methanol/THF solution of 1,11-dibromoundecane 
(3.07 g, 2.3 ml, 10 mmol) and let it to reflux while stirring for o/n. After the evaporation 
of solvent, the reaction was directly load to silica column chromatography and dimethyl 
2-(11-bromoundecyl)malonate (3) was purified as a 1.8 g colorless oil with a 45 % yield. 
1H NMR (300 MHz, CDCl3) δ 3.71 (s, 6H), 3.38 (m, 4H), 1.83 (m, 4H), 1.40-1.29 (m, 
20H), 13C NMR (75 MHz, CDCl3) δ 170.1, 52.5, 51.8, 34.1, 32.9, 29.8, 29.7, 29.6, 29.56, 
29.54, 29.51, 29.4, 29.3, 28.9, 28.8, 28.3. 
2-(11-bromoundecyl)malonic acid (35): To a THF/H2O 1:1 mixt solution of dimethyl 2-
(11-bromoundecyl)malonate (100 mg, 0.27 mmol), lithium hydroxide (398.6 mg, 19 ml, 
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0.5 M) was added. The reaction mixture was let to stir at r.t. for o/n. After the evaporation 
of THF, direct EtOAc/H2O extraction was carried out for 2 times. The organic layer was 
collected, washed with Brine, dried, and evaporated via vacuum. No further purification 
was made, and the product was directly used for the next step. 
13-bromotridectanoic acid (36): 2-(11-bromoundecyl)malonic acid (0.27 mmol) was 
dissolved in 2 ml of concentrated HBr aqueous solution (~8.9 M). The reaction solution 
was let to reflux under stirring condition for o/n and to release carbon dioxide as by-
product. EtOAc was used to extract the water phase for 3 times. The organic layer was 
collected, washed with Brine, dried, and evaporated via vacuum to finally generate a 
brown colored oil. The crude product was purified by silica chromatography first with 
pure hexane then with 9:1 hexanes:ethyl acetate to generate 13-bromotridectanoic acid (6) 
as a 13 mg white solid with an overall yield of 14 %. A larger scaled reaction was then set 
up to prepare enough amounts for the next step. 1H NMR (300 MHz, CDCl3) δ 3.40 (t, 
2H, J=1.2 Hz), 2.34 (t, 2H, J=1.2 Hz), 1.90-1.26 (m, 20H). 13C NMR (75 MHz, CDCl3) δ: 
179.7, 33.86, 33.81, 32.62, 29.30, 29.28, 29.21, 29.18, 29.01, 28.83, 28.54, 27.97, 24.45. 
13-chlorotridecanoic acid (33): 13-bromoundectanoic acid (560 mg, 1 eq, 1.9 mmol) was 
dissolved in methanol/THF 1:1 (5 ml), with the addition of LiCl powder (15 eq, 28.5 
mmol, 1.2 g). The reaction mixture was let to reflux under stirring condition for o/n. After 
the evaporation of methanol followed by the extraction of EtOAc/H2O system, the organic 
layer was collected, washed with Brine, and dried. The evaporation of EtOAc via vacuum 
could finally give out a 299.6 mg white solid with 63 % yield, which was further verified 
by NMR. 1H NMR (300 MHz, CDCl3) δ 3.51 (t, 2H, J=1.2 Hz), 2.29 (t, 2H, J=1.2 Hz), 
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1.79-1.25 (m, 20 H); 13C NMR (75 MHz, CDCl3) δ 180.4, 45.1, 34.1, 32.6, 29.50, 29.48, 
29.43, 29.21, 29.12, 29.02, 28.9, 26.9, 24.6. 
 
 
Figure 62 1HNMR and 13CNMR of 13-chlorotridecanoic acid 
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6.4.2 The synthesis of Boc-Lys-OMe intermediate 
 
Figure 63 Scheme for the synthesis of Boc-Lys-OMe intermidiate 
 
Boc-Lys(Cbz)-OMe (38): Boc-Lys(Cbz)-OH (2 g, 1 eq, 5.3 mmol) and K2CO3 (1.38 g, 2 
eq, 10.6 mmol) were both dissolved in DMF 15 ml, followed by the addition of MeI (495 
µL, 1.5 eq, 7.9 mmol). The reaction was let to stir at r.t. for 30 min. Direct extraction of 
EtOAc/H2O was carried out by the addition of 100 mL H2O and 100 mL EtOAc for three 
times. The organic layer was collected, washed with brine, and evaporated via vacuum. 
The oil product was directly used for the next step without further purification. 
Boc-Lys-OMe (37): 10 mol% Pd/C was put in a round bottle and purged by nitrogen gas 
for 30 min. Boc-Lys(Cbz)-OMe (1.5 g, 1 eq, 5.3 mmol) was dissolved in MeOH (30 mL), 
and added to the round bottle. A hydrogen gass balloon was then set up, and the reaction 
mixture was let to stir for 4 h monitored by TLC. After the starting material fully 
disappeared, filtration was then carried out for the removal of Pd. Then, MeOH was 
evaporated via vacuum. The oil product was directly used for the next steps without further 
purification. 
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6.4.3 The synthesis of FITC-Lys(chloroacyl)-OMe 
In this part, we will use the Boc-Lys-OMe as starting material to make all four 
kinds of dyes. 11-chloroundecanoic acid (32) will be used as example for the synthesis of 
FITC-Lys(11-chloroundecanyl)-OMe (39a). For the other three FITC-Lys(ω-chloroacyl)-
OMe derivatives, a corresponding ω-chloroalphatic acid is used with the similar synthesis 
procedure, respectively. The NMR for Boc- Lys(ω-chloroacyl)-OMe (41a,b,c,d) and 
FITC-Lys(ω-chloroacyl)-OMe (39a,b,c,d) are provided. 
 
Figure 64 Scheme for the synthesis of Boc-Lys-OMe intermidiate 
 
11-chloroundecanoic NHS ester (40a): 11-chloroundecanoic acid (676.7 mg, 1 eq, 3.8 
mmol) and N-hydroxysuccinimide (NHS) (524 mg, 1.2 eq, 4.6 mmol) were both dissolved 
in DCM. A solution of N,N'-Dicyclohexylcarbodiimide (DCC) (939 mg, 1.2 eq, 4.6 mmol) 
in DCM was added dropwisely with ice bath. White precipitation was observed in several 
minutes. Then, ice bath was removed, and the reaction was let to stir at r.t. for o/n. 
Filtration was carried out, followed by the solvent evaporation via vacuum. The product 
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in oil form was directly used for the next step without further purification. 1H NMR (300 
MHz, CDCl3) δ 3.56 (t, 2H, J=1.2 Hz), 2.86 (s, 4H), 2.62 (t, 2H, J=1.2 Hz), 1.98-1.24 (m, 
16H) 
Boc-Lys(11-chloroundecanyl)-OMe (41a): Boc-Lys-OMe (1.4 g, 1 eq, 5.3 mmol) was 
dissolved in DCM, followed by the addition of DIPEA (1.0 mL, 1.2 eq, 6.3 mmol) and 
incubation on ice bath. 11-chloroundecanoic NHS ester (1.7 g 1 eq, 5.3 mmol) dissolved 
in DCM was added slowly, and the mixture was let to stir under r.t. for o/n. The reaction 
mixture was then extracted with 1 M Citric acid pH=2 buffer/EtOAc twice. The organic 
layer was collected, washed with Brine, and evaporated. The crude product was purified 
by flash chromatography (2:1 hexanes:ethyl acetate) to yield Boc-Lys(8-chlorooctanyl)-
OMe as white powders (1.2  g, 66 %). 1H NMR (300 MHz, CDCl3) δ 4.31 (m, 1H), 3.74 
(s, 3H), 3.56 (t, 2H, J=1.2 Hz), 3.25 (q, 2H, J=0.8 Hz), 2.16 (t, 2H, J=1.2 Hz), 2.05-1.24 
(m, 22H). 13C NMR (75 MHz, CDCl3) δ: 172.9, 164.6, 155.1, 79.4, 52.7, 51.8, 44.7, 38.5, 
36.3, 32.2, 31.9, 28.9, 28.9, 28.8, 28.5, 28.3, 27.8, 26.4, 25.3, 22.2. 
FITC-Lys(11-chloroundecanyl)-OMe (39a): Boc-Lys(11-chloroundecanyl)-OMe (250 
mg, 1 eq) was dissolved in 20 mL HCl (1 M in dioxane) and let to stir for 8 h, monitored 
by TLC. After the completely removal of solvent, 160 mg white powder of H-Lys(11-
chloroundecanyl)-OMe in HCl salt form was prepared without further purification. H-
Lys(11-chloroundecanyl)-OMe (118 mg, 0.22 mmol 1.2 eq) was dissolved in a solution 
of DIPEA (41 µL, 0.22 mmol, 1.2 eq) in DMF (2 mL). The reaction mixture was cooled 
to 0°C before the addition of fluorescein 5-isothiocyanate (FITC) (70 mg, 0.18 mmol, 1 
eq). The reaction mixture was allowed to warm to r.t. and let to stir for o/n. The solvent 
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was evaperated and the crude oil was directly applied to silica column chromatography 
using a gradient of DCM:acetone:MeOH (80:10:10 to 0:90:10) to afford compound FITC-
Lys(11-chloroundecanyl)-OMe (12a) (82 mg, 62%) as an orange solid. 1H NMR (MeOH-
d4) δ: 8.30 (s, 1H), 7.36 (d, 1H, J=1.2 Hz), 7.32(d, 1H, J=4.8 Hz), 6.71-6.67 (m, 4H), 6.59-
6.54 (m, 2H), 5.11 (t, 1H, J=1.2Hz), 3.75 (s, 3H), 3.54 (t, 2H, J= 3.3Hz), 3.20 (m, 2H), 
2.16 (m, 2H), 2.02-1.98(m, 2H), 1.74-1.71(m, 2H), 1.60-1.41(m, 24H). 1HNMR and 
13CNMR for all the four compounds are listed at the end of the chapter (Figure 76-79).  
 
6.5 Kinetics study of Halo-tag reaction  
With all the four FITC-Lys(ω-chloroacyln)-OMe (n = 4, 7, 10, 12) in hand, we 
carried out gel-based kinetics study to test whether Halo-tag protein can react with all the 
long medium and short chained chlorofatty acids we chose.  
 
6.5.1 The expression of Halo protein 
We first started with the expression of Halo protein (MW: 61940 Da). We got the 
plasmid pGEX-GST-Halo containing the gene of Halo-tag protein fused with GST tag at 
its N-terminus from Dr. Eric Kool’s group at Stanford University. The plasmid was used 
to transform E. coli BL21(DE3) cells, and a single colony was picked for the setting up of 
10 mL seed culture. The seed culture was then used to inoculate 1 L LB medium with 100 
µg/mL Amp for the expression of Halo-tag protein. The cells were let to grow at 37 oC in 
the 2YT medium to OD600 reaching 0.4, and the expression of GST-HaloTag protein was 
induced with the addition of 0.5 mM IPTG. Next, cells were let to grow continuously at 
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16 oC for 12 h, collected and washed with 100 mM Tris lysis buffer pH 7.5 containing 1 
mM PMSF. The cell pallet was stored at -80 oC for purification. 30 mL 100 mM Tris lysis 
buffer pH 7.5 with 1 mM PMSF was used to resuspend the cell pallet. The expressed GST-
HaloTag was loaded to a column with 1 mL of GST resin, washed by 50 mM Tris buffer 
pH 8 and finally eluted by 10 mM glutathione in 50 mM Tris buffer pH 8 in different 
fractions, which are confirmed by SDS-PAGE (Figure 65). The protein was dialyzed 
against a PBS pH 7.4, and aliquoted into different tubes. The concentration of Halo-tag 
protein was measured as 3.12 mg/mL, which can be calculated as 50.3 µM.  
 
 
Figure 65 The purification of GST-HaloTag protein 
 
6.5.2 Gel-based kinetics study 
All the four FITC-Lys(ω-chloroacyln)-OMe (n = 4, 7, 10, 12) dyes were dissolved 
in DMSO to a concentration between 0.1-1 µM range as original solutions. UV absorbance 
was used to precisely quantify the concentration, followed by the dilution to DMSO to 
make stock solutions. The concentration of each of them are 900 nM for n=4, 710 nM for 
n=7, 900 nM for n=10, and 890 nM for n=12.  
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Each of the dyes was added to a reaction mixture containing 10 nM Halo-tag 
protein to a final concentration of 1 nM. The final volume of the reaction was adjusted to 
20 µL with PBS, and the solution was pipetted to mix well. After reacting for a certain 
period time, 4 µL of 6×loading buffer was added followed by heating up the reaction 
solution to boil. After several trials, we finally select the time interval as 5 s, 10 s, 15 s, 20 
s, 30 s, 60 s, 90 s, 120 s, and 150 s. The boiled samples were loaded to 15 % SDS-PAGE. 
The gel was visualized under UV irrigation before staining with Coommassie blue (Figure 
66).  
The reaction is following pseudo-first order kinetics while the enzyme is about 10 
folds excessive. We use the gel quantification software from Bio-Rad company, and the 
fluorescence intensity after normalization was used to plot and calculate the observed rate 
constant and the second order rate constant. Interestingly, we found Halo-tag could 
recognize short chained fatty acylation even with only 4 carbons in between the carbonyl 
group and the chloride atom.  
 
Figure 66 Gel-based kinetics study of Lys conjugated dye reacting with HaloTag 
protein 
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From the gel result, we can clearly see that all the four dyes with various carbon 
chain number can all react with Halo-tag protein. This result is surprising to us since no 
one has shown that Halo-tag protein can recognize short chain with only 5 carbon atom 
length. We also observed that with the increase of the chain length the Halo-tag 
recognition speeds up. Especially, the reaction between FITC-Lys(ω-chloroacyl12)-OMe 
and Halo-tag protein showed a second order rate constant 106 M-1s-1 agreeing with the 
original result[130]. 
 
6.6 Test on proteins 
With the kinetics data at hand, we then carried out the test of HaloTag recognition 
on protein levels to get an optimized condition for further membrane blotting. We decided 
to use the fatty acids with medium chain length as a model to test, because with our ncAA 
technique, we can easily install a non-natural structure Nε-(8-chlorooctanyl)lysine into 
desired site. Also noted as H-Lys(8-chlorooctanyl)-OH, We first carried out the synthesis 
of the Nε-(8-chlorooctanyl)lysine (CloK). 
 
6.6.1 The synthesis of H-Lys(8-chlorooctanyl)-OH (42) 
 
Figure 67 Scheme for the synthesis of H-Lys(8-chlorooctanyl)-OH 
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Boc-Lys(8-chlorooctanyl)-OH (43): Boc-Lys(8-chlorooctanyl)-OMe (41c from Part 
6.4.3) (1 eq, 2.4 mmol, 1 g) was dissolved in methanol/THF 1:1 (15 ml), with the addition 
of LiCl powder (15 eq, 36 mmol, 1.5 g). The reaction mixture was let to reflux under 
stirring condition for o/n. After the evaporation of solvent followed by the extraction of 
EtOAc/H2O system, the organic layer was collected, washed with Brine, and dried. The 
evaporation of EtOAc via vacuum could finally give out 0.9 g of colorless oil with 95 % 
yield.  
H-Lys(8-chlorooctanyl)-OH (13): Boc-Lys(8-chlorooctanyl)-OH (1 eq, 2.3 mmol, 910 
mg) was dissolved in 10 mL HCl (1 M in dioxane) and let to stir for 8 h. The reaction was 
monitored by TLC. After the completely removal of solvent, 750 mg white powder of H-
Lys(8-chlorooctanyl)-OH in HCl salt form was prepared without further purification. 1H 
NMR (300 MHz, D2O) δ 3.94 (t, 1H, J=10 Hz), 3.38 (t, 2H, J=12 Hz), 3.01 (m, 2H), 2.06 
(t, 2H, J=1.2 Hz), 1.79 (t, 2H, J=1.2 Hz), 1.58-1.13 (m, 14H). 13C NMR (75 MHz, CDCl3) 
δ: 175.9, 171.6, 66.4, 52.5, 45.3, 38.8, 35.6, 32.1, 29.3, 28.4, 28.0, 26.2, 25.4, 21.7. 
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Figure 68 1HNMR and 13CNMR of H-Lys(8-chlorooctanyl)-OH 
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6.6.2 The incorporation of H-Lys(8-chlorooctanyl)-OH (13) 
We had previously selected a specific PylRS mutant for the incorporation of Lys 
with side chain fatty acylation modifications[131]. By applying the same mmOcKRS to co-
transform E. coli BL21(DE3) cells together with another plasmid pBAD-sfGFP-
D134TAG containing a gene for the expression of the sfGFP with an amber mutation at 
the D134 position as well as a His6 tag at the C-terminus. A single colony was picked and 
let to grow in 5 mL LB medium with 100 mg/mL Amp and 34 mg/mL Cm at 37 °C for 
o/n. Then, the transformed cells were used to inoculate 50 mL 2YT medium with 100 
mg/mL Amp and 34 mg/mL Cm, which can express full-length sfGFP with CloK at its 
D134 position (sfGFP-D134CloK) after been induced by 0.2% arabinose and 0.5 mM 
IPTG.  
After growing at 37 °C for 6 h, the cells were collected by centrifugation (6000 
rpm for 15 min). After been resuspended in a 25 mL lysis buffer (50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazole, pH 8.0) and sonicated in an ice water bath three times (4 
min each, with a 5 min interval between each run), the cell lysate was precipitated by 
centrifugation (10000 rpm for 30 min). The supernatant was added to 1 mL Ni SepharoseTM 
6 Fast Flow column (GE Healthcare) and the flow-through was then removed. The resin 
was washed with a wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 
8.0) and finally eluted with an elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole, pH 8.0). After been concentrated with Amicon Ultra-15 Centrifugal Filter 
Devices (10000 MWCO cut, Millopore), the purified sfGFP-D134AcdK was analyzed by 
SDS-PAGE. A clear band can be clearly seen only with 2 mM CocK afforded in the media, 
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while none for the one without CloK added (Figure 69). The yield of sfGFP-D134AcdK 
is 7 mg/L with the presence of 0.5 mm CloK, determined by the BCA method. 
 
Figure 69 The expression of sfGFP-D134CloK 
 
6.6.3 The binding test of HaloTag protein 
With the kinetics data at hand, we further carried out the HaloTag-substrate protein 
binding assay. To get an optimized condition for further membrane blotting, we first tried 
to direct incubate HaloTag protein with sfGFP-D134CocK for some time to let them react 
under aqueous condition. A volume of 20 µL reaction mixture containing 22.2 µg sfGFP-
D134CocK and 27.4 µg HaloTag protein was pipetted to mix well. After 1 h incubation, 
the sample was loaded to 15 % SDS-PAGE. Two negative controls with only HaloTag 
protein or with only sfGFP-D134CocK were also loaded. After finishing running, the 
protein sample was first visualized under UV plates and then stained with Coomassie blue. 
The three gel figures of a same gel from Coomassie blue staining, UV plate and 
fluorimeter are listed in parallel (Figure 70). In lane 1, a mixed sfGFP-D134CloK with 
HaloTag protein sample was loaded, while control for HaloTag and sfGFP-D134CloK 
was loaded to lane 2 and lane 3, respectively. A new band with higher molecular weight 
as the conjugate can be observed only in lane 1. 
  165 
 
Figure 70 The binding test of HaloTag protein with sfGFP-D134CloK 
 
6.7 HaloTag protein labeling 
For the purpose of metabolic labeling and proteomic study, we hope to label 
HaloTag protein with fluorescence dye or Biotin. In our experimental design, the 
mammalian cell lysate will be loaded to run the whole protein SDS-PAGE gel, which is 
fed with synthetic chlorofatty acids. Then we can apply the labeled HaloTag protein to 
blot the membrane serving as an artificial first antibody for long chain fatty acids (Figure 
71). 
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Figure 71 Screen for the metabolic labeling with biotin conjugated HaloTag protein 
 
6.7.1 The labeling of HaloTag protein 
The initial trial of labeling was based on the commercially available biotin-OSu 
active ester. However, the removal of free excessive dye turned out to be a problem. 
Inspired by the 2-Cyanobenzothiazole (CBT)-Cys bioorthogonal reaction, CBT-dye 
labeling is a selective reaction with high yield and no background[132].  
We carried out the molecular cloning to insert another TEV cleavage site to the N-
terminal of HaloTag protein, besides the one in between HaloTag and GST tag. The 
original TEV recognition sequence as Glu-Asn-Liu-Tyr-Phe-Gln-Gly, while the last Gly 
was mutated to Cys for our purpose of labeling (Figure 72A). The novel plasmid was used 
to transform E. coli BL21(DE3) cells, and the target protein was purified with a similar 
process as reported in Part 6.5.1. Before column elution, an on-resin TEV cleavage was 
carried out for the removal of GST tag and to release a N-terminal Cys residue for the 
CBT labeling (Figure 72B). A concentration of 20 µM TEV in 1 mL PBS was added to 
the column and let to incubate for 24 h. With the removal of GST tag, the protein will fall 
off the GST-resin to solution. The final enzyme was aliquoted and stored at -20 oC. 
HN
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ENLYFQC GSTENLYFQG
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 A final concentration of 10 mM CBT-Biotin made by Dr Yadagiri Kurra was 
added to HaloTag protein and let to incubate at 37 oC for 12 h. After labeling, the HaloTag 
protein was analyzed with SDS-PAGE, transferred to membrane, and then visualized with 
Streptavidin-HRP (Figure 72C). Only after the labeling, a clear dark band can be observed 
for the biotin conjugated HaloTag protein.  
 
Figure 72 The biotin labeling of HaloTag protein and its gel characterization (A) the 
insertion of TEV protease site at the C-terminal of HaloTag; (B) the TEV cleavage 
followed by the CBT-dye labeling of HaloTag; (C) the SDS-PAGE and Western blot of 
labeled HaloTag by Streptavidin-HRP. 
 
6.7.2 The blotting examination of HaloTag protein on membrane 
Before the final metabolic labeling on real cell lysate, we hope to confirm its 
potential application as a first antibody with purified protein containing chlorofatty acids. 
The HaloTag protein after labeling was dialyzed to completely remove the small 
molecular reactants. 
Both WT-GFP and sfGFP-D134CocK previously mentioned were loaded to SDS-
PAGE followed by the transfer to membrane. The membrane was first blotted with milk 
buffer (PBS with 15 % milk powder) at r.t. for 1 h, and then incubated with HaloTag 
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solution with a final concentration of around 10 µM. After blotting at 4 oC for 2 h, the 
membrane was directly visualized by the commercially available Streptavidin-
Horseradish peroxidase (HRP). A clear band can be detected only for the sfGFP-
D134CocK, while the same of protein amounts for both lanes provided (Figure 73). This 
demonstrated the successful membrane blotting with Biotin conjugated HaloTag. 
 
Figure 73 The membrane blotting with Biotin conjugated HaloTag protein 
 
6.8 Metabolic labeling on HEK293T cells 
After the methodology demonstration, we started to move ahead to our final 
application as the metabolic labeling of mammalian cells. We decided to choose 
HEK293T cell lane as the starting point and do proteomic analysis over the entire 
proteome after feeding chlorofatty acids with different chain length. Noted that this part 
is not fully finished when this manuscript is prepared. 
 
6.8.1 Cell culture of HEK293T cell 
The origanl HEK293 cell prepared by previous lab member Sasha Chihak was 
stored in liquid Nitrogen. The tubes with HEK293T cell was placed in a 60 ºC water bath 
for 2 minutes until thawed. The cells were carefully transferred from the vial to a 15 mL 
  169 
conical tube with 37 ºC culture medium. After centrifuging to remove the supernatant (1 
min, 100 rpm), 15 ml DMEM with 10 % FBS was added and the cell was placed on a 100 
mm culture dish. The dish was put in the incubator and let to grow under 37 °C with 5% 
CO2 for o/n. The cell growth was monitored by a microscope. 
The HEK293T cells on dish were passaged when reaching 80% confluent. The 
medium was removed by gently pipetting without touching cell surface, followed by 
washing with PBS. After carefully removing the PBS, trypsin buffer was then added to 
the dish and let to incubate in 37 ºC incubator for about 2 min. The cell aspiration was 
monitored by microscope to guarantee the release of cells from the plate bottom. Then 10 
mL DMEM was added to inactivate the trypsin inside, followed by the resuspend of the 
cells by careful pipetting. The cell suspension was added to new sterile dishes and 
incubated under 37 °C with 5% CO2. 
 
6.8.2 Cell culture with chlorofatty acids 
After passaging the HEK293T cells for 3 generations, we started to feed the cells 
with the synthetic chlorofatty acids. During the last passaging process, the cell was 
transferred to a 4 cm 6-well plate with 3 mL each and let to grow in the incubator under 
37 °C with 5% CO2 till confluent reached 50 %. 
All four ω-chlorofattyn-acids (n = 4, 7, 10, 12) were first dissolved in sterile DMSO 
after filtration to a final concentration of 50 mM. Then the stock solution was diluted with 
DMEM/FBS to a final concentration of 0.1 mM, respectively. Mammalian cells are 
trypsinized and quenched with the DMEM with chlorofatty acids. The solution was added 
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to another 4 cm 6-well plate with 3 mL each and let to grow in the incubator under 37 °C 
with 5% CO2. The cell growth was regularly monitored with microscope.  
The cell showed lower growing rate generally with the addition of fatty acids. After 
24 h, the cell confluency reached 50 %. Then the medium was removed followed by 
washing with PBS once for further lysis. 
 
6.8.3 Cell lysis and sample preparation 
For each well on the 6-well plate, 100 µL ice-cold RIPA lysis buffer with protease 
inhibitor cocktail was added and let to incubate on ice for 5 min. Then, the cells are 
carefully gathered together by a scraper, and the cell lysate was collected in 1.5 mL 
Eppendorf tube. The cell lysate was quickly frozen over dry ice-acetone bath, and let to 
thaw in 37 oC water bath, followed by the vigorous shaking by vortexing for 1 min. Repeat 
this fast freeze-thaw cycle for 5 times to complete break the aggregations or chunks in the 
cell lysate, and the tube was centrifuged for 15 min over 14000 rpm. The supernatant was 
kept and whole cell lysate BSA assay was carried out to determine the entire protein 
concentration. The readings of all five including control were between 1.0-5.0 µg/mL. A 
standard acetone precipitation was carried out to precipitate all the proteins in the cell 
lysate. Each sample was aliquoted as 100 µg cell lysate dissolving in 20 µL PBS and then 
stored at -20 oC for further gel analysis. 
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6.8.4 Gel analysis 
After normalization, the cell lysates with or without ω-chlorofattyn-acids (n = 4, 7, 
10, 12) diet were analyzed by two gradient SDS-PAGE gels. One of them was stained by 
Coomassie blue and the other was transferred to membrane for the Western blot analysis. 
After standard blotting with milk, Biotin conjugated HaloTag protein was used as first 
antibody to blot the membrane.  
For the protein myristoylation, several darker bands could be observed for the 
experimenta group fed with 13-chlorotridecanoic acid (n = 12) as the myristic acid 
mimetic (Figure 74C), while the entire protein amount and pattern remained almost 
identical. Similar situations happened for 11-chloroundecanoic acid (n = 10) and 8-
chlorooctanoic acid (n = 7) (Figure 74A&B), which suggesting a wide acylation of cellular 
proteome by the dietary fatty acids. But almost no difference can be seen for 5-
chloropentanic acid (n = 4), which may result from a fast metabolic degradation kinetics 
due to the fact of short chain length. Notably, there are many essence Biotin conjugated 
proteins in cells, and thus even without the addition of ω-chlorofattyn-acids, some of the 
cellular proteins could still be visualized with Streptavidin-HRP.  
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Figure 74 The metabolic labeling of HEK293T cell lysate via biotin labeled HaloTag 
protein (A) SDS-PAGE and Western blot of cells fed with ω-chlorofatty-acid n = 7; (B) 
SDS-PAGE and Western blot of cells fed with ω-chlorofatty-acid n = 10; (C) SDS-PAGE 
and Western blot of cells fed with ω-chlorofatty-acid n = 12. 
 
6.9 Metabolic labeling on HEK293T cells 
Since the fatty acylation can be modified over either Lys or Cys side chain or the 
N-terminus, we want to further identify them and study their distribution. 
 
6.9.1 Background design 
For Cys acylation, since the thioester linkage is not as stable as amide bond, we 
can use nucleophilic reagents such as hydroxylamine to remove them, which can be further 
detected via the Western blot analysis. On the other hand, Sirtuin family enzymes are 
known to remove Lys acylation modifications, which can all be inhibited by nicotinamide. 
Then we hypothesized the addition of nicotinamide into the culture could inhibit the 
Sirtuin activity. Thus, the bands on the Western blot with increasing amount of intensity 
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will be acylations on Lys residues. To demonstrate the principle, only the 13-
chlorotridecanoic acid will be used in the next part as a mimetic for myristic acid.  
 
6.9.2 Cys myristoylation 
To start with, we wanted to separate the Cys myristoylation modifications from 
the Lys ones. The cells fed with 13-chlorotridecanoic acid were lysed with the same 
process as previously mentioned. After been transferred to membrane and blotted by milk 
buffer, PBS with 10 % hydroxylamine was first added to blot the membrane for 1 h, 
followed by the blotting with Biotin conjugated HaloTag protein as first antibody. And 
cells blotting with PBS were used as negative control that could still show Cys 
myristoylation (Figure 75A). 
From the Western blot result we can clearly tell that after the treating with 
hydroxylamine, a lighter band pattern was observed, while the entire protein amount was 
kept the same. This showed that by nucleophilic attacking the thioester bond of Cys 
myristoylation, less labeled proteins can be detected, and this further confirmed the wide 
existence of myristoylation on Cys residues. 
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Figure 75 The metabolic labeling of HEK293T cell lysate under different conditions 
via biotin labeled HaloTag protein (A) SDS-PAGE and Western blot of cells with 
hydroxylamine treatment to remove Cys myristoylation; (B) SDS-PAGE and Western blot 
of cells fed with nicotinamide to inhibit Sirtuin enzymes. 
 
6.9.3 Lys myristoylation 
The next step, we wanted to distinguish the Lys myristoylation by inhibiting 
Sirtuin family enzymes. A final concentration of 100 mM nicotinamide was added to the 
medium together with 13-chlorotridecanoic acid to feed the cells with the same process as 
previously mentioned. After transferring the gel with cell lysate to membrane, standard 
milk blotting followed by the blotting with Biotin conjugated HaloTag protein was then 
carried out.  
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The Western blot result showed that after the addition of nicotinamide, many new 
bands can be detected in a different pattern, while the entire protein amount was kept the 
same (Figure 75B). This demonstrated that by inhibiting Sirtuin enzymes we can boost up 
the fatty acylation level in mammalian cells, and we are also able to clearly see the 
myristoylation on Lys residues. 
 
6.10 Summary 
Many questions remain for the study of Lys lipidation especially for Lys fatty 
acylation modifications. For protein fatty acylation, modifications have been discovered 
mainly on the two amino acid residues as Lys and Cys and the N-terminus. Although fatty 
acylation has been found on many important protein substrates which plays vital 
regulatory roles in epigenetic control of structures and functions, there detailed molecular 
mechanisms are remaining unclear. To solve the question of lacking reporting groups, we 
hope to introduce a novel design based on the HaloTag and chlorofatty acid interaction.  
We demonstrated the wide application of HaloTag in recognition of fatty acids 
with long, medium, or even short chains. With this technique, proteins with various 
modifications of dietary fatty acids and their derivatives can be distinguished and collected 
for further identification and characterization in combination of proteomic techniques. By 
applying biotin labeled HaloTag protein as a probe, we can directly visualize whole cell 
lysate and find out proteins with fatty acylations. With the new technique, a deeper 
understanding of the impact of dietary fatty acids to human life will be generated from an 
epigenetic point of view. 
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Figure 76 1HNMR of FITC-Lys(5-chloropentanyl)-OMe 
 
 
Figure 77 1HNMR of FITC-Lys(8-chlorooctanyl)-OMe 
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Figure 78 1HNMR of FITC-Lys(11-chloroundecanyl)-OMe 
 
Figure 79 1HNMR of FITC-Lys(13-chlorotridecanyl)-OMe 
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CHAPTER VII 
CONCLUSION AND OUTLOOK 
7.1 Conclusion 
Over the past decade, an increasing amount of protein PTMs have been gradually 
discover due to the development of analytical instruments, which are of great significance 
to many cellular activities. Especially for Lys residue, many novel PTM types with a large 
variety of structures have been characterized widely existing in human proteome. 
However, the detailed molecular mechanisms are remaining unclear. One of the main 
factors that are greatly harmful for the functional study is to gain sufficient amounts of 
target proteins with site-specific PTMs. Recombinant protein expression can, no doubt, 
achieve most of the goals when facing different target proteins. But it can hardly be applied 
to proteins with PTMs. Chemical biology has enable us to have a fine control of 
theoretically any proteins at atomic level. However, many previous strategies are not 
robust or versatile enough when facing more and more challenges. 
In this dissertation, a new combinatory strategy with ncAA and bioorthogonal 
reaction has been described. More specifically, two ncAA based Lys PTM installation 
systems are mainly introduced, followed by the direct application of the protein products 
with site-specific methyllysine or acyllysine into enzymatic assays. With high selectivity 
and wide applicability of bioorthogonal reactions, ubiquitin, sfGFP, and hp53 were 
applied as water-soluble protein models with small, medium, and large volume, 
respectively, while histone H3 as a water non-soluble protein. All of our designs are 
proved to work as expected on these model proteins to generate site specific Lys PTMs. 
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The protein products are submitted to many important epigenetic enzymatic assays as 
LSD1, Tip60, Sirt5, etc. 
Importantly, this strategy is also providing different functional groups for other 
chemical biology handling. For AcdK system, the AlK generated contains an aldehyde 
group which can serve as an electrophilic center with high reactivity over different 
nucleophiles. AznL, on the other hand, is also providing an azido group as a key chemical 
biology function group. Many important reactions can undergo with this azido group, such 
as “Click reaction”, Staudinger reduction, Staudinger ligation, traceless Staudinger 
ligation, and so on. Therefore, both AcdK and AznL can be further applied for a wider 
chemical biology functionalization purposes. 
 
7.2 Outlook 
Besides the challenges mentioned in each chapter, there are several overall points 
worth mentioning here. To start with, many PTM targets are still unachievable with our 
strategy. For instance, lysine trimethylation Kme3 carrying a positive charge cannot be 
directly incorporated by PylRS, while there is no way to generate a tertiary amine from 
reductive amination reaction. All the reported examples of site-specific installation of 
Kme3 come from protein chemical synthesis. The development of current organic 
synthesis especially the metal-catalyzed reaction is providing our new insights into the 
building up of those common structures such as amide bond[109]. To introduce them into 
protein chemical biology field may help to set up new avenues in our trials of solving 
those cumbersome problems[133]. 
  180 
The optimization of bioorthogonal reaction conditions are definitely one of the 
main developing directions. The modification at a single amino acid residue makes the 
product very similar with the starting material. Currently widely used reactions cannot 
reach full conversion easily, which brings the concern of product purification. Another 
major challenge is to modify biomolecules in higher levels not just purified protein or 
protein complex[121]. How to apply more and more chemical reactions really into the 
biological systems are still not applicable in most cases, not only in cell lysate or living 
cells[134], but also in higher organs such as tissue or entire animal level. To achieve this 
goal, more robust and versatile reactions are welcome to be introduced to the field. 
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